EurekaMag PDF full texts Chapter 67,137

King, M.V.; Shortall, S.E.; Green, A.R.; Fone, K.C.F. 2014: P.1.g.026 Contribution of 5-Ht and dopamine to the physiological and behavioural effects of mephedrone following binge dosing in the rat. European Neuropsychopharmacology 24: S217-S218

Musazzi, L.; Treccani, G.; Milanese, M.; Perego, C.; Nava, N.; Bonifacino, T.; Lamanna, J.; Malgaroli, A.; Racagni, G.; Nyengaard, J.R.; Wegener, G.; Bonanno, G.; Popoli, M. 2014: P.1.g.029 Acute stress increases the readily releasable pool of glutamate vesicles in cortical areas. European Neuropsychopharmacology 24: S219-S220

Leo, D.; Sukhanov, I.; Illiano, P.; Mus, L.; Espinoza, S.; Sotdnikova, T.; Hoener, M.C.; Gainetdinov, R.R. 2014: P.1.g.030 Pronounced dopaminergic dysregulation in dopamine transporter knockout rats. European Neuropsychopharmacology 24: S220-S221

Logvinov, I.O.; Antipova, T.A.; Tarasiuk, A.V.; Gudasheva, T.A.; Seredenin, S.B. 2014: P.1.g.032 Gsb-106, a low molecular weight dipeptide analogue of Bdnf, protected cells via the TrkB, Akt, Erk 1/2 activation. European Neuropsychopharmacology 24: S221-S222

Saberi, M.; Vesali, R.; Pourneghash Tehrani, S.; Saberi, F.; Fakour, Y. 2014: P.1.g.034 The interaction of levetiracetam analgesia with morphine-induced tolerance in the tail-flick mouse model. European Neuropsychopharmacology 24: S222-S223

Lee, J.G.; Seo, M.K.; Lee, C.H.; Baek, J.H.; Kim, J.G.; Park, S.W.; Kim, Y.H. 2014: P.1.g.036 Effects of mood-stabilising drugs on dendritic outgrowth and synaptic protein levels in the primary hippocampal neurons. European Neuropsychopharmacology 24: S223-S224

Rysz, M.; Bromek, E.; Daniel, W.A. 2014: P.1.g.037 Repeated stimulation of brain serotonergic system affects liver cytochrome P450. European Neuropsychopharmacology 24: S224-S225

Jeanson, T.; Figueiredo, A.C.; Bourgoin, S.; Picoli, C.; Mouthon, F.; Giaume, C.; Charvériat, M.; Hamon, M. 2014: P.1.g.039 Connexin channel inhibitor promotes the anti-hyperalgesic effect of amitriptyline in sciatic nerve-ligated rats. European Neuropsychopharmacology 24: S225-S226

Kokova, V.; Apostolova, E.G.; Peychev, L.P. 2014: P.1.g.041 Experimental studies of the analgesic effect of pregabalin. European Neuropsychopharmacology 24: S226-S227

Almada, R.C.; Roncon, C.M.; Elias-Filho, D.H.; Coimbra, N.C. 2014: P.1.g.042 Substantia nigra inputs modulate nigrotectal pathways during the organisation of defensive behaviour in a dangerous environment. European Neuropsychopharmacology 24: S227-S228

Alvarsson, A.; Stan, T.L.; Schintu, N.; Kadkhodaei, B.; Millan, M.J.; Perlmann, T.; Svenningsson, P. 2014: P.1.g.044 Trace amine-associated receptor 1 inhibits a hyperglutamatergic state induced by dopamine deficiency. European Neuropsychopharmacology 24: S228-S229

Ramirez, A.C.L.ño; Arango-Dávila, C.A. 2014: P.1.g.046 Neuroprotective effect of fluoxetine associated with Bcl-2 expression in an experimental model of ischemic stroke in mice. European Neuropsychopharmacology 24: S229-S230

Viana, G.; Calou, I.; Bandeira, M.A.; Galvão, W.; Brito, G.A. 2014: P.1.g.047 Myracrodruon urundeuva Allemo, a Brazilian medicinal species, presents neuroprotective effects on a Parkinsons disease model, in rats. European Neuropsychopharmacology 24: S230-S231

Álvaro-Bartolomé, M.; García-Sevilla, J.A. 2014: P.1.g.049 Disruption of MekErk activation in brain during midazolam-induced sleep in mice. European Neuropsychopharmacology 24: S231-S232

Adham, N.; Gyertyan, I.; Kiss, B. 2014: P.1.g.052 Cariprazine demonstrates greater potency than aripiprazole in animal models of psychosis, cognitive impairment, and negative symptoms. European Neuropsychopharmacology 24: S233-S234

Mongeau, R.; Martin, C.B.P.; Chevarin, C.; Gassman, M.; Hamon, M.; Rudolph, U.; Bettler, B.; Lanfumey, L. 2014: P.1.g.054 Effect of genetic and pharmacological blockade of Gaba receptors on a serotonergic regulation of stress. European Neuropsychopharmacology 24: S234-S235

Suprun, O.; Gromov, L.; Belenichev, I.; Suprun, E. 2014: P.1.g.057 Il-1Ra stabilises the thioldisulfide system in the brain tissues of rats with experimental diabetes and cerebral ischemia. European Neuropsychopharmacology 24: S236-S237

Belyakova, A.; Voskresenskaya, O.G.; Sinjushin, A.A.; Kamensky, A.A. 2014: P.1.g.059 A novel analogue of fragment of vasopressin causes decrease of depression components in rats after neonatal intranasal injection. European Neuropsychopharmacology 24: S237-S238

Udristoiu, T.; Mogoanta, L.; Udristoiu, I.; Marinescu, I.; Marinescu, D. 2014: P.1.g.061 Paliperidone palmitate versus haloperidol decanoate an animal study. European Neuropsychopharmacology 24: S238-S239

Yonguc, G.N.; Dodurga, Y.; Adiguzel, E.; Gundogdu, G.; Kucukatay, V.; Ozbal, S.; Yilmaz, I.; Cankurt, U.; Yilmaz, Y.; Akdogan, I. 2014: P.1.g.064 Effects of grape seed extract and vitamin E on oxidative stress and apoptosis in the hippocampus of rats with streptozotocin-induced diabetes. European Neuropsychopharmacology 24: S240-S241

Borroto Escuela, D.O.; Calvo, F.; Narvaez, M.; Romero-Fernandez, W.; Millon, C.; DiPalma, M.; Pérez-Alea, M.; Tena, M.; Agnati, L.F.; Tarakanov, A.O.; Garriga, P.; Díaz-Cabiale, Z.; Fuxe, K. 2014: P.1.g.067 The GalR1GalR2 heteroreceptor complex can be the receptor for galanin fragment 115. European Neuropsychopharmacology 24: S242-S243

Guercio, G.D.; Madeira, C.; Bevictori, L.E.; Vargas-Lopes, C.; Panizzutti, R. 2014: P.1.g.069 D-serine prevents cognitive deficits caused by acute stress. European Neuropsychopharmacology 24: S243-S244

Marinova, Z.; Walitza, S.; Grünblatt, E. 2014: P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells. European Neuropsychopharmacology 24: S244-S245

Heal, D.; Gosden, J.; Prow, M.R.; Hutson, P.H.; Cheetham, S.C. 2014: P.1.g.074 Acquired binge-eating behaviour produces alterations in dopaminergic neurochemistry in the brains of rats. European Neuropsychopharmacology 24: S246-S247

Rodrigues, F.T.S.; Borella, V.C.M.; Almeida, A.B.; Monte, A.S.; Souza, M.R.M.; Santos Junior, M.A.; Gomes, P.X.L.; Queiroz, A.I.G.; Souza, G.C.; Macêdo, D.S.; Vale, O.C.; Vasconcelos, S.M.M. 2014: P.1.g.076 The neuroprotective effect of Erythrina velutina on cerebral ischemia in mice. European Neuropsychopharmacology 24: S247-S248

Surchev, K.; Surcheva, S.; Surchev, L.; Vlaskovska, M. 2014: P.1.g.079 Effect of a 5-Ht2A/2C receptor agonist on spinal glial activation. European Neuropsychopharmacology 24: S249-S250

Tosic, J.; Karapandza, K.; Stanojevic, Z.; Isakovic, A. 2014: P.1.g.081 Desloratadine exerts antitumor effect against glioma cell lines. European Neuropsychopharmacology 24: S250-S251

Oliveira, R.; Romanini, C.V.; Ferreira, E.D.F.; Soares, L.M.; Milani, H. 2014: P.1.g.083 Effects of apocynin on retrograde memory dysfunction and glial response induced by transient global cerebral ischemia in rats. European Neuropsychopharmacology 24: S251-S252

Gillougley, C.; Rentesi, G.; LeBeau, F.; Cunningham, M.; Alvaro, G.; Large, C. 2014: P.1.g.086 Divergent actions of a Kv3 positive modulator on gamma frequency oscillations in the mammalian neocortex in vitro. European Neuropsychopharmacology 24: S253-S254

Krupina, N.; Khlebnikova, N.; Kushnareva, E.; Kudrin, V. 2014: P.1.g.088 Prolyl endopeptidase inhibitor prevents changes in the monoaminergic systems in the brain of rats with anxiety-depressive state. European Neuropsychopharmacology 24: S254-S255

Licheri, V.; Talani, G.; DiLucente, J.; Biggio, G.; Sanna, E. 2014: P.1.g.089 Ethanol modulates in a biphasic manner hyperpolarisation-activated currents (Ih) in rat hippocampal Ca3 pyramidal neurons. European Neuropsychopharmacology 24: S255-S256

McGowan, F.; Rea, K.; Khalid, S.; Roche, M.; Finn, D.P. 2014: P.1.g.091 The endocannabinoid system in the prelimbic cortex mediates fear-conditioned analgesia in rats. European Neuropsychopharmacology 24: S256-S257

Nikolic, T.; Petronijevic, M.; Stojkovic, T.; Velimirovic, M.; Jevtic, G.; Radonjic, N.; Nenadovic, M.; Petronijevic, N. 2014: P.1.g.092 Sexual dimorphism in rats perinatally treated with phencyclidine: effects of antipsychotics on bone mass and body composition. European Neuropsychopharmacology 24: S257-S258

Romano, G.L.; Bucolo, C.; Platania, C.B.M.; Leggio, G.M.; Salomone, S.; Drago, F. 2014: P.1.g.095 Age-related neurodegenerative diseases: what we can learn from glaucoma. European Neuropsychopharmacology 24: S259-S260

Rusu, G.; Lupusoru, C.E.; Nechifor, M.; Ciubotariu, D.; Popa, E.G.; Mititelu-Tartau, L. 2014: P.1.g.097 The effects of some serotonin receptor antagonists on memory processes performance in rats. European Neuropsychopharmacology 24: S260-S261

Neganova, M.E.; Klochkov, S.G.; Afanasieva, S.V.; Chudinova, E.S.; Serkova, T.P.; Shevtsova, E.F. 2014: P.1.g.098 Allomargaritarine as a basis for the creation of mitochondrial targeted potential neuroprotectors. European Neuropsychopharmacology 24: S261-S262

Hansen, H.D.; DaCunha-Bang, S.; Svarer, C.; Knudsen, G.M. 2014: P.1.g.100 Validation of the extended simplified reference tissue model for pharmacological within-scan challenges in dynamic Pet. European Neuropsychopharmacology 24: S262-S263

Spiacci, G.; Resstel, L.B.M. 2014: P.1.g.102 Modulation of the conditioned emotional response by dorsal hippocampus Trpv1 receptor. European Neuropsychopharmacology 24: S263-S264

Doboszewska, U.; Szewczyk, B.; Sowa-Kucma, M.; Mlyniec, K.; Ostachowicz, B.; Nowak, G. 2014: P.1.g.105 Effect of dietary zinc deprivation on expression of Nmda receptor subunits and depressive-like behaviour: a time-course study. European Neuropsychopharmacology 24: S265-S266

Puerta, E.; Erburu, M.M.; Soriano, M.; Muñoz-Cobo, I.; Beltran, E.; Tordera, R.M. 2014: P.1.g.108 Differential regulation of synaptic plasticity markers and behaviour by histone deacetylase inhibitors. European Neuropsychopharmacology 24: S267-S268

Brito Cortez Lima, E.; Soares de Sousa, C.N.; Nascimento Meneses, L.; Coelho Ximenes, N.; Jonas Gonçalves Maia, P.; Silva Vasconcelos, G.; Freitas e Silva Pereira, Y.; Silvano Monteiro, V.; Brito Cortez Lima, N.; Mendes Vasconcelos, S.M. 2014: P.1.g.110 Evaluation of oxidative stress of Cocos nucifera L. extract on the central nervous system of mice. European Neuropsychopharmacology 24: S268-S269

Petronijevic, N.; Jevtic, G.; Nikolic, T.; Mircic, A.; Stojkovic, T.; Trajkovic, V.; Markovic, I.; Velimirovic, M.; Trbovich, A.; Radonjic, N. 2014: P.1.g.112 Mitochondrial impairment, apoptosis and autophagy in the rat brain as immediate and long term effects of perinatal phencyclidine treatment. European Neuropsychopharmacology 24: S269-S270

Falconi-Sobrinho, L.L.; Almada, R.C.; DeFreitas, R.L.; Coimbra, N.C. 2014: P.1.g.114 Anterior cingulum Nmda receptors modulate fear-induced antinociception evoked by Gabaergic dysfunction in posterior hypothalamus. European Neuropsychopharmacology 24: S270-S271

Mutlu, O.; Ulak, G.; Celikyurt, I.; Akar, F.; Bektas, E.; Tanyeri, P. 2014: P.1.h.002 Asenapine and paliperidone exert antidepressant- and anxiolytic-like effects in mice. European Neuropsychopharmacology 24: S271-S272

Burjanadze, M.; Naneishvili, T.; Dashniani, M.; Chkhikvishvili, N.; Chighladze, M. 2014: P.1.h.004 Spatial long-term memory and modulation of Nmda receptor subunit expression in medial septal immunolesioned rats. European Neuropsychopharmacology 24: S272-S273

Chkhikvishvili, N.; Kruashvili, L.; Meparishvili, M.; Dashniani, M.; Burjanadze, M.; Naneishvili, T.; Beselia, G. 2014: P.1.h.006 Modulation of Nr2B subunit expression of Nmda receptors in the hippocampus and spatial short-term memory by septohippocampal projections. European Neuropsychopharmacology 24: S273-S274

Morozova, A.; Zubkov, E.A.; Storozheva, Z.I.; Chekhonin, V.P. 2014: P.1.h.008 A new model of depression-like behaviour in rodents for screening of prospective drugs with antidepressant action. European Neuropsychopharmacology 24: S274-S275

Burke, N.N.; Deaver, D.R.; Finn, D.P.; Roche, M.; Kelly, J.P. 2014: P.1.h.011 The effects of subacute administration of buprenorphine and the novel opioid modulator samidorphan on home-cage locomotor activity in rats. European Neuropsychopharmacology 24: S276-S277

Saghazadeh, M.; Mesdaghinia, A. 2014: P.1.h.013 Involvement of Cck receptors in morphine-induced antinociception in an animal model of neuropathic pain. European Neuropsychopharmacology 24: S277-S278

Samardzic, J.; Svob Strac, D.; Baltezarevic, D.; Petrovic, K.; Djuric, M.; Obradovic, D.I. 2014: P.1.h.015 Neurosteroid dehydroepiandrosterone improves active avoidance learning in the rat. European Neuropsychopharmacology 24: S278-S279

Plucinska, K.; Jerzemowska, G.; Herman, A. 2014: P.1.h.018 Mk-801 injection into pedunculopontine tegmental nucleus alters behaviour elicited by ipsilateral stimulation of the mesolimbic system. European Neuropsychopharmacology 24: S280-S281

Ullah, F.; Dos Anjos-Garcia, T.; DeOliveira, R.; Santos, I.R.; Coimbra, N.C. 2014: P.1.h.020 Independent periaqueductal gray and hypothalamic circuits for flight response and oriented behaviours elicited by innate fear. European Neuropsychopharmacology 24: S281-S282

Basar, K.; Sesia, T.; Pelloux, Y.; Paleressompoulle, D.; Temel, Y.; Baunez, C. 2014: P.1.h.022 Effect of nucleus accumbens deep brain stimulation on impulsive choice: core versus shell. European Neuropsychopharmacology 24: S282-S283

Seffer, D.; Krug, A.; Rippberger, H.; Dietsche, B.; Backes, H.; Schwarting, W.; Kircher, T.; Wöhr, M. 2014: P.1.h.026 Advanced paternal age as a risk factor for social deficits: from rats to humans. European Neuropsychopharmacology 24: S284-S285

Süer, C.; Nurcan, D.; Kavraal, S.; Bitiktas, S.; Tan, B. 2014: P.1.h.028 Selenium supplementation may reduce impaired long-term potentiation and long-term depression induced by propylthiouracil treatment. European Neuropsychopharmacology 24: S285-S286

Sanna, F.; Piludu, M.A.; Corda, M.G.; Argiolas, A.; Giorgi, O.; Melis, M.R. 2014: P.1.h.031 Dopamine is involved in the different copulatory patterns of Roman high and low avoidance rats: studies with apomorphine and haloperidol. European Neuropsychopharmacology 24: S287-S288

Marchette, R.C.N.; Santos, S.; Lima, T.C.M. 2014: P.1.h.033 Influence of housing conditions on social defeat paradigm in mice. European Neuropsychopharmacology 24: S288-S289

Ptaszek, K.; Plucinska, K.; Grembecka, B.; Glac, W.; Myslinska, D.; Jurkowlaniec, E. 2014: P.1.h.035 The influence of electrical stimulation of raphe magnus on immunological parameters in the peripheral blood of rats a pilot study. European Neuropsychopharmacology 24: S289-S290

Alttoa, A.; Post, A.; Weissflog, L.; Reif, A. 2014: P.1.h.038 Early life stress and neuronal nitric oxide synthase deficiency: effects on affective behaviour. European Neuropsychopharmacology 24: S291-S292

Schraut, K.; Leibold, N.; Weidner, M.T.; Schmitt, A.G.; Förstner, K.; Ortega, G.; Van den Hove, D.L.; Lesch, K.P. 2014: P.1.h.040 Differential effects of prenatal stress in female 5-Htt deficient mice: towards molecular mechanisms of resilience. European Neuropsychopharmacology 24: S292-S293

Soares, L.; Prickaerts, J.; Mori, M.A.; Schiavon, A.P.; Milani, H.; DeOliveira, R.M.W. 2014: P.1.h.042 Rolipram improves functional outcome in mice subjected to bilateral common carotid artery occlusion. European Neuropsychopharmacology 24: S293-S294

Popp, S.; Frey, A.; Siren, A.L.; Schmitt, A.; Hommers, L.; Ertl, G.; Lesch, K.P.; Frantz, S. 2014: P.1.h.043 Chronic heart failure and depression: anhedonia, motivation deficits, and functional brain changes in mice with myocardial infarction. European Neuropsychopharmacology 24: S294-S295

Albac, C.; Dauphinot, L.; Delatour, B.; Santin, M.D.; Potier, M.C. 2014: P.1.h.045 Down syndrome model characterisation: gene expression after treatment with selective 5 Gabaa modulator and quantification of metabolites. European Neuropsychopharmacology 24: S295-S296

Saar-Ashkenazy, R.; Guez, J.; Shalev, H.; Friedman, A.; Cohen, J. 2014: P.1.i.001 Altered event-related potentials during visual emotional stimulation in posttraumatic stress disorder. European Neuropsychopharmacology 24: S296-S297

Go, H.; Choi, J.; Jeong, B.; Jun, T. 2014: P.1.i.002 Subcortical shape and diffusion tensor findings in children with Adhd with and without co-existing tic disorder. European Neuropsychopharmacology 24: S297-S298

Shmeleva, L.; Kissin, M. 2014: P.1.i.004 Resting-state functional connectivity in temporal lobe epilepsy patients with affective symptoms. European Neuropsychopharmacology 24: S298-S299

Kim, M.; Kim, B.; Kim, J.; Choi, T.; Kim, T.; Lee, S. 2014: P.1.i.006 Brain white matter connectivity associated with treatment response to paliperidone Er treatment in patients with schizophrenia. European Neuropsychopharmacology 24: S299-S300

Seiger, R.; Hahn, A.; Küblböck, M.; Kranz, G.S.; Hummer, A.; Ganger, S.; Spies, M.; Windischberger, C.; Kasper, S.; Lanzenberger, R. 2014: P.1.i.007 Modulatory effects of cross-sex steroid hormones in the adult human brain: a voxel-based morphometry study. European Neuropsychopharmacology 24: S300-S301

Symonds, C.S.; McKie, S.; Elliott, R.; McAllister-Williams, R.H.; Ferrier, I.N.; Deakin, W.; Anderson, I.M. 2014: P.1.i.009 Emotional and working memory in treatment resistant depression: a functional magnetic resonance imaging study. European Neuropsychopharmacology 24: S301-S302

Kim, B.; Kim, J.H.; Lee, S.H.; Choi, T.K. 2014: P.1.i.011 The effects of the Vrk2 (rs2312147) gene on white matter connectivity in patients with schizophrenia. European Neuropsychopharmacology 24: S302-S303

Bossong, M.G.; Schubart, C.D.; Van Hell, H.H.; Iseger, T.A.; Van Saane, W.; Jager, G.; Van Osch, P.; Jansma, J.M.; Kahn, R.S.; Boks, M.P.; Ramsey, N.F. 2014: P.1.i.012 Genetic modulation of acute effects of delta-9-tetrahydrocannabinol (Thc) on resting state brain function. European Neuropsychopharmacology 24: S303-S304

Sugranyes, G.; Dela Serna, E.; Padros, M.; Calvo, A.; Sanchez-Gistau, V.; Romero, S.; Sole-Padulles, C.; Moreno, D.; Baeza, I.; Castro-Fornieles, J. 2014: P.1.i.014 Neurostructural characteristics of child and adolescent schizophrenia and bipolar offspring: a comparative, longitudinal study. European Neuropsychopharmacology 24: S304-S305

Baldinger, P.; Hahn, A.; Rami-Mark, C.; Spies, M.; Wadsak, W.; Höflich, A.; Mitterhauser, M.; Lanzenberger, R.; Kasper, S. 2014: P.1.i.015 Neural correlates of the anxiolytic effects of silexan. European Neuropsychopharmacology 24: S305-S306

Sato, H.; Dresler, T.; Nieratschker, V.; Farger, G.; Fallgatter, A.; Ehlis, A.C. 2014: P.1.i.017 Independent effects of acute tryptophan depletion on mood and cortical activation during working memory tasks. European Neuropsychopharmacology 24: S306-S307

Cremaschi, L.; Palazzo, M.C.; DiGiorgio, A.; Cristoffanini, M.; Fazio, L.; Cinnante, C.; Avignone, S.; Dobrea, C.; Triulzi, F.; Bertolino, A.; Dell'Osso, B.; Altamura, A.C. 2014: P.1.i.020 A 3T functional magnetic resonance imaging study with N-back task to assess working memory activation in euthymic bipolar I and Ii patients. European Neuropsychopharmacology 24: S308-S309

Charlet, K.; Beck, A.; Jorde, A.; Vollstädt-Klein, S.; Gallinat, J.; Walter, H.; Kiefer, F.; Heinz, A. 2014: P.1.i.022 Neural activity during the n-back working memory task predicts relapse risk in alcohol dependence. European Neuropsychopharmacology 24: S309-S310

Setiawan, E.; Wilson, A.A.; Mizrahi, R.; Rusjan, P.M.; Miler, L.; Rajkowska, G.; Suridjan, I.; Kennedy, J.L.; Rekkas, P.V.; Houle, S.; Meyer, J.H. 2014: P.1.i.023 Increased translocator protein distribution volume, a marker of microglial activation, in the brain during major depressive episodes. European Neuropsychopharmacology 24: S310-S311

Kraus, C.; Hahn, A.; Pfabigan, D.M.; Küblböck, M.; Seidel, E.M.; Sladky, R.; Kasper, S.; Windischberger, C.; Lamm, C.; Lanzenbeger, R. 2014: P.1.i.025 Gray matter changes associated with factors of alexithymia in healthy young adults. European Neuropsychopharmacology 24: S311-S312

Schrantee, A.; Ferguson, B.; Stoffers, D.; Reneman, L. 2014: P.1.i.028 Effects of dexamphetamine on frontostriatal network connectivity in recreational users. European Neuropsychopharmacology 24: S313-S314

Simon, M.; Varga, E.; Hajnal, A.; Orsi, G.; Herold, R.; Fekete, S.; Tenyi, T. 2014: P.1.i.030 Neural substrates of irony comprehension: are there any gender differences?. European Neuropsychopharmacology 24: S314-S315

Rizvi, S.; Cyriac, A.; Rusjan, P.; Strafella, A.; Sproule, B.A.; Giacobbe, P.; Lozano, A.; Kennedy, S.H. 2014: P.1.i.033 Predictors of Dbs response: the impact of anhedonia and dopamine. European Neuropsychopharmacology 24: S316-S317

Calvo, R.; Rosa, M.; Puig, O.; Calvo, A.; Bargalló, N.; Lázaro, L. 2014: P.1.i.035 Abnormalities within visual networks relate to differences in complex visual performance in pediatric autism spectrum disorder. European Neuropsychopharmacology 24: S317-S318

Kim, T.; Kim, J.H.; Lee, S.H.; Kim, B. 2014: P.1.i.036 Frontal white matter alterations in panic disorder patients without comorbid conditions: a diffusion tensor imaging study. European Neuropsychopharmacology 24: S318-S319

Gazarini, L.; Stern, C.A.J.; Takahashi, R.N.; Bertoglio, L.J. 2014: P.1.j.001 Combined pharmacological intervention targeting the glucocorticoidadrenergicendocannabinoid circuitry induces a traumatic memory. European Neuropsychopharmacology 24: S319-S320

Demirtas, T.; Utkan, T.; Yazir, Y.; Karson, A.; Balci, F.; Bayramgurler, D. 2014: P.1.j.005 Infliximab rescues cognitive impairment induced by unpredictable chronic mild stress in a rat model of depression. European Neuropsychopharmacology 24: S321-S322

Adamia, I.; Roinishvili, M. 2014: P.1.j.007 Short- and long-term alteration in cognitive functioning of patients with schizophrenia. European Neuropsychopharmacology 24: S322-S323

Mhalla, A.; Essid, N.; Bouh, F.H.; Beltaief, F.; Elloumi, H.; Gaha, L. 2014: P.1.j.008 Cognitive insight in schizophrenia: study about 30 Tunisian patients. European Neuropsychopharmacology 24: S323-S324

Kurzbuch, K.; Pauli, E.; Chang, B.S.; Romatoski, K.; Barnard, M.E.; Kasper, B.S. 2014: P.1.j.010 Neuropsychological profiles in periventricular nodular heterotopia. European Neuropsychopharmacology 24: S324-S325

Kopf, J.; Kamawal, A.; Dresler, T.; Hahn, T.; Reicherts, P.; Reif, A. 2014: P.1.j.013 Nos1ex1f-Vntr alters prefrontal activation in a set shifting task. European Neuropsychopharmacology 24: S326-S327

Yüksek, E.; Eroz, S.; Yassa, A.; Akturk, D.; Zakirov, F.; Akcam, F.E.; Emul, M. 2014: P.1.j.015 The effects of brain radiotherapy on facial emotion recognition and association with hippocampal and frontal dosimetry. European Neuropsychopharmacology 24: S327-S328

Espinoza, S.; Lignani, G.; Sukhanov, I.; Caffino, L.; Maggi, S.; Leo, D.; Tucci, V.; Fumagalli, F.; Gainetdinov, R.R. 2014: P.1.j.018 Taar1 deficiency produces frontostriatal dysfunctions. European Neuropsychopharmacology 24: S329-S330

Dorofeikova, M.; Petrova, N. 2014: P.1.j.020 Characterisation of cognitive functioning in schizophrenia and schizoaffective disorder. European Neuropsychopharmacology 24: S330-S331

Dirzius, E.; Zukauskaite, G.; Vebraite, B.; Leskauskas, D.; Bulatov, A. 2014: P.1.j.021 Mller Lyer illusion manifestation peculiarities among people with paranoid schizophrenia. European Neuropsychopharmacology 24: S331-S332

Pandova, M.; Hranov, L.G. 2014: P.1.j.023 Cognitive impairment in schizophrenia and bipolar disorder during the lifetime. European Neuropsychopharmacology 24: S332-S333

Almeida-Correa, S.; Moulin, T.C.; Carneiro, C.F.D.; Gonçalves, M.M.C.; Amaral, O.B. 2014: P.1.j.024 Calcineurin inhibition has different effects on within- and between-session fear extinction in mice. European Neuropsychopharmacology 24: S333-S334

Seedat, S.; Spies, G.; Ahmed-Leitao, F.; Fennema-Notestine, C.; Cherner, M. 2014: P.1.j.026 Effects of Hiv and childhood trauma on brain morphometry and neurocognitive function. European Neuropsychopharmacology 24: S334-S335

Stankevich, Y.; Evens, R.; Riedel, O.; Storch, A.; Lueken, U. 2014: P.1.j.028 Behavioural and neural correlates of cognitive control in Parkinson's disease. European Neuropsychopharmacology 24: S335-S336

Louzolo, A.; Kalckert, A.; Ehrsson, H.; Petrovic, P. 2014: P.1.j.031 When passive feels active reduced motor predictions and hypersalience alter moving rubber hand illusion in delusion proneness. European Neuropsychopharmacology 24: S337-S338

Smolders, R.; Mazaheri, A.; Figee, M.; Van Wingen, G.; Van de Munckhof, P.; Schuurman, P.R.; Denys, D. 2014: P.1.j.033 Symptom provocation induces low-frequency oscillations in the ventral striatum of patients with obsessivecompulsive disorder. European Neuropsychopharmacology 24: S338-S339

Bagci, B.; Sarioglu, Y.; Yazir, Y.; Utkan, T.; Aricioglu, F. 2014: P.1.j.037 Agmatine attenuates vascular dementia in ageing. European Neuropsychopharmacology 24: S340-S341

Bahk, W.M.; Min, K.J.; Yoon, B.H.; Kim, M.D.; Kwon, Y.J.; Lee, K.H.; Lee, S.Y. 2014: P.1.k.002 Changes in prescription pattern of aripiprazole among psychiatric inpatients. European Neuropsychopharmacology 24: S341-S342

Guillena, S.L.R.; Cejudo, A.D.; Ballesteros, M.E.D.; Saenz, B.M.; Gamito, M.C.R. 2014: P.1.k.004 Historical cohort study in psychiatric emergency care: 20072013. European Neuropsychopharmacology 24: S342-S343

Guillena, S.L.R.; Saenz, B.M.; Gamito, M.C.R.; Cejudo, A.D.; Ballesteros, M.E.D. 2014: P.1.k.005 The economic crisis and mental health. European Neuropsychopharmacology 24: S343-S344

Gonda, X.; Vazquez, G.H.; Rihmer, Z. 2014: P.1.k.007 From genes to temperament to culture: differential distribution of affective temperaments parallels cultural index scores. European Neuropsychopharmacology 24: S344-S345

Kundi, P.; Przybyl, K.; Roldan, A. 2014: P.1.k.010 Prevalence of eating disorders in patients admitted to a female-only psychiatric inpatient unit in the Uk. European Neuropsychopharmacology 24: S346-S347

Tamam, L.; Paltaci, O.; Keskin, N. 2014: P.1.k.012 Characteristics of impulse control disorders in a group of medical students. European Neuropsychopharmacology 24: S347-S348

Jonusiene, G.; Zilaitiene, B.; Adomaitiene, V.; Aniuliene, R. 2014: P.1.k.014 Predictors for development of female sexual dysfunctions in postmenopause. European Neuropsychopharmacology 24: S348-S349

Essawy, H.; Ghanem, M.; Hatab, M.A.; Sabry, A. 2014: P.1.k.015 Childhood depression: screening among Egyptian school children. European Neuropsychopharmacology 24: S349-S350

Mohr, P.; Latalova, K.; Ceplova, Z.; Jelenova, D.; Stopkova, P.; Mikolas, P. 2014: P.1.k.017 Adult Adhd in a general psychiatric population. European Neuropsychopharmacology 24: S350-S351

Thome, J.; Lebrec, J.; Kraemer, S.; Fregenal, I.; Ramos-Quiroga, J.A.; Arif, M.; Deberdt, W. 2014: P.1.k.019 Prevalence of Adhd in non-psychotic adult psychiatric care (Adpsyc): a multinational cross-sectional study in Europe. European Neuropsychopharmacology 24: S351-S352

Krasauskaite, D.; Klimasauskaite, I.; Charkavliuk, A.; Adomaitiene, V.; Babarskiene, M.R.; Jonusiene, G. 2014: P.1.k.022 Sexual function and emotional state of patients with chronic heart failure in Lithuania. European Neuropsychopharmacology 24: S353-S354

Schäfer, J.; Schönfeld, S.; Höfler, M.; Wittchen, H.U. 2014: P.1.k.024 Associations between attentional control and suicidality in German soldiers after deployment in Afghanistan. European Neuropsychopharmacology 24: S354-S355

Siu, C.; Brambilla, C. 2014: P.1.k.025 Pitfalls of using absolute risk score for risk assessment and subtyping. European Neuropsychopharmacology 24: S355-S356

Choi, M.; Gim, M. 2014: P.1.k.027 The disease network of mental disorders in Korea. European Neuropsychopharmacology 24: S356-S357

Giubbolini, G.; Nitti, M.; DiVolo, S.; Costoloni, G.; Durante, F.; Casolaro, I.; Morbidelli, G.; Zanobini, F.; Biagioli, B.; Fagiolini, A. 2014: P.1.k.029 Psychiatric disorders in intensive care unit post cardio-surgery. European Neuropsychopharmacology 24: S357-S358

Juskiene, A.; Podlipskyte, A.; Varoneckas, G.; Alonderis, A.; Bunevicius, R. 2014: P.1.k.032 Associations of obstructive sleep apnea with anxiety and depression symptoms in male patients with coronary artery disease. European Neuropsychopharmacology 24: S359-S360

Tijdink, J.; Smulders, Y.M.; Vergoüwen, A.C.M. 2014: P.1.l.001 Publication pressure and scientific misconduct: implications for medical science. European Neuropsychopharmacology 24: S360-S361

Sapic, R.; Marinkovic, G. 2014: P.2.a.002 Effect of cognitive behavioural therapy, and antidepressant medications on management strategies for cardiovascular diseases. European Neuropsychopharmacology 24: S361-S362

Bezykornoviene, D.; Adomaitiene, V.; Steibliene, V. 2014: P.2.a.003 Anxiety and depression symptoms among patients with type 2 diabetes mellitus and poor glycaemia control. European Neuropsychopharmacology 24: S362-S363

Fedotova, J. 2014: P.2.a.005 Blockade of D1 dopaminergic receptors corrects depression-like behaviour in gonadectomised rats treated with a low dose of testosterone. European Neuropsychopharmacology 24: S363-S364

Bokhan, N.A.; Losenkov, I.S.; Vyalova, N.M.; Simutkin, G.G.; Ivanova, S.A. 2014: P.2.a.008 Correlation between levels of Akt1/Gsk-3 signaling pathway proteins and severity of depressive symptoms. European Neuropsychopharmacology 24: S365-S366

Todtenkopf, M.S.; Dean, R.L.; Eyerman, D.J.; Cunningham, J.I.; Deaver, D.R. 2014: P.2.a.010 Buprenorphine in combination with samidorphan (Alks 33) results in antidepressive-like effects in two distinct rat models. European Neuropsychopharmacology 24: S366-S367

Diniz, C.R.A.F.; Casarotto, P.C.; Joca, S.R.L. 2014: P.2.a.013 Antidepressant like effect of losartan infused into the ventral hippocampus. European Neuropsychopharmacology 24: S368-S369

Leiser, S.C.; Iglesias-Bregna, D.; Sanchez, C. 2014: P.2.a.015 Vortioxetine's reduced disruption of sleepwake rhythms involves 5-Ht3 receptor antagonism a study in rats. European Neuropsychopharmacology 24: S369-S370

Bruzos-Cidon, C.; Ugedo, L.; Torrecilla, M. 2014: P.2.a.018 Dysfunctional inhibitory mechanisms in locus coeruleus neurons of the Wistar Kyoto rat. European Neuropsychopharmacology 24: S371-S372

Ribeiro, D.; Casarotto, P.C.; Biojone, C.; Joca, S.R. 2014: P.2.a.020 Hippocampal P2X7 receptor expression is modulated by stress and antidepressant treatment in the learned helplessness model. European Neuropsychopharmacology 24: S372-S373

Crawford, A.; Lewis, S.; Hodgson, K.; McGuffin, P.; Aitchison, K.; Nutt, D.; Peters, T.; Cowen, P.; O'Donovan, M.; Wiles, N.; Lewis, G. 2014: P.2.a.021 Genome-wide association study of antidepressant-induced sexual dysfunction in depressed males. European Neuropsychopharmacology 24: S373-S374

Maffioletti, E.; Cattaneo, A.; Zanardini, R.; Rosso, G.; Tardito, D.; Gennarelli, M.; Maina, G.; Bocchio-Chiavetto, L. 2014: P.2.a.023 Common and specific blood microRna alterations in unipolar and bipolar depression. European Neuropsychopharmacology 24: S374-S375

Erburu, M.M.; Dominguez, J.; Muñoz-Cobo, I.; Puerta, E.; Tordera, R.M. 2014: P.2.a.024 Regulation of Hdac5 and Sirt2 by chronic stress and imipramine treatment in the prefrontal cortex. European Neuropsychopharmacology 24: S375-S376

Mlyniec, K.; Budziszewska, B.; Skrzeszewski, J.; Holst, B.; Nowak, G. 2014: P.2.a.026 Zinc deficiency versus Gpr39-zinc receptor knockout mice in the pathophysiology of depression. European Neuropsychopharmacology 24: S376-S377

Bahk, W.M.; Min, K.J.; Yoon, B.H.; Kim, M.D.; Kwon, Y.J.; Lee, K.H.; Lee, S.Y. 2014: P.2.b.002 Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. European Neuropsychopharmacology 24: S378-S379

Clayton, A.H.; Gommoll, C.; Chen, D.; Nunez, R.; Mathews, M. 2014: P.2.b.005 Effects of vilazodone on sexual dysfunction in major depressive disorder: randomised, double-blind trial with placebo and active controls. European Neuropsychopharmacology 24: S380-S381

Liaugaudaite, V.; Peceliuniene, J.; Raskauskiene, N.; Bunevicius, R. 2014: P.2.b.007 Prevalence and psychiatric correlates of suicidal ideation in primary care patients: gender differences. European Neuropsychopharmacology 24: S381-S382

Kayser, S.; Bewernick, B.H.; Switala, C.; Gippert, S.M.; Schlaepfer, T.E. 2014: P.2.b.011 Stable autobiographical memory function in magnetic seizure therapy. European Neuropsychopharmacology 24: S383-S384

Balestri, M.; Calati, R.; Souery, D.; Kasper, S.; Montgomery, S.; Zohar, J.; Mendlewicz, J.; Serretti, A. 2014: P.2.b.013 Socio-demographic and clinical predictors of antidepressant remission and response in treatment resistant depression. European Neuropsychopharmacology 24: S384-S385

Català, M.C.; Zalacain, I.M.; Goldberg, X.; Via, E.; Rodríguez, O.C.; Hernández, R.; Pujol, J.; Menchón, J.M.; Mas, C.S.; Cardoner, N. 2014: P.2.b.014 Modulation of limbicprefrontal connectivity by electroconvulsive therapy in depression: a structural equation modeling approach. European Neuropsychopharmacology 24: S385-S386

Khan, A.; Gommoll, C.; Mathews, M.; Chen, D.; Nunez, R. 2014: P.2.b.016 Efficacy and safety of vilazodone 20 mg and 40 mg in major depressive disorder (Mdd): a randomised, double-blind, placebo- and active-controlled trial. European Neuropsychopharmacology 24: S386-S387

Singh, J.; Fedgchin, M.; Daly, E.; DeBoer, P.; Cooper, K.; Lim, P.; Pinter, C.; Murrough, J.; Sanacora, G.; Shelton, R.; Kurian, B.; Winokur, A.; Fava, M.; Manji, H.; Drevets, W. 2014: P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study. European Neuropsychopharmacology 24: S387-S388

Mandelli, L.; Emiliani, R.; Porcelli, S.; Fabbri, C.; Albani, D.; Serretti, A. 2014: P.2.b.019 The complexity of genetic effects in pharmacogenetics: focus on neuroplasticity, environmental stress and response to antidepressants. European Neuropsychopharmacology 24: S388-S389

Vasile, D.; Vasiliu, O.; Bratu, R.E.; Sopterean, G.A.; Vasile, F.; Ojog, D.G. 2014: P.2.b.020 Comparative analysis of pregabalin and buspirone as adjunctive agents in major depressive disorder partially responsive to Ssris. European Neuropsychopharmacology 24: S389-S390

Bagdy, G.; Hullam, G.; Eszlari, N.; Gonda, X.; Antal, P.; Anderson, I.M.; Hökfelt, T.G.; Deakin, J.F.W.; Juhasz, G. 2014: P.2.b.022 Different genes modulate risk for depression after childhood maltreatment and recent negative life events. European Neuropsychopharmacology 24: S390-S391

Komulainen, E.; Meskanen, K.; Heikkilä, R.; Nummenmaa, L.; Raij, T.; Isometsä, E.; Ekelund, J. 2014: P.2.b.023 A single dose of mirtazapine modulates neuronal responses to spoken emotional narratives in healthy volunteers. European Neuropsychopharmacology 24: S391-S392

Mihailescu, A.I.; Matei, V.P.; Al-Bataineh, R. 2014: P.2.b.025 Depression in people with early onset of somatic illness analysis of 1970 British Cohort Study. European Neuropsychopharmacology 24: S392-S393

Martinotti, G.; DiGiannantonio, M. 2014: P.2.b.028 Agomelatine antidepressant activity and serum concentration of brain-derived neurotrophic factor (Bdnf): a positive correlation. European Neuropsychopharmacology 24: S394-S395

Soria, V.; Labad, J.; Salvat, N.; DeArriba, A.; Segaiàs, C.; Real, E.; Urretavizcaya, M.; Menchón, J.M. 2014: P.2.b.030 Interaction between depression remission status and salivary cortisol in relation to cognitive function in major depressive disorder. European Neuropsychopharmacology 24: S395-S396

Mocking, R.J.T.; Verburg, H.F.; Westerink, A.M.; Assies, J.; Vaz, F.M.; Koeter, M.W.J.; Ruhé, H.G.; Schene, A.H. 2014: P.2.b.031 Longitudinal interplay between paroxetine response, cortisol and fatty acid metabolism in major depressive disorder. European Neuropsychopharmacology 24: S396-S397

Allen, A.P.; Naughton, M.; Clarke, G.; Dowling, J.; Walsh, A.; Ismail, F.; Shorten, G.; Scott, L.; Cryan, J.F.; Dinan, T.G. 2014: P.2.b.032 Serum brain-derived neurotrophic factor and symptom improvements post-ketamine treatment in treatment-resistant depression. European Neuropsychopharmacology 24: S397-S398

Falconi, A.; Dell'Osso, B.; DiFrancesco, A.; Palazzo, M.C.; Benatti, B.; Galimberti, B.; Altamura, A.C.; Maccarrone, M.; Dainese, E.; D'Addario, C. 2014: P.2.b.034 Affective disorders and epigenetics: study of possible mechanisms and biological targets. European Neuropsychopharmacology 24: S398-S399

Meskanen, K.; Komulainen, E.; Lipsanen, J.; Lahti, J.; Ekelund, J.; Isometsä, E. 2014: P.2.b.036 Attachment style, alexithymia and social support affect emotional states and experiences. European Neuropsychopharmacology 24: S399-S400

Mikoteit, T.; Beck, J.; Hemmeter, U.; Eckert, A.; Brand, S.; Bischof, R.; Delini-Stula, A.; Holsboer-Trachsler, E. 2014: P.2.b.037 Increase of alertness correlates with early brain-derived neurotrophic factor serum level rise and treatment outcome in major depression. European Neuropsychopharmacology 24: S400-S401

Ristevska-Dimitrovska, G.; Shishkov, R. 2014: P.2.b.039 Different serum levels of brain-derived neurotrophic factor in first depressive episode: results from Bdnf studies in Macedonia and Bulgaria. European Neuropsychopharmacology 24: S401-S402

Juruena, M.F.; Cleare, A.J.; Poon, L.; Papadopoulos, A.S.; Lightman, S.; Pariante, C.M. 2014: P.2.b.040 Mr and Gr balance predicts treatment outcome in treatment resistant depression. European Neuropsychopharmacology 24: S402-S403

Heun, R.; Corral, R.; Ahokas, A.; Nicolini, H.; Teixeira, J.M.; Dehelean, P.; Picarel-Blanchot, F.; DeBodinat, C. 2014: P.2.b.042 Sustained efficacy and safety of agomelatine versus placebo over 24 weeks in elderly out-patients suffering from major depressive disorder. European Neuropsychopharmacology 24: S403-S404

Gross, R.; Goral, A.; Grossman, E.; Muhsen, K. 2014: P.2.b.043 Hypertension, depressive symptoms, and risk behaviors: results from a national health survey. European Neuropsychopharmacology 24: S404-S405

Kennedy, S.; Avedisova, A.; Picarel-Blanchot, F.; DeBodinat, C. 2014: P.2.b.045 Efficacy of 3 agomelatine dose regimens versus placebo on the core symptoms of depression and functioning. European Neuropsychopharmacology 24: S405-S406

Iacovides, A.; Grammatikou, V.; Roukas, D.; Ferentinos, P. 2014: P.2.b.047 Efficacy of agomelatine in everyday clinical practice: results from a pan-Hellenic study: Sesame. European Neuropsychopharmacology 24: S406-S407

Kittel-Schneider, S.; Reuss, M.; Weber, H.; Lesch, K.P.; Reif, A. 2014: P.2.c.001 Multi-level biomarker analysis of nitric oxide synthase isoforms in bipolar disorder and adult Adhd. European Neuropsychopharmacology 24: S407-S408

Haddjeri, N.; Abrial, E.; Arnt, J.; Didriksen, M.; Lambás-Señas, L. 2014: P.2.c.002 Asenapine effects on dorsal raphe 5-Ht7 receptor responsiveness and in animal models of mania and resistant depression. European Neuropsychopharmacology 24: S408-S409

Gubert, C.; Fries, G.R.; Pfaffenseller, B.; Ferrari, P.; Coutinho-Silva, R.; Morrone, F.B.; Kapczinski, F.; Battastini, A.M.O. 2014: P.2.c.004 The receptor P2X7 participates in the amphetamine-induced increase of a proinflammatory environment in an animal model of mania. European Neuropsychopharmacology 24: S409-S410

Kirkham, E.; Skinner, J.; Anderson, T.; Bazire, S.; Twigg, M.J.; Desborough, J.A. 2014: P.2.c.006 What does lithium do to your creatinine?. European Neuropsychopharmacology 24: S410-S411

Sarrazin, S.; D'Albis, M.A.; McDonald, C.; Poupon, C.; Wessa, M.; Linke, J.; Phillips, M.; Delavest, M.; Emsell, L.; Versace, A.; Almeida, J.; Mangin, J.F.; LeDudal, K.; Daban, C.; Hamdani, N. 2014: P.2.c.007 An international multicenter study of areas of the corpus callosum in bipolar disorder with and without psychotic features. European Neuropsychopharmacology 24: S411-S412

Pfaffenseller, B.; Fries, G.R.; Vasconcelos-Moreno, M.P.; Gubert, C.; Santos, B.T.M.Q.dos; Sartori, J.; Eisele, B.; Ferrari, P.; Fijtman, A.; Rüegg, J.; Gassen, N.C.; Kapczinski, F.; Rein, T.; Kauer-Sant'Anna, M. 2014: P.2.c.009 Epigenetically-induced modulation of the stress axis associated with the progression of bipolar disorder. European Neuropsychopharmacology 24: S412-S413

Uslu, E.; Kara, S. 2014: P.2.d.001 Investigation of bipolar subtypes which have been proposed to have different genetic etiology with respect to neurocognitive functions. European Neuropsychopharmacology 24: S413-S414

Manea, M.; Miclutia, I.; Stefanescu, C.; Teodorescu, R. 2014: P.2.d.003 Wave-bd a large observational ambispective study: comparative results between the Romanian cohort and the total study population. European Neuropsychopharmacology 24: S414-S415

Song, H.R.; Woo, Y.S.; Bahk, W.M.; Min, K.J.; Yoon, B.H.; Kim, M.D.; Kwon, Y.J.; Lee, K.H.; Lee, S.Y. 2014: P.2.d.005 The current state of maintenance treatments for bipolar patients: a focus on the transition from acute treatments. European Neuropsychopharmacology 24: S415-S416

Buoli, M.; Caron, L.; Melter, C.C.; Caldiroli, A.; Dobrea, C.; Cigliobianco, M.; Zanelli, F.; Altamura, A.C. 2014: P.2.d.007 Misdiagnosis and role of duration of untreated illness (Dui)/untreated psychosis (Dup) in psychotic bipolar patients. European Neuropsychopharmacology 24: S416-S417

Guillena, S.L.R.; Gotor, F.; Santamaría, O. 2014: P.2.d.008 Cognitive deficits and subjective well-being in bipolar disorder. European Neuropsychopharmacology 24: S417-S418

Ugur, K.; Tamam, L.; Ozpoyraz, N.; Keskin, N. 2014: P.2.d.010 Assessment of suicidal behaviour in bipolar disorder. European Neuropsychopharmacology 24: S418-S419

Young, A.; Eberhard, J. 2014: P.2.d.013 Evaluating depressive symptoms in mania study using a structured diagnostic tool, the Dsm-5 with mixed features specifier Mini module. European Neuropsychopharmacology 24: S420-S421

Ferensztajn, E.; Skibinska, M.; Kaczmarek, M.; Losy, J.; Rybakowski, J.K. 2014: P.2.d.015 Mood disorders in the offspring of lithium treated bipolar patients clinical and neurobiological correlates. European Neuropsychopharmacology 24: S421-S422

Parikh, S.; Hawke, L.; Velyvis, V. 2014: P.2.d.017 Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. European Neuropsychopharmacology 24: S422-S423

Pålsson, E.; Lundberg, U.; Johnson, L.; Ekman, C.J.; Sellgren, C.; Landén, M. 2014: P.2.d.018 Sense of coherence as a predictor of suicide attempts in bipolar disorder. European Neuropsychopharmacology 24: S423-S424

Barral, D.; Cruz, N.; Molina, J.D.; Sánchez, M.V.; Rosique, M.T.; Castrillo, M.; Fernández, A.; Barral, F. 2014: P.2.d.020 Impact of alcohol use disorder in a sample of bipolar patients. European Neuropsychopharmacology 24: S424-S425

Hidalgo-Mazzei, D.; Undurraga, J.; Bonnin, C.M.; Reinares, M.; Saez, C.; Mur, M.; Nieto, E.; Vieta, E. 2014: P.2.d.021 Understanding the real-world cost and burden of mania: the Manacor study. European Neuropsychopharmacology 24: S425-S426

Yatham, L.N.; Vieta, E.; Lu, K.; Nagy, K.; Laszlovszky, I.; Earley, W.; Durgam, S. 2014: P.2.d.023 Safety and tolerability of cariprazine in patients with acute bipolar mania: pooled analysis of 3 phase Ii/Iii pivotal studies. European Neuropsychopharmacology 24: S426-S427

Nieto, E.; Plans, L.; Carreras, J.; Gomez, A. 2014: P.2.d.025 Naturalistic study of either lithium or valproate in combination treatment with antipsychotics for pure manic inpatients. European Neuropsychopharmacology 24: S427-S428

Jakobsson, J.; Isgren, A.; Pålsson, E.; Ekman, C.J.; Johansson, A.G.M.; Sellgren, C.; Blennow, K.; Zetterberg, H.; Landén, M. 2014: P.2.d.028 Microglial activation in mood stabilised bipolar disorder patients. European Neuropsychopharmacology 24: S429-S430

Vai, B.; Radaelli, D.; Papa, G.S.; Poletti, S.; Colombo, C.; Benedetti, F. 2014: P.2.d.030 Effect of total sleep deprivation and light therapy on corticolimbic connectivity in bipolar depression: a dynamic causal modeling study. European Neuropsychopharmacology 24: S430-S431

Niitsu, T.; Fabbri, C.; Serretti, A. 2014: P.2.d.031 Predictors for manic switch at depressive episodes in bipolar disorder: the Systematic Treatment Enhancement Program for Bipolar Disorder. European Neuropsychopharmacology 24: S431-S432

Grande, I.; Magalhães, P.V.; Chendo, I.; Stertz, L.; Panizutti, B.; Colpo, G.D.; Rosa, A.R.; Gama, C.S.; Kapczinski, F.; Vieta, E. 2014: P.2.d.033 Staging bipolar disorder: biological, clinical and functional correlates. European Neuropsychopharmacology 24: S432-S433

Özalp, D.C.T.; Tuna, G.; Kirkali, G.; Tunca, Z.; Dizdaroglu, M.; Can, G.; Arat, H.E.; Ozerdem, A. 2014: P.2.d.035 Base excision repair and oxidative Dna damage in patients with bipolar disorder. European Neuropsychopharmacology 24: S433-S434

Bermúdez-Ampudia, C.; Martínez-Cengotitabengoa, M.; García-Alocén, A.; López, P.; Ugarte, A.; Fernández, M.; Vega, P.; Gonzalez-Pinto, A. 2014: P.2.d.036 Relationship between premorbid adjustment and functionality in mixed episodes of bipolar disorder. European Neuropsychopharmacology 24: S434-S435

Özalp, D.C.T.; Tuna, G.; Kirkali, G.; Tunca, Z.; Dizdaroglu, M.; Can, G.; Arat, H.E.; Ozerdem, A. 2014: P.2.d.038 Oxidative Dna base damage in bipolar disorder. European Neuropsychopharmacology 24: S435-S436

Solé, B.; Bonnin, C.M.; Mayoral, M.; Amann, B.L.; Torres, I.; González-Pinto, A.; Jiménez, E.; Crespo, J.M.; Colom, F.; Tabarés-Seisdedos, R.; Reinares, M.; Ayuso-Mateos, J.L.; Soria, S.; Garcia-Portilla, M.P.; Ibáñez, A. 2014: P.2.d.039 Functional remediation in bipolar Ii patients: improvement of functioning and subsyndromal symptoms. European Neuropsychopharmacology 24: S436-S437

Houtepen, L.; Boks, M.P.M.; Kahn, R.S.; Joëls, M.; Vinkers, C.H. 2014: P.2.d.041 Determinants of acute stress reactivity in euthymic bipolar disorder patients and their unaffected siblings. European Neuropsychopharmacology 24: S437-S438

Najar, H.; Palsson, E.; Landén, M. 2014: P.2.d.043 A naturalistic study of antipsychotic-induced weight gain in bipolar disorder. European Neuropsychopharmacology 24: S438-S439

Atagün, M.; Gonenc, A.; Can, S.S.; Sikoglu, E.M.; Ulusoy-Kaymak, S.S.; Karakas-Ugurlu, G.; Caykoylu, A.; Algin, O.; Moore, C.M.; Ongur, D.; Phillips, M.L. 2014: P.2.d.046 A Dti-tractography study of the uncinate fasciculus in schizophrenia and bipolar disorder: preliminary results. European Neuropsychopharmacology 24: S440-S441

Piccin, S.; Bonivento, C.; Fabbro, D.; Marinelli, V.; Bellani, M.; Paoli, R.A.; Caletti, E.; Cigliobianco, M.; Marsano, A.; Sala, M.; Abbiati, V.; Cappucciati, M.; Dusi, N.; Perlini, C.; Ruggeri, M. 2014: P.2.d.048 Comt modulates working memory and impulsivity control in bipolar disorder. European Neuropsychopharmacology 24: S441-S442

Tan, D.; Yilmaz, T.; Ersan, F.; Karadag, F.; Hariri, A.G.; Ozerdem, A. 2014: P.2.d.049 The neurocognitive profile in adult bipolar disorder and Adhd. European Neuropsychopharmacology 24: S442-S443

Ketter, T.; Pikalov, A.; Sarma, K.; Silva, R.; Kroger, H.; Cucchiaro, J.; Loebel, A. 2014: P.2.d.051 Lurasidone in bipolar I depression: a 24 week, open-label extension study. European Neuropsychopharmacology 24: S443-S444

Thase, M.; Tsai, J.; Kroger, H.; Pikalov, A.; Cucchiaro, J.; Loebel, A. 2014: P.2.d.052 Lurasidone treatment for bipolar I depression: effect on core depression symptoms. European Neuropsychopharmacology 24: S444-S445

Soczynksa, J.; Kennedy, S.H.; Alsuwaidan, M.; Mansur, R.; Li, M.; McAndrews, M.P.; Brietzke, E.; Taylor, V.; McIntyre, R.S. 2014: P.2.d.054 A pilot, open-label, 8-week study evaluating the efficacy of adjunctive minocycline for the treatment of bipolar I/Ii depression. European Neuropsychopharmacology 24: S445-S446

Baskak, B.; Ozel-Kizil, E.T.; Zivrali, E.; Ates, E.; Cihan, B.; Uran, P.; Hosgoren-Alici, Y.; Kirici, S.; Bastug, G. 2014: P.2.d.056 Verbal fluency deficits in patients with schizophrenia, psychotic bipolar disorder and their unaffected relatives. European Neuropsychopharmacology 24: S446-S447

Morais, M.; Pinheiro, A.; Patricio, P.; Alves, D.; Pinto, L.; Sousa, N.; Bessa, J. 2014: P.2.e.003 The impact of antipsychotic drugs in depression: a role for adult neurogenesis?. European Neuropsychopharmacology 24: S448-S449

Rossetti, A.; Calabrese, F.; Savino, E.; Papp, M.; Molteni, R.; Riva, M.A. 2014: P.2.e.005 Regulation of clock gene expression in the chronic mild stress model: modulatory activity of the novel drug lurasidone. European Neuropsychopharmacology 24: S449-S450

Guillena, S.L.R.; Barquero, N.C.; Alcocer-Gómez, E.; Cordero, M.D. 2014: P.2.e.007 Inflammasome complex is implicated in the severity of major depressive disorder. European Neuropsychopharmacology 24: S450-S451

Pan, Y.J.; Kuo, K.H. 2014: P.2.f.001 Pharmacological treatment of depression with headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants. European Neuropsychopharmacology 24: S451-S452

Lee, K.; Lee, J.B.; Park, Y.W.; Lee, J.H.; Lee, S.J.; Koo, B.H.; Sung, H.M.; Cheon, E.J. 2014: P.2.f.003 Comparison of aripiprazole augmentation versus bupropion combination for patient with major depressive disorder. European Neuropsychopharmacology 24: S452-S453

Daly, E.; Kent, J.; Drevets, W.; Kezic, I.; Lane, R.; Lim, P.; DeSmedt, H.; Mazzucco, C.; DeBoer, P.; Van Nueten, L.; Ceusters, M. 2014: P.2.f.005 Efficacy and safety of a novel mGlu2 receptor positive allosteric modulator as an adjunctive treatment in anxious depression. European Neuropsychopharmacology 24: S453-S454

Montejo, A.L.; Deakin, J.F.W.; Harmer, C.J.; Gaillard, R.; Meyniel, F.; Jabourian, A.P.; Gruget, C.; Gabriel, C.; Laredo, J.; Goodwin, G.M. 2014: P.2.f.006 Better sexual acceptability of agomelatine compared to escitalopram in healthy volunteers during a 9-week placebo-controlled trial. European Neuropsychopharmacology 24: S454-S455

Petrescu, B.; Vasile, D.; Vasiliu, O.; Tudor, C.; Mangalagiu, A.; Ungureanu, D. 2014: P.2.f.008 Ssri dose escalation versus duloxetine in treatment of major depressive disorder not responding to initial Ssri. European Neuropsychopharmacology 24: S455-S456

Fava, M.; Gommoll, C.; Chen, C.; Greenberg, W.M.; Ruth, A.; D'Souza, I.; Terner-Rosenthal, J. 2014: P.2.f.009 The efficacy of levomilnacipran extended-release (Er) in the treatment of patients with depression-associated fatigue symptoms. European Neuropsychopharmacology 24: S456-S457

DeCarlo, V.; Calati, R.; Souery, D.; Montgomery, S.; Kasper, S.; Zohar, J.; Mendlewicz, J.; Serretti, A. 2014: P.2.f.011 Socio-demographic and clinical predictors of non response/non remission in treatment resistant depressed patients: a systematic review. European Neuropsychopharmacology 24: S457-S458

Gaillard, R.; Salvador, A.; Vinckier, F.; Meyniel, F.; Deakin, J.F.W.; Harmer, C.J.; Montejo, A.L.; Jabourian, A.L.; Gruget, C.; Gabriel, C.; Laredo, J.; Goodwin, G.M. 2014: P.2.f.013 Effects of agomelatine compared to escitalopram on motivation in healthy male and female volunteers after 9 weeks of treatment. European Neuropsychopharmacology 24: S458-S459

O'Connor, J.; Chen, L.; Gommoll, C.; Banerjee, P.; Zukin, S. 2014: P.2.f.014 Levomilnacipran inhibits both norepinephrine and serotonin reuptake across the clinical dose range. European Neuropsychopharmacology 24: S459-S460

Guillena, S.L.R.; de Diego, B.O.P.G.; Saenz, B.O.M. 2014: P.2.f.017 Agomelatine versus desvenlafaxine versus bupropion Xr in the treatment of anhedonia in major depressive disorder. European Neuropsychopharmacology 24: S461-S462

Watanabe, T.; Hyashi, Y.; Aoki, A.; Ishiguro, S.; Inoue, Y.; Akiyama, K.; Tsuchimine, S.; Yasui-Furukori, N.; Shimoda, K. 2014: P.2.f.019 Effect of Cyp2D6*10 polymorphism on mirtazapine metabolism in Japanese psychiatric patients. European Neuropsychopharmacology 24: S462-S463

Baldwin, D.S.; Loft, H.; Jacobsen, P.L.; Florea, I. 2014: P.2.f.020 The efficacy of vortioxetine in treating patients with severe depression or with depression and high level of anxiety symptoms. European Neuropsychopharmacology 24: S463-S464

Jacobsen, P.L.; Mahableshwarkar, A.R.; Chen, Y.; Chrones, L.; Clayton, A.H. 2014: P.2.f.022 Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction. European Neuropsychopharmacology 24: S464-S465

Vieta, E.; Loft, H.; Mahableshwarkar, A.R.; Florea, I. 2014: P.2.f.023 The efficacy of vortioxetine in the treatment of patients with major depressive disorder (Mdd) in short-term placebo-controlled studies: a meta-analysis of 11 studies. European Neuropsychopharmacology 24: S465-S466

Kulenovic, A.D.; Kucukalic, A.; Bravo-Mehmedbasic, A. 2014: P.2.f.025 Venlafaxine in depressive disorder comorbid with generalized anxiety disorder. European Neuropsychopharmacology 24: S466-S467

Renemane, L.; Logins, R.; Kupca, B. 2014: P.2.g.002 Depression and body image dissatisfaction in burn reconstruction patients in State Burn Centre of Riga. European Neuropsychopharmacology 24: S469-S470

Waller, J.A.; Pehrson, A.L.; Sanchez, C. 2014: P.2.g.004 Vortioxetine modulates Gaba and glutamate marker expression in a subchronic Pcp model of impaired executive functioning in rats. European Neuropsychopharmacology 24: S470-S471

Cordero, M.D.; Gómez, E.A.; Barquero, N.C.; Romero-Guillena, S.L.; Bullon, P.; Carrión, A.M. 2014: P.2.g.005 Implication of coenzyme Q in mood disorder. European Neuropsychopharmacology 24: S471-S472

Oosthuizen, F.; Bangalee, V.; Lubbe, M. 2014: P.2.h.001 The prevalence of diabetes with the use of antidepressants. European Neuropsychopharmacology 24: S472-S473

Lee, D.; Kang, D.; Kim, S.; Jang, J.; Kim, Y. 2014: P.2.h.004 Risk factors for suicidal ideation among patients with complex regional pain syndrome. European Neuropsychopharmacology 24: S474-S475

Guirguis, A.; Friedli, K.; Fineberg, N.A.; Day, C.; Almond, M.; Davenport, A.; DaSilva-Gane, M.; Chilcot, J.; Farrington, K. 2014: P.2.h.007 Characteristics of fatigue and depressive symptoms in haemodialysis patients. European Neuropsychopharmacology 24: S476-S477

Pini, S.; Felice, F.; DiStefano, R.; Mazzotta, G.F.; Bovenzi, F.; Bertoli, D.; Abelli, M.; Gesi, C.; Borelli, L.; Balbarini, A. 2014: P.2.h.009 Relationship of depression, anxiety and circulating endothelial progenitor cells in patients with acute coronary syndrome. European Neuropsychopharmacology 24: S477-S478

Kim, E.Y.; Kim, S.H.; Yoon, D.H.; Ahn, Y.M. 2014: P.2.h.010 Association between thyroid stimulation hormone levels and risk of depression among general population with normal range free T4 levels. European Neuropsychopharmacology 24: S478-S479

Durante, F.; Bossini, L.; Casolaro, I.; Pellegrini, F.; Porcelli, B.; Trusso, M.A.; Verdino, V.; Fagiolini, A. 2014: P.2.h.012 Gluten sensitivity, celiac disease and mood disorders. European Neuropsychopharmacology 24: S479-S480

Padurariu, M.; Ciobica, A.; Stefanescu, C.; Anton, E. 2014: P.2.h.014 The relevance of oxidative stress status in first episode and recurrent depression. European Neuropsychopharmacology 24: S480-S481

Vasile, D.; Macovei, R.A.; Vasiliu, O.; Vasile, F. 2014: P.2.h.015 Pharmacologic treatment strategies in premenstrual dysphoric disorder. European Neuropsychopharmacology 24: S481-S482

Paik, I.H.; Huh, H.; Kim, S.Y.; Chae, J.H. 2014: P.2.h.017 Are anxiety and depression differently associated with interpersonal relationship problems?. European Neuropsychopharmacology 24: S482-S483

Meana, J.J.; Miranda-Azpiazu, P.; García-Bea, A.; Muguruza, C.; Callado, L.F.; Gabilondo, A.M.; Díez-Alarcia, R.; González-Maeso, J. 2014: P.3.a.001 Selective up-regulation of serotonin 5-Ht2A receptor coupling to Gi1-proteins in postmortem brain of subjects with schizophrenia. European Neuropsychopharmacology 24: S483-S484

DeNijs, J.; Pet, M.A. 2014: P.3.a.004 Metabolic syndrome in patients with schizophrenia is associated with poor cognitive performance and poor premorbid school performance. European Neuropsychopharmacology 24: S485-S486

Ivanova, S.A.; Geers, L.M.; AlHadithy, A.F.Y.; Pechlivanoglou, P.; Semke, A.V.; Vyalova, N.M.; Fedorenko, O.Y.; Brouwers, J.R.B.J.; Wilffert, B.; Loonen, A.J.M. 2014: P.3.a.006 Tardive dyskinesia, dehydroepiandrosterone sulfate and cytochrome P450c17 gene polymorphism in psychiatric inpatients. European Neuropsychopharmacology 24: S486-S487

Freudenberg, F.; Kollert, L.; Candemir, E.; Töpner, T.; Geis, M.; Müller, A.; Weissflog, L.; Reif, A. 2014: P.3.a.007 The interaction between Nos-I and Nos1Ap in dendrite development: implications for schizophrenia. European Neuropsychopharmacology 24: S487-S488

Kinyasheva, K.; Gareeva, A.; Khusnutdinova, E. 2014: P.3.a.010 The involvement of Grm3 gene polymorphic loci in schizophrenia. European Neuropsychopharmacology 24: S489-S490

Popovic, D.; Benabarre, A.; Crespo, J.M.; Goikolea, J.M.; González-Pinto, A.; Gutiérrez-Rojas, L.; Montes, J.M.; Vieta, E. 2014: P.3.b.001 Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. European Neuropsychopharmacology 24: S490-S491

Popovic, I.; Ravanic, D.; Popovic, V.; Vladejic, S.; Stanojevic, A. 2014: P.3.b.002 Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome. European Neuropsychopharmacology 24: S491-S492

Suttajit, S.; Sutrak, P. 2014: P.3.b.005 Predictors of quality of life in individuals with schizophrenia. European Neuropsychopharmacology 24: S493-S494

Koychev, I.; Winton-Brown, T.; Egerton, A.; Howes, O.; Mullins, P.; Kapur, S.; Mathews, P.; McGuire, P.; Stone, J. 2014: P.3.b.007 Altered dorsolateral prefrontal cortex glutamate and striatal dopamine relationship in subjects at ultra high risk of psychosis. European Neuropsychopharmacology 24: S494-S495

Martinez-Cengotitabengoa, M.; Barbeito, S.; Gonzalez-Ortega, I.; García-Alocén, A.; Gonzalez-Pinto, A. 2014: P.3.b.010 Long-term drug adherence in first-episode psychosis: the role of cannabis use and involuntary admission. European Neuropsychopharmacology 24: S496-S497

Gotor, F.; Guillena, S.L.R.; Navarro, R. 2014: P.3.b.011 Subjective well-being and experiential negative symptoms in schizophrenia. European Neuropsychopharmacology 24: S497-S498

Vai, B.; Papa, G.S.; Poletti, S.; Radaelli, D.; Bollettini, I.; Cavallaro, R.; Smeraldi, E.; Benedetti, F. 2014: P.3.b.013 Disrupted effective connectivity of emotional circuitry in schizophrenia: a dynamic causal modeling study. European Neuropsychopharmacology 24: S498-S499

Pejkovska-Dimovska, S.; Videnova, V.; Najdenova-Ugrinovska, V. 2014: P.3.b.015 Attitudes toward maintenance therapy among schizophrenia outpatients. European Neuropsychopharmacology 24: S499-S500

Smirnova, D.; Walters, J.; Fine, J.; Muchnik-Rozanov, Y.; Paz, M.; Lerner, V.; Belmaker, H.; Bersudsky, Y. 2014: P.3.b.017 Second language reflects more psychopathology but compensates the verbal fluency in bilinguals with schizophrenia. European Neuropsychopharmacology 24: S500-S501

Schreiner, A.; Gopal, S.; Thiagarajah, S.; Busch, M.; Alphs, L.; Coppola, D.; Hargarter, L.; Vidal, J.A.B.; Remmerie, B.; Samtani, M.N.; Zhang, F.; Savitz, A.; Hough, D. 2014: P.3.b.018 Posthoc analysis of patient relapse rates when switching from risperidone or other antipsychotics to paliperidone palmitate. European Neuropsychopharmacology 24: S501-S502

Pappa, S.; Sahib, L.; Larkin, F. 2014: P.3.b.020 Long acting paliperidone palmitate a service evaluation of its use in clinical practice and its effects on hospital stay. European Neuropsychopharmacology 24: S502-S503

Labad, J.; Stojanovic, A.; Montalvo, I.; Solé, M.; Cabezas, A.; Ortega, L.; Vilella, E.; Martorell, L.; Reynolds, R.; Gutiérrez-Zotes, A. 2014: P.3.b.023 Reduced albumin plasma levels mediate the relationship between life stress and the risk of psychosis transition in at-risk mental states. European Neuropsychopharmacology 24: S504-S505

Bustillo, M.; Alonso, M.; González-Pinto, A.; Segarra, R.; Zabala, A.; Román, S.; Ugarte, A.; García, J.; Santos, B.; Gutiérrez, M. 2014: P.3.b.025 Plasma levels of risperidone in relation to dose, clinical improvement and side-effects in first-episode psychosis. European Neuropsychopharmacology 24: S505-S506

Mesa, E.D.; Fumero, A.M.; Abreu-Gonzalez, P.; Suarez-Benitez, N.; Gonzalez-Gonzalez, I.; Henry-Benitez, M.; Gracia-Marco, R. 2014: P.3.b.026 Relationship between psychopathology and interleukins 6 and 10 in acute paranoid schizophrenia. European Neuropsychopharmacology 24: S506-S507

Litman, R.; Smith, M.; Doherty, J.; Cross, A.; Raines, S.; Zukin, S. 2014: P.3.b.030 Azd8529, a positive allosteric modulator at the Mgglur2 receptor, does not improve symptoms in schizophrenia: a proof of principle study. European Neuropsychopharmacology 24: S508-S509

Pecenak, J.; Kopeliovic, B. 2014: P.3.b.032 Evaluation of preferences of chimeric, reversed and normal self-face in patients with schizophrenia and healthy controls a pilot study. European Neuropsychopharmacology 24: S509-S510

Szego, A.; Elemery, M.; Faludi, G.; Kovacs, G. 2014: P.3.b.035 Psychotropics in emergency therapy in Hungary: a comparison with international trends. European Neuropsychopharmacology 24: S511-S512

Chrobak, A.; Siwek, G.; Siuda, K.; Siwek, M.; Arciszewska, A.; Pilecki, M.W.; Dudek, D. 2014: P.3.b.037 Convergence insufficiency in schizophrenia and its relationship with cerebellar symptoms. European Neuropsychopharmacology 24: S512-S513

Matei, V.; Mihailescu, A.I.; Al-Bataineh, R. 2014: P.3.b.039 Predictors of adherence to antipsychotic treatment in first episode schizophrenia results of the Romanian cohort in the Eufest study. European Neuropsychopharmacology 24: S513-S514

Petek Eric, A.; Dodig Curkovic, K.; Curkovic, M.; Kralik, K. 2014: P.3.b.040 The correlation of therapeutic adherence among adolescent and adult patients with psychosis using a Hplc&Lc-Ms method. European Neuropsychopharmacology 24: S514-S515

Leger, M.; Grayson, B.; Marsh, S.; Alvaro, G.; Large, C.; Harte, M.; Neill, J. 2014: P.3.c.002 Kv3 channel modulation alleviates cognitive dysfunction and negative symptoms in an animal model of schizophrenia. European Neuropsychopharmacology 24: S515-S516

Karbownik, M.S.; Szemraj, J.; Wieteska, L.; Panek, M.; Mokros, L.; Michalik, M.; Pietras, T. 2014: P.3.c.005 Clozapine and expression of the neurodevelopmental genes: a pilot study. European Neuropsychopharmacology 24: S517-S518

Simion, A.; Crasan, A.; Calin, D.; Muscalu, M.; Macovei, S. 2014: P.3.c.007 Challenges in treating children and adolescents with antipsychotic agents. European Neuropsychopharmacology 24: S518-S519

Stojkovic, T.; Velimirovic, M.; Nikolic, T.; Jevtic, G.; Petronijevic, N. 2014: P.3.c.009 Effects of antipsychotics on the glutathione and antioxidative enzymes in the brain of rats treated perinatally with phencyclidine. European Neuropsychopharmacology 24: S519-S520

Toll Privat, A.; ManéSantacana, A.; BergéBaquero, D.; SamsóBuxareu, B.; Chavarria Romero, V.; Pérez Solà, V. 2014: P.3.d.002 Incidence of readmission between short-term electroconvulsive therapy and maintenance electroconvulsive therapy. European Neuropsychopharmacology 24: S521-S522

Hajji, K.; Bouali, W.; Zarrouk, L.; Marrag, I.; Nasr, M. 2014: P.3.d.005 Metabolic syndrome in patients on antipsychotics: about 148 patients. European Neuropsychopharmacology 24: S523-S524

Steibliene, V.; Bunevicius, R. 2014: P.3.d.007 Safety and efficacy of adjunct L-triiodothyronine therapy in patients with acute schizophrenia: a randomised study. European Neuropsychopharmacology 24: S524-S525

Yu, J.; Oh, G.H.; Choi, K.S.; Joo, E.J.; Jeong, E.J. 2014: P.3.d.008 Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: a Mixed Treatment Comparison analysis. European Neuropsychopharmacology 24: S525-S526

Whale, R.; Pereira, M.; Fialho, R. 2014: P.3.d.010 Predictors of 12 month continuation of paliperidone long acting injection treatment for schizophrenia: a naturalistic cohort study. European Neuropsychopharmacology 24: S526-S527

Fricchione Parise, V.; Addeo, L.; Laezza, R. 2014: P.3.d.013 Motives for quetiapine discontinuation in real-world clinical setting: a retrospective review. European Neuropsychopharmacology 24: S528-S529

AhYoung, C.; Eun Young, K.; Nam Young, L.; Yong Min, A. 2014: P.3.d.015 Prolactin levels in schizophrenia patients treated with paliperidone switching from risperidone, aripiprazole and olanzapine. European Neuropsychopharmacology 24: S529-S530

Todorova-Nenova, K.; Arnaoudova, M. 2014: P.3.d.017 Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia patients two case reports and discussion. European Neuropsychopharmacology 24: S530-S531

Hosford, D.; Dvergsten, C.; Beaver, J.; Segreti, A.C.; Toler, S.; Farr, M.G.; Joseph, M.; Jett, J.; Lippiello, P.; Bencherif, M. 2014: P.3.d.018 Phase 2 clinical trial of Tc-5619, an alpha 7 nicotinic receptor agonist in the treatment of negative and cognitive symptoms in schizophrenia. European Neuropsychopharmacology 24: S531-S532

Acciavatti, T.; Cinosi, E.; Lupi, M.; Marini, S.; Santacroce, R.; DiIorio, G.; Martinotti, G.; DiGiannantonio, M. 2014: P.3.d.020 Neurocognition and social cognition in schizophrenia: the impact of antipsychotic therapy. European Neuropsychopharmacology 24: S532-S533

Megía López, P.; Fructuoso Castellar, A.; Contreras Barbas, M. 2014: P.3.d.021 Effectiveness of paliperidone in negative symptoms of schizophrenia after six months of treatment. European Neuropsychopharmacology 24: S533-S534

Fu, D.J.; Alphs, L.; Lindenmayer, J.P.; Schooler, N.; Nemeth, G.; Durgam, S.; Laszlovszky, I.; Simonson, R.B.; Turkoz, I.; Walling, D. 2014: P.3.d.023 Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology 24: S534-S535

Gabernet, R.; Catalan, A.; García, L.; Bergé, D.; Sánchez, S.; Penas-Cortes, A.; Rodríguez-Navarro, D.; Ovejero, S.; Mané, A.; Díaz-Marsá, M.; Rodríguez, A.; Labad, J. 2014: P.3.d.024 Antipsychotic treatment and outcome in first-episode psychosis: a 2-year longitudinal, multicenter, pragmatic study. European Neuropsychopharmacology 24: S535-S536

Porcelli, S.; Calati, R.; Gressier, F.; Serretti, A. 2014: P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis. European Neuropsychopharmacology 24: S536-S537

Takekita, Y.; Kato, M.; Sakai, S.; Sunada, N.; Koshikawa, Y.; Serretti, A.; Kinoshita, T. 2014: P.3.d.027 Does medication history profile affect treatment response of antagonist and partial agonist at the D2 receptors in schizophrenia?. European Neuropsychopharmacology 24: S537-S538

Dold, M.; Leucht, S. 2014: P.3.d.029 Analyzing the efficacy of second-generation antipsychotic drugs in treatment-resistant schizophrenia: a meta-analysis. European Neuropsychopharmacology 24: S538-S539

Nabavi, B. 2014: P.3.d.031 Audit of patients on paliperidone palmitate in a mental health trust in England. European Neuropsychopharmacology 24: S539-S540

Kane, J.M.; Zhao, C.; Johnson, B.; Baker, R.A.; Eramo, A.; McQuade, R.D.; Duca, A.; Sanchez, R.; Peters-Strickland, T. 2014: P.3.d.034 Effects of aripiprazole once-monthly on functioning in patients with schizophrenia. European Neuropsychopharmacology 24: S541-S542

Kane, J.M.; Zhao, C.; Johnson, B.; Baker, R.A.; Eramo, A.; McQuade, R.; Duca, A.; Sanchez, R.; Peters-Strickland, T. 2014: P.3.d.037 Effects of aripiprazole once-monthly in patients with schizophrenia switched from oral antipsychotics to aripiprazole once-monthly. European Neuropsychopharmacology 24: S543-S544

Eramo, A.; Baker, R.A.; Nylander, A.G.; Tsai, L.F.; Peters-Strickland, T.; Sanchez, R. 2014: P.3.d.040 Previous oral aripiprazole dose (10 or 30 mg/day): effect on the efficacy and tolerability of aripiprazole once-monthly. European Neuropsychopharmacology 24: S545-S546

Enomoto, T.; Sekine, K.; Ito, T.; Ashizawa, Y.; Uju, Y.; Hayakawa, T.; Tsukada, K.; Yoshimi, T.; Yoshida, E. 2014: P.3.d.043 Early responders show greater improvements than early non-responders during the whole long-term treatment of clozapine. European Neuropsychopharmacology 24: S547-S548

Mauro, A.; DiMassimo, G. 2014: P.3.d.045 Aripiprazole in pregnancy: literature review and case series. European Neuropsychopharmacology 24: S548-S549

Kane, J.M.; Zhao, C.; Johnson, B.; Baker, R.A.; Eramo, A.; McQuade, R.D.; Duca, A.; Sanchez, R.; Peters-Strickland, T. 2014: P.3.d.046 Switching from oral antipsychotics to aripiprazole once-monthly in a naturalistic setting: hospitalisation rates from a mirror study. European Neuropsychopharmacology 24: S549-S550

Starr, H.; Mao, L.; Rodriguez, S.; Alphs, L. 2014: P.3.d.048 Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia. European Neuropsychopharmacology 24: S550-S551

Zarranz, I.; Bolaño, S. 2014: P.3.d.050 Assessment of personal and social functioning and caregiver burden in schizophrenics treated with paliperidone palmitate long acting injectable, followed up for 1 year. European Neuropsychopharmacology 24: S551-S552

Paletta, S.; DiPace, C.; Maffini, M.; Reggiori, A.; Mauri, M.C.; Altamura, A.C. 2014: P.3.d.051 Olanzapine long-acting therapy in schizophrenic patients: clinical dimensions and plasma levels. European Neuropsychopharmacology 24: S552-S553

Samalin, L.; Blanc, O.; Llorca, P.M. 2014: P.3.d.053 Beliefs toward antipsychotic medication in patients with schizophrenia: preliminary results. European Neuropsychopharmacology 24: S553-S554

Krysta, K.; Pilarska, E.; Krupka-Matuszczyk, I.; Siudek, W.; May-Majewski, A. 2014: P.3.d.055 Cognitive rehabilitation in schizophrenic patients with a comorbid addiction to amphetamine and cannabis. European Neuropsychopharmacology 24: S554-S555

Montero Manzano, E.; Garcia Navarro, M.; Vazquez Estevez, R.; Molina Castillo, J. 2014: P.3.d.057 Analysis of characteristics associated to psychopharmacological prescription among schizophrenic versus schizoaffective disorders. European Neuropsychopharmacology 24: S555-S556

Sacchetti, E.; Palma dos Reis, R.; Andersson, H.; Fallon, M.; Murthy, V. 2014: P.3.d.058 Maintenance efficacy of lurasidone compared to high-dose quetiapine Xr in schizophrenia: results from a post-hoc analysis. European Neuropsychopharmacology 24: S556-S557

Newcomer, J.; Pikalov, A.; Watabe, K.; Cucchiaro, J.; Rajagopalan, K.; Loebel, A. 2014: P.3.d.061 Effect of lurasidone or risperidone on metabolic syndrome status in patients with schizophrenia: a post hoc analysis of a long-term study. European Neuropsychopharmacology 24: S558-S559

Tandon, R.; Loebel, A.; Phillips, D.; Pikalov, A.; Hernandez, D.; Mao, Y.; Cucchiaro, J. 2014: P.3.d.063 Lurasidone for maintenance of efficacy in patients with schizophrenia: a double-blind, placebo-controlled, randomised withdrawal study. European Neuropsychopharmacology 24: S559-S560

Michopoulos, I.; Arvanitakis, P.; Theodoropoulou, P.; Dimopoulou, K.; Tzebelikos, E.; Kalkavoura, C. 2014: P.3.d.066 Hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. European Neuropsychopharmacology 24: S561-S562

Amiaz, R.; Smith, R.; Si, T.M.; Maayan, L.; Jin, H.U.A.; Boules, S.; Sershen, H.; Li, C.; Ren, J.; Yanhong, R.; Lajtha, A.; Guidotti, A.; Weiser, M.; Davis, J. 2014: P.3.d.068 Varenicline effects on smoking, cognition and psychiatric symptoms in schizophrenia. European Neuropsychopharmacology 24: S562-S563

Moller, M.; DuPreez, J.L.; Viljoen, F.P.; Berk, M.; Harvey, B.H. 2014: P.3.e.001 Clozapine alone and in combination with N-acetylcysteine reverses social isolation rearing induced serotonergic metabolism. European Neuropsychopharmacology 24: S563-S564

Dulea, I.; Dehelean, L.; Manea, M.O. 2014: P.3.e.003 Recurrence risk and protective factors in patients with a first episode of psychosis. European Neuropsychopharmacology 24: S564-S565

Ermakov, E.; Smirnova, L.P.; Buneva, V.N.; Shchigoreva, J.G.; Semke, A.V.; Ivanova, S.A. 2014: P.3.e.004 Abzymes with catalase-like activity of patients with schizophrenia after treatment with haloperidol. European Neuropsychopharmacology 24: S565-S566

Nakhli, J.; Bouhlel, S.; Amamou, B.; ElKissi, Y.; Ben Hadj Ali, B. 2014: P.3.f.002 Sexual dysfunction in outpatients with schizophrenia. European Neuropsychopharmacology 24: S566-S567

Ritsner, M.; Ratner, Y.; Gibel, A. 2014: P.3.f.004 Remission structure in 10-year course of schizophrenia: a naturalistic study. European Neuropsychopharmacology 24: S567-S568

El-Missiry, M.; Asaad, T.; Ibrahim, M.; Abdul Maguid, M.; Taha, S. 2014: P.3.f.005 Sexual dysfunction in drug naive psychotic patients treated with antipsychotics. European Neuropsychopharmacology 24: S568-S569

Maner, F.; Babalioglu, M.; Cetinkaya, O.; Ergen, N.; Ustun, I.; Ipekcioglu, D.; Yesil, R.; Yerebakan, M.; Alici, S.; Ulukaya, S.E.M.A. 2014: P.3.f.007 Arachnoid cyst in patients with first episode psychosis: three case reports. European Neuropsychopharmacology 24: S569-S570

Manea, M.M.; Handa, R.A. 2014: P.3.f.009 Low disease perception reduces compliance and functioning in schizophrenia in comparison with second pulmonary tuberculosis. European Neuropsychopharmacology 24: S570-S571

Merkin, A.; Kazin, V.; Nikiforov, I.; Beloskurskaya, O.; Dinov, E.; Bichkova, A.; Aronov, P. 2014: P.3.f.010 Some peculiarities in diagnosing delirium in elderly patients in a general hospital by different medical specialists. European Neuropsychopharmacology 24: S571-S572

Canli, D.; Ozdemir Rezaki, H.; Kocak, O.M. 2014: P.3.f.012 Positive schizotypy associated negative facial emotion recognition and neurocognitive deficits. European Neuropsychopharmacology 24: S572-S573

Pietrini, F.; Spadafora, M.; Talamba, G.A.; Godini, L.; Santangelo, A.; Chiarello, F.; Ballerini, A. 2014: P.3.f.013 Long-acting second-generation antipsychotics, beyond efficacy: a 12-month prospective study on patients' attitudes towards treatment. European Neuropsychopharmacology 24: S573-S574

Ben Nasr, S.; Ben Romdhane, A.; Nakhli, J.; Braham, A.; ElKissi, Y.; Ben Hadj Ali, B. 2014: P.3.f.015 Expressed emotion in relatives of patients with schizophrenia, bipolar disorder and diabetes: a comparison. European Neuropsychopharmacology 24: S574-S575

Altinbas, K.; Yesilyurt, S.; Ipek, H.I. 2014: P.3.f.018 Metabolic syndrome related cardiovascular disease risk in schizophrenia. European Neuropsychopharmacology 24: S576-S577

Batista, L.A.; Moreira, F.A. 2014: P.4.a.002 Role of endocannabinoid signaling in the dorsolateral periaqueductal gray on the modulation of distinct panic-like responses. European Neuropsychopharmacology 24: S577-S578

Beesdo-Baum, K.; Wittchen, H.U.; Craske, M.G.; Hoyer, J.; Jurkschat, S.; ElHadad, A.; Knappe, S. 2014: P.4.a.006 Psychometric properties of the 1-week dimensional anxiety scales for Dsm-5 in a non-clinical student sample. European Neuropsychopharmacology 24: S579-S580

Jurek, B.; Slattery, D.A.; Liu, Y.; Aguilera, G.; Van den Burg, E.H.; Neumann, I.D. 2014: P.4.a.008 Oxytocin controls the Crf gene via Crtc3: implications for stress-related disorders. European Neuropsychopharmacology 24: S580-S581

Fitzgibbon, M.; Liu, M.; Bannon, J.; Shen, S.; Roche, M. 2014: P.4.a.009 Unc-51-like kinase 4 heterozygous mice display anxiety-like behaviour and alterations in the Gabaergic system within the amygdala. European Neuropsychopharmacology 24: S581-S582

Mutlu, O.; Komsuoglu Celikyurt, I.; Uyar, E.; Ulak, G.; Bektas, E.; Yildiz Akar, F.; Erden, F.; Tarkun, I. 2014: P.4.a.011 Chronic exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses the neuropathy in a diabetic mice model. European Neuropsychopharmacology 24: S582-S583

Lisboa, S.F.; Camargo, L.H.A.; DaSilva, A.L.; Resstel, L.B.M.; Guimarães, F.S. 2014: P.4.a.014 Repeated treatment with an anandamide metabolism inhibitor attenuates long-lasting consequences in a mouse model of post-traumatic stress disorder (Ptsd). European Neuropsychopharmacology 24: S584-S585

Torrisi, S.A.; Leggio, G.M.; Castorina, A.; Bucolo, C.; Caraci, F.; Salomone, S.; Drago, F. 2014: P.4.a.016 Genetic deletion of dopamine D3 receptor accelerates the development of tolerance to the anxiolytic effect of diazepam. European Neuropsychopharmacology 24: S585-S586

Lange, S.; Lueken, U.; Maslowski, N.I. 2014: P.4.b.001 High anxiety sensitivity is associated with reduced resting heart rate variability. European Neuropsychopharmacology 24: S587-S588

Luigjes, J.; Figee, M.; Tobler, P.N.; Van den Brink, W.; DeKwaasteniet, B.; Van Wingen, G.; Denys, D. 2014: P.4.b.003 Doubt in the insula: risk processing in obsessivecompulsive disorder. European Neuropsychopharmacology 24: S588-S589

Bolos, A.; Chirita, R.; Chirita, V. 2014: P.4.b.006 The role of atypical antipsychotics in obsessivecompulsive disorder resistant to treatment. European Neuropsychopharmacology 24: S590-S591

Sulejmanpasic-Arslanagic, G.; Fisekovic, S.; Ler, S.; Frenjo, A. 2014: P.4.b.008 Risperidone augmentation for post-traumatic combat nightmares. European Neuropsychopharmacology 24: S591-S592

Bravo-Mehmedbasic, A.; Dzubur Kulenovic, A.; Kucukalic, A. 2014: P.4.b.012 Efficacy and safety of sertraline treatment of posttraumatic stress disorder. European Neuropsychopharmacology 24: S593-S594

Belhadj-Tahar, H.; Vilamot, B.; Granberg, M.; Passamar, M. 2014: P.4.b.014 Brain-derived neurotrophic factor (Bdnf) as a predictive factor for post-traumatic stress disorder (Ptsd). European Neuropsychopharmacology 24: S594-S595

Gesi, C.; Abelli, M.; Lari, L.; Cardini, A.; Pini, S. 2014: P.4.b.015 Separation anxiety and mood symptoms among patients with panic disorder. European Neuropsychopharmacology 24: S595-S596

Subirà, M.; Picó, M.; Van Arendonk, F.; López-Solà, C.; Alonso, P.; Martínez-Zalacaín, I.; Hernández-Ribas, R.; Pujol, J.; DeWit, S.J.; Van den Heuvel, O.A.; Mataix-Cols, D.; Menchón, J.M.; Harrison, B.J.; Cardoner, N.; Soriano-Mas, C. 2014: P.4.b.017 Functional connectivity of basolateral and centromedial amygdala in obsessivecompulsive disorder. European Neuropsychopharmacology 24: S596-S597

Almeida, J.; Tullen, J.; Van der Ween, F.; Kushner, S. 2014: P.4.b.020 Time-dependent atomoxetine administration decreases negative conditioned response in a differential fear conditioning paradigm. European Neuropsychopharmacology 24: S598-S599

Altunoz, U.; Ozel-Kizil, E.T.; Kokurcan, A.; Graef-Calliess, I.T. 2014: P.4.b.022 Native Turkish patients and Turkish immigrants: a comparison in terms of clinical features of generalised anxiety disorder. European Neuropsychopharmacology 24: S599-S600

Duits, P.; Lissek, S.; Cath, D.C.; Hox, J.J.C.M.; Hamm, A.O.; Engelhard, I.M.; Van den Hout, M.A.; Baas, J.M.P. 2014: P.4.b.023 An updated meta-analysis of classical fear conditioning in the anxiety disorders. European Neuropsychopharmacology 24: S600-S601

Kim, T.Y.; Chung, H.K.; Choi, J.H.; Kang, S.H.; Choi, T.K.; Bang, Y.J.; So, H.S. 2014: P.4.b.025 Association between symptoms of posttraumatic stress disorder and blood pressure in the elderly. European Neuropsychopharmacology 24: S601-S602

Tiugan, A. 2014: P.4.b.028 Medication therapy in anxiety disorder. European Neuropsychopharmacology 24: S603-S604

Bertelloni, C.; Carmassi, C.; Manni, C.; Calderani, E.; Gemignani, S.; Massimetti, G.; Dell'Osso, L. 2014: P.4.b.030 Impairment in eating habits among 512 earthquake survivors: role of gender and Dsm-5 Ptsd. European Neuropsychopharmacology 24: S604-S605

Van Ameringen, M.; Patterson, B. 2014: P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review. European Neuropsychopharmacology 24: S605-S606

Fogaça, M.V.; Campos, A.C.; Guimarães, F.S. 2014: P.4.c.002 Behavioural effects of cannabidiol in chronically stressed mice is mediated by neurogenesis and autophagy through Cb1 receptor activation. European Neuropsychopharmacology 24: S606-S607

Glombik, K.; Stachowicz, A.; Trojan, E.; Slusarczyk, J.; Leskiewicz, M.; Olszanecki, R.; Basta-Kaim, A. 2014: P.4.c.004 Proteomic analysis of changes in protein expression in hippocampus mitochondria of prenatally stressed rats treated with fluoxetine. European Neuropsychopharmacology 24: S607-S608

Monte, A.S.; Aguiar, C.C.T.; Almeida, A.B.; Araújo, P.V.P.; Vasconcelos, G.S.; Sousa, C.N.S.; Meneses, L.N.; Ximenes, N.C.; Gaspar, D.M.; Vasconcelos, S.M.M. 2014: P.4.C.005 Effect of flavonoids isolated from Erythrina velutina on oxidative stress in mouse brains. European Neuropsychopharmacology 24: S608-S609

Szklarczyk-Smolana, K.; Korostynski, M.; Cieslak, P.; Wawrzczak-Bargiela, A.; Przewlocki, P. 2014: P.4.c.007 Opioid receptors as potential drug targets for controlling fear responses and preventing post-traumatic stress disorder. European Neuropsychopharmacology 24: S609-S610

Diniz, C.R.A.F.; Antero, L.S.; Resstel, L.B.M.; Joca, S.R.L. 2014: P.4.C.009 Fluoxetine modulating dorsal and ventral hippocampal Bdnf as responsible for facilitating extinction memory retention. European Neuropsychopharmacology 24: S610-S611

Lueken, U.; Hahn, T.; Straube, B.; Wittchen, H.U.; Wittmann, A.; Ströhle, A.; Pfleiderer, B.; Arolt, V.; Reif, A.; Kircher, T. 2014: P.4.d.001 Developing fMri markers for individual response prediction in panic disorder with agoraphobia: a machine-learning approach. European Neuropsychopharmacology 24: S611-S612

Fond, G.; Ducasse, D.; Michel, P.; Loundou, A.; Boyer, L. 2014: P.4.d.002 D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessivecompulsive disorders. European Neuropsychopharmacology 24: S612-S613

Martinez-Cengotitabengoa, M.; Bermudez, C.; López, P.; Besga, A.; Bermúdez, S.; Chicote, N.; Cuesta, E.; Enriquez, J.; Abrain, A.; Olles, R.; Esnal, S.; Salem, H.; González-Pinto, A. 2014: P.4.d.004 Falls in the elderly: are we using benzodiazepines right?. European Neuropsychopharmacology 24: S613-S614

Kamaradova, D.; Taborsky, J.; Prasko, J.; Latalova, K. 2014: P.4.d.006 Predictors of therapeutic response in patients with obsessivecompulsive disorder, panic disorder and social phobia. European Neuropsychopharmacology 24: S614-S615

Ooms, P.; Blankers, M.; Figee, M.; Mantione, M.; Munckhof, P.; Schuurman, P.R.; Denys, D. 2014: P.4.d.008 Rebound of affective symptoms following acute cessation of deep brain stimulation in obsessivecompulsive disorder. European Neuropsychopharmacology 24: S615-S616

Carmi, L.; Al-Yagon, U.; Zangen, A.; Dar, R.; Zohar, J. 2014: P.4.d.009 From over-awareness to obsessive behaviour error monitoring system dysfunction in patients with obsessivecompulsive disorder. European Neuropsychopharmacology 24: S616-S617

Lohoff, F. 2014: P.4.d.011 Influence of Dat1 and Drd2 gene variants on antidepressant response in generalised anxiety disorder. European Neuropsychopharmacology 24: S617-S618

Sahin, C.; Albayrak, O.; Yanikkaya Demirel, G.; Aricioglu, F. 2014: P.4.e.001 Sub-chronic stress not only induces pro-inflammatory cytokines but also activates Nrlp3 inflammasome in rats. European Neuropsychopharmacology 24: S618-S619

Agorastos, A.; Pittman, J.O.E.; Angkaw, A.C.; Nievergelt, C.M.; Parisi, S.A.; Barkauskas, D.A.; Baker, D.G. 2014: P.4.f.001 The cumulative effect of childhood trauma on adult mental and physical health: results from the Marine Resiliency Study. European Neuropsychopharmacology 24: S619-S620

Giese, M.; Beck, J.; Brand, S.; Muheim, F.; Hemmeter, U.; Hatzinger, M.; Holsboer-Trachsler, E. 2014: P.4.f.003 Fast Bdnf serum level increase and association of diurnal Bdnf profile with antidepressant therapy response after sleep deprivation. European Neuropsychopharmacology 24: S620-S621

Blom, R.M.; Figee, M.; Vulink, N.C.; Derks, E.M.; Denys, D. 2014: P.4.f.005 The experience of free will in patients with obsessivecompulsive disorder or Parkinson's disease treated with deep brain stimulation. European Neuropsychopharmacology 24: S621-S622

Koh, S.H.; Soh, E.; Kim, G.; Chun, M. 2014: P.4.f.007 Fatigue and decreased quality of life in early stage thyroid cancer survivors. European Neuropsychopharmacology 24: S622-S623

Kaser, M.; Hacioglu, M.; Yildirim, E.A.; Saatcioglu, O. 2014: P.4.f.008 Comparison of neurocognitive performance in patients with early onset and late onset obsessivecompulsive disorder. European Neuropsychopharmacology 24: S623-S624

Usta Saglam, N.G.; Cetiner, G.; Aksoy Poyraz, C.; Turan, S.; Duran, A. 2014: P.4.f.010 Factors associated with the duration of untreated illness in obsessivecompulsive disorder. European Neuropsychopharmacology 24: S624-S625

Lee, K.J.; Park, S.H.; Kim, H. 2014: P.5.a.002 Association of plasma C-reactive protein levels with mild cognitive impairment and Alzheimer's disease. European Neuropsychopharmacology 24: S625-S626

Dominiak, A.; Wilkaniec, A.; Wroczynski, P.; Adamczyk, A. 2014: P.5.a.005 Selol exhibits antioxidative and cytoprotective properties in Pc12 cells by activating glutathione peroxidase. European Neuropsychopharmacology 24: S627-S628

Lenkiewicz, A.; Wilkaniec, A.; Adamczyk, A. 2014: P.5.a.007 Extracellular oligomers of alpha-synuclein induce Parkin modifications and dopaminergic Pc12 cell death. European Neuropsychopharmacology 24: S628-S629

Mishra, N.; Sharma, D. 2014: P.5.a.009 Study of biochemical and behavioural changes induced by exogenous adminstration of A1-40 and A1-42 in the hippocampus and amygdala. European Neuropsychopharmacology 24: S629-S630

Shevtsov, P.N.; Burbaeva, G.S.; Shevtsova, E.F.; Bachurin, S.O. 2014: P.5.a.011 Metal-induced microtubules assembly disturbances. European Neuropsychopharmacology 24: S631-S632

Song, H.R.; Woo, Y.S.; Bahk, W.M.; Min, K.J.; Yoon, B.H.; Kim, M.D.; Kwon, Y.J.; Lee, K.H.; Lee, S.Y. 2014: P.5.b.001 Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep. European Neuropsychopharmacology 24: S632-S633

Martins, S.; Simões, M.R.; Fernandes, L. 2014: P.5.b.003 Delirium can increase hospital stay. European Neuropsychopharmacology 24: S633-S634

Arnaoudova, M.; Todorova-Nenova, K.; Aleksandrov, I.; Ruseva, D. 2014: P.5.b.005 The role of the clock drawing test among the diagnostic markers in elderly psychiatric patients. European Neuropsychopharmacology 24: S634-S635

Lee, C.U.; Lim, H.K.; Hann, C. 2014: P.5.b.006 Morphological and functional connectivity change of basal ganglia in amnestic mild cognitive impairment. European Neuropsychopharmacology 24: S635-S636

Curran, S.; Habibi, M.; Mitra, L.; Stephenson, J.; Nagarajan, P.; Khan, A. 2014: P.5.b.008 Use of acetylcholinesterase inhibitors in routine clinical practice. European Neuropsychopharmacology 24: S636-S637

Jeon, H.J.; Lee, J.Y.; Ryu, S.H. 2014: P.5.b.010 Multistrategic memory training in non-dementic elders. European Neuropsychopharmacology 24: S637-S638

Lee, H.; Kwon, Y.; Hahn, S.; Shim, S.; Bahk, W.; Jeong, H. 2014: P.5.b.012 A total inspection of cognitive dysfunction in elderly persons of one city. European Neuropsychopharmacology 24: S638-S639

Hosgoren-Alici, Y.; Ozel-Kizil, E.T.; Kirici, S.; Bilgin, B.; Bicer, S.; Yurur-Kutlay, N. 2014: P.5.b.014 Huntington's disease mimicking bipolar disorder: a case report. European Neuropsychopharmacology 24: S639-S640

Dulovic, M.; Jovanovic, M.; Harhaji-Trajkovic, L.J.; Stefanis, L.; Xilouri, M.; Kostic, V.; Trajkovic, V.; Markovic, I. 2014: P.5.c.001 The protective role of Ampk and Akt in neurotoxicity caused by intracellular and extracellular alpha-synuclein accumulation in vitro. European Neuropsychopharmacology 24: S641-S642

Rafa-Zablocka, K.; Jurga, A.; Baginska, M.; Parlato, R.; Schuetz, G.; Nalepa, I.; Kreiner, G. 2014: P.5.c.003 Involvement of noradrenergic system in Parkinson's disease study on novel transgenic mouse models. European Neuropsychopharmacology 24: S642-S643

Yenkoyan, K.; Davtyan, T.; Margaryan, T.; Chavushyan, V.; Aghajanov, M. 2014: P.5.c.004 The influence of hypothalamic proline-rich polypeptide-1 on stem cell maintenance in hippocampus of amyloid-exposed rats. European Neuropsychopharmacology 24: S643-S644

Atturu, H.; Gupta, R.; Sermin, N. 2014: P.5.d.002 Vitamin D deficiency in patients with intellectual disability on carbamazepine. European Neuropsychopharmacology 24: S644-S645

Reznik, I. 2014: P.5.d.004 Medical marijuana/cannabis treatment of Tourette's syndrome: focus on the quality of life. European Neuropsychopharmacology 24: S645-S646

Navarrete Rueda, F.; García-Gutiérrez, M.S.; Aracil-Fernández, A.; Molina-Arjona, J.A.; Leiva-Santana, C.; Manzanares, J. 2014: P.5.d.005 Role of cannabinoid Cb2 receptor in Parkinson's disease. European Neuropsychopharmacology 24: S646-S647

Armasu, M.; Musteata, M.; Stanciu, G.D.; Balan, C.; Solcan, G. 2014: P.5.e.002 The importance of brainstem auditory evoked response in dogs with congenital hydrocephalus. European Neuropsychopharmacology 24: S647-S648

Chang, S.M.; Jung, S.W.; Choi, T.Y. 2014: P.5.f.002 Psychometric properties of the mini-mental state examination Korean version. European Neuropsychopharmacology 24: S648-S649

Paik, S.H.; Kim, M.H. 2014: P.5.f.003 Relationship between psychotic symptoms of delirium and clinical outcomes. European Neuropsychopharmacology 24: S649-S650

Kennedy, P.; Allen, A.P.; O'Neill, A.; Quigley, E.M.M.; Cryan, J.F.; Dinan, T.G.; Clarke, G. 2014: P.5.f.005 Acute tryptophan depletion modulates kynurenine production: a challenging component of cognitive impairment in braingut axis disorders. European Neuropsychopharmacology 24: S650-S651

Costoloni, G.; Mostacciuolo, W.; DiVolo, S.; Bolognesi, S.; Goracci, A.; Fagiolini, A. 2014: P.5.f.010 Evaluation of the treatment of elderly agitated patients:a preliminary study. European Neuropsychopharmacology 24: S652-S653

Shreder, E.; Zabrodina, V.; Shreder, O.; Durnev, A. 2014: P.6.a.002 Dna damages and behaviour disorders in pups of rats exposed to alcohol in the antenatal period, and its correction by afobazole. European Neuropsychopharmacology 24: S653-S654

Denisenko, M. 2014: P.6.a.004 Gender differences of alcohol dependence in Russia and in Germany. European Neuropsychopharmacology 24: S654-S655

Kunchulia, M.; Thomaschke, R. 2014: P.6.a.006 How alcohol intake affects on time-based expectancies. European Neuropsychopharmacology 24: S655-S656

Garcia-Gutierrez, M.S.; Navarrete, F.; Aracil-Fernández, A.; Bartoll, A.; Lanciego, J.; Rubio, G.; Manzanares, J. 2014: P.6.a.009 Increased ethanol self-administration associated with synaptic plasticity alterations induced by early life stress in mice. European Neuropsychopharmacology 24: S657-S658

Bazovkina, D.; Tsybko, A.; Osipova, D.; Kulikov, A. 2014: P.6.a.011 Role of C1473G polymorphism in mouse tryptophan hydroxylase 2 gene in ethanol treatment effect on behaviour and brain serotonin system. European Neuropsychopharmacology 24: S658-S659

Navarrete Rueda, F.; Rodríguez-Arias, M.; Carmen-Arenas, M.; Bartoll-Andrés, A.; Aguilar, M.A.; Blanco-Gandía, M.C.; Rubio, G.; Miñarro, J.; Manzanares, J. 2014: P.6.a.012 Social defeat in adolescent mice increased the vulnerability for alcohol consumption. European Neuropsychopharmacology 24: S659-S660

Stragier, E.; Martin, V.; Davenas, E.; Poilbout, C.; Mongeau, R.; Corradetti, R.; Lanfumey, L. 2014: P.6.a.014 Chronic ethanol consumption in C57Bl/6J mice induces Bdnf epigenetic and signaling alterations, and cognitive deficits. European Neuropsychopharmacology 24: S660-S661

Bonassoli, V.T.; DeMartinis, B.S.; Bueno, L.H.P.; Milani, H.; DeOliveira, R.M.W. 2014: P.6.a.017 Chronic ethanol exposure increases inducible nitric oxide synthase expression in the dorsolateral periaqueductal gray matter of rats. European Neuropsychopharmacology 24: S662-S663

Krupitsky, E.; Rybakova, K.; Skurat, E.; Kiselev, A. 2014: P.6.b.001 A double-blind placebo-controlled randomised trial of pregabalin for alcohol dependence: interim analysis. European Neuropsychopharmacology 24: S663-S664

Das, R.; Lawn, W.; Kamboj, S.K. 2014: P.6.b.004 Disgust counterconditioning during reconsolidation reduces liking of and abolishes attentional bias to alcohol cues. European Neuropsychopharmacology 24: S665-S666

Prokopieva, V.D.; Yarygina, E.G.; Bokhan, N.A. 2014: P.6.b.006 Carnosine protects blood plasma proteins from damaging effect of acetaldehyde. European Neuropsychopharmacology 24: S666-S667

Jang, Y.L.; Choi, J.; Min, Y.; Shim, H.; Lee, H. 2014: P.6.b.008 Temperaments and characters associated with the relapse in alcohol-dependent patients. European Neuropsychopharmacology 24: S667-S668

Altamirano, J.; Ortega, L.L.; Michelena, J.; Puicercus, I.; Jones, P.D.; Bataller, R.; Gual, A.; Lligoña, A. 2014: P.6.b.009 High-risk alcohol relapse scale is a good instrument for predicting long-term abstinence after an episode of alcoholic hepatitis. European Neuropsychopharmacology 24: S668-S669

Martinotti, G.; DiGiannantonio, M.; DiNicola, M.; Janiri, L. 2014: P.6.b.011 Nalmefene in dual diagnosed alcoholics: an open study. European Neuropsychopharmacology 24: S669-S670

Santacroce, R.; Martinotti, G.; Cinosi, E.; Lupi, M.; Acciavatti, T.; Marini, S.; DiGiannantonio, M. 2014: P.6.b.013 Alcohol, coffee and energy drink consumption patterns in a sample of Italian adolescents and young adults. European Neuropsychopharmacology 24: S670-S671

Aubin, H.J.; Sørensen, P.; Von der Goltz, C. 2014: P.6.b.016 Effect of nalmefene as needed on alcohol consumption and mood in alcohol dependent patients with comorbid mood disorder. European Neuropsychopharmacology 24: S672-S673

Banca, P.; Lange, I.; Worbe, Y.; Howell, N.A.; Irvine, M.; Harrison, N.A.; Moutoussis, M.; Voon, V. 2014: P.6.b.018 Reflection impulsivity in binge drinking: behavioural and volumetric correlates. European Neuropsychopharmacology 24: S673-S674

Devroye, C.; Cathala, A.; Drago, F.; Piazza, P.V.; Spampinato, U. 2014: P.6.c.002 Blockade of central serotonin 2B receptors reduces cocaine-induced hyperlocomotion independently of subcortical Da outflow. European Neuropsychopharmacology 24: S675-S676

Konstantinopolsky, M.; Kolik, L.; Gudasheva, T. 2014: P.6.c.004 New peptide-origin anxiolytics, Gb-115 and Selank, as possible tools in treatment of opiate addiction: an experimental study. European Neuropsychopharmacology 24: S676-S677

Jafarova Demirkapu, M.; Yananli, H.R.; Goren, M.Z.; Kaleli, M.; Topkara, B.; Sakalli, H.E.; Aydin, B. 2014: P.6.c.007 The role of adenosine receptors in the nucleus accumbens during morphine withdrawal. European Neuropsychopharmacology 24: S678-S679

Olevska, A.; Bernardi, R.E.; Brambilla, R.; Spanagel, R. 2014: P.6.c.009 The role of ras guanine nucleotide-releasing factor 1 (ras-Grf1) in cocaine self-administration. European Neuropsychopharmacology 24: S679-S680

Zhvania, M.; Bikashvili, T.; Japaridze, N.; Gelazonia, L.; Chilachava, L. 2014: P.6.c.012 Immediate and persisting effect of toluene chronic inhalation on behaviour in maze and on hippocampal structure in adult and adolescent rats. European Neuropsychopharmacology 24: S681-S682

García-Cabrerizo, R.; García-Fuster, M.J. 2014: P.6.c.014 Acute and chronic effects of Mdma on hippocampal cell fate markers in adolescent and adult rats. European Neuropsychopharmacology 24: S682-S683

Yadid, G.; Massart, R.; Barnea, R.; Dikhstein, Y.; Suderman, M.; Meir, O.; Hallett, M.; Kennedy, P.; Nestler, E.J.; Szyf, M. 2014: P.6.c.016 Dynamic epigenetic landscapes define progression to cocaine addiction. European Neuropsychopharmacology 24: S683-S684

Zamberletti, E.; Gabaglio, M.; Prini, P.; Rubino, T.; Parolaro, D. 2014: P.6.c.019 Persistent microglia activation contributes to the depressive/psychotic-like phenotype induced by adolescent Thc exposure in rats. European Neuropsychopharmacology 24: S685-S686

Amit, B.H.; Shoval, G.; Zamir-Davis, R.; Mell, H. 2014: P.6.d.001 Prevalence of cognitive impairments and emotional recognition bias in substance abuse or dependence currently in remission. European Neuropsychopharmacology 24: S686-S687

Peles, E.; Linzy, S.; Sason, A.; Adelson, M. 2014: P.6.d.002 Is internet addiction prevalent among methadone maintenance treatment (Mmt) patients? Data from Las Vegas and Tel Aviv. European Neuropsychopharmacology 24: S687-S688

Galindo, L.; Fonseca, F.; Torrens, M. 2014: P.6.d.004 Response to methadone maintenance treatment: what is the role of personality?. European Neuropsychopharmacology 24: S688-S689

Yaroslavtseva, T.; Krupitsky, E.; Zvartau, E.; Blokhina, E.; Woody, G. 2014: P.6.d.005 The impact of oral and implantable formulations of naltrexone on overall functioning and social adjustment in opioid dependent patients. European Neuropsychopharmacology 24: S689-S690

Cinosi, E.; Marini, S.; Lupi, M.; Santacroce, R.; Corazza, O.; Acciavatti, T.; Martinotti, G.; DiGiannantonio, M. 2014: P.6.d.008 Novel psychoactive substances as new frontiers of polyabuse: the case of Camfetamine. European Neuropsychopharmacology 24: S690-S691

Guterstam, J.; Jayaram-Lindström, N.; Berrebi, J.; Ingvar, M.; Franck, J. 2014: P.6.d.010 Neural correlates of cue-induced craving for amphetamine. European Neuropsychopharmacology 24: S691-S692

Martorelli, C.; Roggi, M.; DiVolo, S.; Bolognesi, S.; Goracci, A.; Fagiolini, A. 2014: P.6.d.013 Assessment of early psychiatric symptoms among substance users: a preliminary study. European Neuropsychopharmacology 24: S693-S694

Sánchez, S.M.; Lazcano, A.L.; Prats, A.F.; Garreta, A.L. 2014: P.6.d.015 Opioid consumers: from the pain clinic to the addictive behaviours unit. European Neuropsychopharmacology 24: S694-S695

Mokrysz, C.; Gage, S.; Landy, R.; Munafò, M.R.; Roiser, J.P.; Curran, H.V. 2014: P.6.d.016 Neuropsychological and educational outcomes related to adolescent cannabis use, a prospective cohort study. European Neuropsychopharmacology 24: S695-S696

Freeman, T.P.; Morgan, C.J.A.; Hindocha, C.; Schafer, G.L.; Das, R.K.; Curran, H.V. 2014: P.6.d.018 Effects of delta-9-tetrahydrocannabinol and cannabidiol on estimated cannabis potency and actual titration. European Neuropsychopharmacology 24: S696-S697

Vrajová, M.; Schutová, B.; Klaschka, J.; Štepánková, H.; Rípová, D.; Šlamberová, R. 2014: P.6.e.002 Prenatal methamphetamine exposition and and age-related changes in the expression of Nmda receptor subunits in rats. European Neuropsychopharmacology 24: S697-S698

Buzescu, A.; Cristea, A.N.; Arama, C. 2014: P.6.e.003 Experimental evidence on the increase of glutamic acid brain levels, induced by repeated ingestion of dietary monosodium glutamate. European Neuropsychopharmacology 24: S698-S699

Mick, I.; Myers, J.; Stokes, P.; Colasanti, A.; Erritzoe, D.; Gunn, R.; Clark, L.; Rabiner, E.A.; Lingford-Hughes, A.; Nutt, D. 2014: P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [11C]carfentanil Pet study. European Neuropsychopharmacology 24: S699-S700

Trautmann, S.; Schönfeld, S.; Behrendt, S.; Wittchen, H.U. 2014: P.6.f.003 Increase in Ptsd but not depression symptoms is associated with increases in alcohol and cigarette consumption after military deployment. European Neuropsychopharmacology 24: S700-S701

Taranto, F.; Goracci, A.; Bolognesi, S.; Borghini, E.; Fagiolini, A. 2014: P.6.f.005 Internet addiction disorder in a sample of students. European Neuropsychopharmacology 24: S701-S702

Morris, L.S.; Kundu, P.; Irvine, M.A.; Robbins, T.W.; Bullmore, E.T.; Voon, V. 2014: P.6.f.007 Compulsivity in binge-eating disorder. European Neuropsychopharmacology 24: S702-S703

Alberti, S.; Mandelli, L.; Martinotti, G.; DeNicola, M.; Albani, D.; Serretti, A.; Janiri, L. 2014: P.6.f.008 Does genetics predict severity of gambling disorder? A preliminary study on an Italian sample of gamblers. European Neuropsychopharmacology 24: S703-S704

Lucas, N.; Legrand, R.; Akkermann, K.; Harro, J.; Bole-feysot, C.; Breton, J.; Dechelotte, P.; Fetissov, S.O. 2014: P.7.a.002 Anti--melanocyte-stimulating hormone autoantibodies in patients with eating disorders and melanocortin 4 receptor signaling. European Neuropsychopharmacology 24: S704-S705

Corominas-Roso, M.; Ramos-Quiroga, J.A.; Palomar, G.; Ferrer, R.; Real, A.; Lopez-Craver, M.V.; Olivares, B.; Casas, M. 2014: P.7.b.001 Cortisol response to stress in adults with attention deficit hyperactivity disorder. European Neuropsychopharmacology 24: S705-S706

Ozel-Kizil, E.T.; Kokurcan, A.; Aksoy, U.M.; Biçer-Kanat, B.; Sakarya, D.; Bastug, G.; Colak, B.; Altunöz, U.; Kirici, S.; Demirbas, H.; Oncü, B. 2014: P.7.b.005 Hyperfocusing as a dimension of adult Adhd. European Neuropsychopharmacology 24: S707-S708

Hwang, J.; Seo, J.Y.; Koo, Y.J. 2014: P.7.b.006 The psychopathology and quality of life in children and adolescents with precocious puberty. European Neuropsychopharmacology 24: S708-S709

Maijer, K.; Palmen, S.J.M.C.; Sommer, I.E.C. 2014: P.7.b.008 Auditory verbal hallucinations in youth: a longitudinal observational study. European Neuropsychopharmacology 24: S709-S710

Díaz-Caneja, C.M.; Pina-Camacho, L.; Fraguas, D.; González-Pinto, A.; Rodríguez-Jiménez, R.; García, A.; Sanjuán, J.; Saiz, P.; Arias, B.; Corripio, I.; Arango, C. 2014: P.7.b.009 Predictors of weight gain after six months of treatment with second-generation antipsychotics in pediatric and adult patients. European Neuropsychopharmacology 24: S710-S711

Gajria, K.; Livote, E.; Sikirica, V.; Reilly, K.; Kosinski, M.; Erder, M.H. 2014: P.7.b.011 Validation of the Weiss Functional Impairment Rating Scale Parent Report Form in attention deficit/hyperactivity disorder. European Neuropsychopharmacology 24: S711-S712

Pivovarciova, A.; Hnilicova, S.; Tomova, A.; Ostatnikova, D.; Mace, F.C. 2014: P.7.b.012 Testosterone and explosive aggression in children with autism spectrum disorders. European Neuropsychopharmacology 24: S712-S713

Cantisani, A.; Grassi, G.; Pagano, L.; Comanducci, A.; Lanzo, G.; Amantini, A.; Grippo, A.; Salerno, L.; Pallanti, S. 2014: P.7.b.015 Neurophysiological alterations in adults with attention deficit/hyperactivity disorder: an event-related potential study. European Neuropsychopharmacology 24: S714-S715

Del Rey-Mejias, A.; Fraguas, D.; Martínez-Díaz-Caneja, C.; Pina-Camacho, L.; Castro-Fornieles, J.; Baeza, I.; Espliego, A.; Merchán-Naranjo, J.; González-Pinto, A.; Dela Serna, E.; Paya, B.; Arango, C.; Parellada, M. 2014: P.7.b.017 Premorbid to post-morbid functional adjustment course in adolescents after a first episode psychosis. European Neuropsychopharmacology 24: S715-S716

Pina-Camacho, L.; Jensen, S.; Gaysina, D.; Barker, E.D. 2014: P.7.b.018 Maternal depression symptoms, unhealthy diet and child emotionalbehavioural dysregulation. European Neuropsychopharmacology 24: S716-S717

Stuhec, M. 2014: P.7.c.001 The use of medication against attention deficit/hyperactivity disorder in Slovenia: a drug consumption study. European Neuropsychopharmacology 24: S717-S718

Quansah, E.; Zhu, Y.; Zetterström, T. 2014: P.7.C.003 Effects of methylphenidate on dopamine targets in the left and right brain hemispheres. European Neuropsychopharmacology 24: S718-S719

DiMiceli, M.; Gronier, B. 2014: P.7.C.004 Voluntary chronic methylphenidate oral intake in rats, effect on ventral tegmental area dopamine neurons. European Neuropsychopharmacology 24: S719-S720

Lakic, A.; Kesic, A. 2014: P.7.d.002 Effects of risperidone in the treatment of conduct disorder in children without intellectual disability. European Neuropsychopharmacology 24: S720-S721

Martsenkovsky, I. 2014: P.7.d.004 Divalproex sodium and risperidone in the treatment of cognitive, behavioral and social dysfunction in preschool children with Pdd and Adhd. European Neuropsychopharmacology 24: S721-S722

Blazquez Hinojosa, A.; GassóAstorga, P.; Herrero, S.M.; Turró, M.T.P.; Flo, A.L.; García, L.L. 2014: P.7.d.005 Cytochromes Cyp2D6 and Cyp2C9 and relapse depression rates in a cohort of adolescents. European Neuropsychopharmacology 24: S722-S723

Upadhyaya, H.P.; Soutullo, C.; Saito, T.; Day, K.; Fregenal, I.; Adams, D.H.; Wietecha, L.A. 2014: P.7.d.007 Review of atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in patients with common comorbidities. European Neuropsychopharmacology 24: S723-S724

Sabuncuoglu, O. 2014: P.7.d.008 Characteristics of readmitted Adhd children who had non-adherence to medication before. European Neuropsychopharmacology 24: S724-S725

Balia, C.; Placini, F.; Liori, A.; Peddis, C.; Carucci, S.; Zuddas, A. 2014: P.7.d.010 Face and emotion recognition in children with Adhd and autism spectrum disorders: effects of methylphenidate. European Neuropsychopharmacology 24: S725-S726

Huss, M.; Hervas, A.; Newcorn, J.H.; Harpin, V.; Lyne, A.; Robertson, B.; Sikirica, V. 2014: P.7.d.013 Guanfacine extended release for attention-deficit/hyperactivity disorder following inadequate response to prior methylphenidate. European Neuropsychopharmacology 24: S727-S728

Ferguson, B.; Schrantee, A.G.M.; DeRuiter, M.B.; Bottelier, M.A.; Reneman, L. 2014: P.7.e.001 Opposite effects of acute methylphenidate administration in children versus adult Adhd patients during emotional processing. European Neuropsychopharmacology 24: S728-S729

Sanchez-Gistau, V.; Baeza, I.; Arango, C.; González-Pinto, A.; Dela Serna, E.; Parellada, M.; Graell, M.; Paya, B.; Llorente, C.; Castro-Fornieles, F. 2014: P.7.f.002 The affective dimension of early-onset first episode of psychosis. European Neuropsychopharmacology 24: S729-S730

Kestelman, P.; Kutnowski, C. 2014: P.7.f.003 Mental disorders in children with Hiv/Aids. European Neuropsychopharmacology 24: S730-S731

Kim, E. 2014: P.7.f.005 The impact of specific behavioral problems on the health-related quality of life of children and adolescents with epilepsy. European Neuropsychopharmacology 24: S731-S732

Dronjak, D.; Cvetkovic, M. 2014: P.7.f.007 Abuse of psychotropic drugs among Serbian adolescents. European Neuropsychopharmacology 24: S732-S733

Häge, A.; Dittmann, R.W.; Pennick, M.; Sorooshian, S.; Ermer, J.; Adeyi, B.; Squires, L.; Coghill, D.R. 2014: P.7.f.009 Lisdexamfetamine dimesylate: hydrolysis, pharmacokinetics and duration of therapeutic action in children and adolescents with Adhd. European Neuropsychopharmacology 24: S733-S734

Carmi, L.; Zohar, J. 2014: P.8.b.001 Secondary prevention in depression, bipolar and addiction via mobile phone. European Neuropsychopharmacology 24: S734-S735

Stuhec, M. 2014: P.8.b.003 Pharmacotherapy review as a safety and cost tool in patients management in Slovenian Psychiatric Hospital. European Neuropsychopharmacology 24: S735-S736

Stuhec, M. 2014: P.8.b.005 Excessive sweating induced by interaction between agomelatine and duloxetine: a cooperation with clinical pharmacist. European Neuropsychopharmacology 24: S736-S737

Janjic, V.; Radmanovic, B.; Dejanovic, S.D.; Ravanic, D.; Borovcanin, M. 2014: P.8.b.006 Side effects of zolpidem and temazepam in treating primary insomnia. European Neuropsychopharmacology 24: S737-S738

Kamaradova, D.; Prasko, J.; Latalova, K. 2014: P.8.b.008 Self-stigmatisation and adherence to treatment. European Neuropsychopharmacology 24: S738-S739

Garip, B. 2014: P.8.b.010 Relationships between plasma testosterone and suicidal behaviour in antisocial personality disorder. European Neuropsychopharmacology 24: S739-S740

Parise, V.F.; Addeo, L.; Laezza, R. 2014: P.8.b.013 Therapeutic efficacy of generic drugs versus branded antipsychotics and antidepressants: comparative results. European Neuropsychopharmacology 24: S740-S741

Rutigliano, G.; Briganti, E.; Chatzianagnostou, K.; Quiñones-Galvan, A.; Arvia, C.; Iervasi, G.; Dell'Osso, L. 2014: P.8.b.014 Magnesium supply improves adherence to hypocaloric diets in women: effects on weight control competence preliminary results. European Neuropsychopharmacology 24: S741-S742

Wojtanowska-Bogacka, M.; Skibinska, M.; Remlinger-Molenda, A.; Wojciak, P.; Kucharska, A.; Abramowicz, M.; Ferensztajn, E.; Rybakowski, J.K. 2014: P.8.b.019 Prevalence of anti-glutamic acid decarboxylase (anti-Gad) antibodies in psychiatric patients. European Neuropsychopharmacology 24: S744-S745

Henry, M.; Henry-Gonzalez, A.A.; Morera-Fumero, A.; Diaz-Mesa, E.; Gonzalez-Martin, I.; Padron-Ruperez, F.; Gracia-Marco, R. 2014: P.8.b.021 Respiratory improvement in chronic asthma treated with autogenic therapy. European Neuropsychopharmacology 24: S745-S746

Ramsey, J.M.; Bahn, S. 2014: P.8.b.023 Overlapping and distinct sex-specific serum molecular profiles in schizophrenia, depression, bipolar disorder, and Asperger syndrome. European Neuropsychopharmacology 24: S746-S747

Jarungsuccess, S.; Srisaksakul, E.; Ruangdechanan, A.; Sanichwankul, K.; Pumpaisalchai, W.; Suwan, S.; Wannamanee, S.; Puangmalai, K.; Udombhornprabha, A. 2014: P.8.b.026 Pharmacokinetics predictive of risperidone in man with clinical implications. European Neuropsychopharmacology 24: S748-S749

Peuskens, J. 2014: C.02.01 Efficacy and tolerability of antipsychotic treatment. European Neuropsychopharmacology 24: S752-S753

Fagiolini, A. 2014: C.04.03 Clinical management of mania with depressive symptoms. European Neuropsychopharmacology 24: S755-S756

Llorca, P. 2014: C.07.02 Agitation continuum as critical symptom in psychiatric emergencies. European Neuropsychopharmacology 24: S756-S757

Nasrallah, H. 2014: C.08.02 Are psychotic events neurotoxic?. European Neuropsychopharmacology 24: S757-S758

McAllister-Williams, R. 2014: C.09.01 Complicating factors in the diagnosis and treatment of depression. European Neuropsychopharmacology 24: S758-S759

Van den Brink, W. 2014: C.10.03 Clinical evidence with opioid modulators in alcohol dependence. European Neuropsychopharmacology 24: S760-S761

Haddad, P. 2014: C.11.02 Balancing antipsychotic efficacy with minimal metabolic burden: new developments in schizophrenia management. European Neuropsychopharmacology 24: S761-S762

Emsley, R. 2014: C.12.01 The nature of relapse in schizophrenia. European Neuropsychopharmacology 24: S762-S763

Redlich, R.; Grotegerd, D.; Dohm, K.; Opel, N.; Zwitserlood, P.; Dannlowski, U. 2015: S.01.03 Neurobiology of adult separation anxiety disorder. European Neuropsychopharmacology 25: S111-S112

Wicks, P. 2015: S.02.04 Digital biomarkers for mood disorders. European Neuropsychopharmacology 25: S112-S113

Vollstädt-Klein, S.; Nakovics, H.; Kirsch, M.; Sommer, W.; Mann, K.; Kiefer, F. 2015: S.03.03 Cue-induced brain activation and its association with automated and obsessive-compulsive alcohol consumption. European Neuropsychopharmacology 25: S113-S114

Spalletta, G.; Schiff, M.; Chiapponi, C.; Bossù, P.; Muhlenhoff, M.; Caltagirone, C.; Gerardy-Schahn, R.; Hildebrandt, H.; Piras, F. 2015: S.04.04 Clinical and brain structural correlates of Ncam and polysialic acid serum levels in schizophrenia. European Neuropsychopharmacology 25: S115-S116

Sienaert, P.; Verwijk, E.; Bouckaert, F.; Comijs, H.; Stek, M.; Kok, R.; Spaans, H. 2015: S.05.02 Efficacy and cognitive side effects of ultrabrief pulse electroconvulsive therapy (Ntr1304). European Neuropsychopharmacology 25: S116-S117

Van Amelsvoort, T. 2015: S.06.03 Neurobiological risk factors for schizophrenia in adults with 22q11.2Ds. European Neuropsychopharmacology 25: S118-S119

Adriani, W. 2015: S.07.04 Neuroimmunological regulators of compulsivity. European Neuropsychopharmacology 25: S120-S121

Shomron, N. 2015: S.08.03 Gene and microRna expression in the mode of action of treatments for major depression. European Neuropsychopharmacology 25: S121-S122

Boxer, A. 2015: S.09.01 Pharmacological treatment of frontal lobe dementia: recent advances. European Neuropsychopharmacology 25: S122-S123

Mehta, M. 2015: S.10.02 Experimental medicine with phMri: study designs. European Neuropsychopharmacology 25: S124-S125

Callicott, J.; Ihne, J.; Ursini, G.; Blasi, G.; Berman, K.F.; Bertolino, A.; Weinberger, D.R. 2015: S.11.01 Gene-environment interaction and prefrontal cortical function as measured by fMri. European Neuropsychopharmacology 25: S125-S126

Tamminga, C.A.; Keshavan, M.S.; Pearlson, G.D.; Sweeney, J.S.; Ivleva, E.I.; Clementz, B.C. 2015: S.11.04 Are endophenotypes a useful concept?. European Neuropsychopharmacology 25: S126-S127

Gasull-Camós, J.; Artigas, F.; Castañé, A. 2015: S.12.03 Modulation of glutamatergic transmission in the infralimbic cortex evokes antidepressant-like effects in rats. European Neuropsychopharmacology 25: S127-S128

Nouhi, M.; Zhang, X.; Yao, N.; Chergui, K. 2015: S.12.05 Allosteric modulation of Nmda receptors rescues impaired synaptic plasticity in experimental Parkinsonism. European Neuropsychopharmacology 25: S128-S129

Weiser, M.; Saporta, L.; Levi, L.; Feldman, R. 2015: S.13.03 Rct administering oxytocin for schizophrenia, a three week add-on study. European Neuropsychopharmacology 25: S130-S131

Potenza, M.N.; Worhunsky, P.D.; Kober, H.; Angarita, G.; Gallezot, J.; Matuskey, D.; Nabusi, N.; Luhmann, C.; Lee, D.; Ding, Y.; Carson, R.E.; Malison, R.T. 2015: S.14.02 Dopaminergic function, choice impulsivity and cocaine use in cocaine-dependent humans. European Neuropsychopharmacology 25: S131-S132

Yücel, M.; Fontenelle, L.F. 2015: S.14.04 How a stick becomes a reward to reinforce compulsivity in Ocd: implications for addiction. European Neuropsychopharmacology 25: S132-S133

Dresler, M. 2015: S.16.04 Sleep-related neuroplasticity in major depression. European Neuropsychopharmacology 25: S136-S137

Nieuwenhuis, M.; Mourao-Miranda, J.; Van Haren, N.E.M.; Schnack, H.G.; Kahn, R.S.; Dazzan, P. 2015: S.18.03 Machine learning as a tool to assist in diagnosis. European Neuropsychopharmacology 25: S138-S139

Gass, N.; Meyer-Lindenberg, A.; Schwarz, A.J.; Weber-Fahr, W.; Sartorius, A.; Bastlund, J.F.; Didriksen, M. 2015: S.19.02 Structural and functional imaging effects of Cnvs in mouse and man. European Neuropsychopharmacology 25: S139-S140

Cryan, J.F.; Dinan, T.G. 2015: S.20.01 The microbiome-gut-brain axis: how bacteria can cause mood and psychotic disorders. European Neuropsychopharmacology 25: S140-S141

Nutt, D. 2015: S.21.02 How to rescue Cns active drugs which fail in one indication: experience from the Ecnp Medicines Chest Initiative. European Neuropsychopharmacology 25: S141-S142

Binder, E. 2015: S.23.03 Genetic and epigenetic moderator of the first transcriptome response to stress: importance for stress-related psychiatric disorders?. European Neuropsychopharmacology 25: S144-S145

Collo, G.; Cavalieri, L.; Mora, C.; Chiamulera, C.; Millan, M.J.; Pich, E.M.; Spano, P. 2015: S.24.01 mTor controls structural plasticity of dopaminergic neurons: implication in the actions of ketamine. European Neuropsychopharmacology 25: S145-S146

Rujescu, D. 2015: S.26.02 Genomics research in suicidology. European Neuropsychopharmacology 25: S148-S149

Schnack, H. 2015: S.27.01 Novel developments in machine learning techniques for neuroimaging. European Neuropsychopharmacology 25: S149-S150

Dantzer, R.; Walker, A.K.; Zhou, W.; Heijnen, C.J.; Kavelaars, A. 2015: S.28.02 Role of kynurenine and glutamate in inflammation-induced depression. European Neuropsychopharmacology 25: S150-S151

Leibenluft, E. 2015: E.03.01 Irritability and Dsm-5 disruptive mood dysregulation disorder: correlates, predictors, and outcome in children. European Neuropsychopharmacology 25: S153-S154

Fabbri, C.; Serretti, A. 2015: P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. European Neuropsychopharmacology 25: S159-S160

Tadevosyan, K.; Atshemyan, S.; Boyajyan, A. 2015: P.1.a.003 Genetic polymorphisms of chimerin-1 in schizophrenia and ischemic stroke. European Neuropsychopharmacology 25: S160-S161

Gumuslu, E.; Mutlu, O.; Ulak, G.; Uyar, E.; Tatar, O.C.; Celikyurt, I.K.; Akar, F.; Erden, F. 2015: P.1.a.005 Effects of atypical antipsychotics on emotional memory and locomotion: altered gene expression levels of Bdnf and Creb in the hippocampus of mice. European Neuropsychopharmacology 25: S161-S162

Kato, M.; Nonnen, S.; Takekita, Y.; Wakeno, M.; Sakai, S.; Serretti, A.; Kinoshita, T. 2015: P.1.a.007 Four polymorphisms of Slc6A4 are novel predictors of Ssri/Snri response in depressive disorder: sequencing analysis of Slc6A4. European Neuropsychopharmacology 25: S162-S163

Ziegler, C.; Laeger, I.; Stevens, S.; Lesch, K.; Arolt, V.; Gerlach, A.; Deckert, J.; Zwanzger, P.; Domschke, K. 2015: P.1.a.008 Oxytocin receptor gene hypomethylation as a potential risk factor in social anxiety?. European Neuropsychopharmacology 25: S163-S164

Kim, J.J.; Yi, J.S.; Kim, S.H.; Pae, C.U. 2015: P1.a.011 Association of Ahi1 polymorphisms with the diagnosis and treatment outcome of schizophrenia. European Neuropsychopharmacology 25: S164-S165

Takekita, Y.; Fabbri, C.; Kato, M.; Nonen, S.; Sakai, S.; Sunada, N.; Koshikawa, Y.; Kinoshita, T.; Serretti, A. 2015: P1.a.013 Effect of Htr7 gene variants on the efficacy of second-generation antipsychotics with 5-Ht7R antagonism in Japanese schizophrenia patients. European Neuropsychopharmacology 25: S165-S166

Schartner, C.; Weber, H.; Kollert, S.; Wischmeyer, E.; Kent, L.; Domschke, K.; Deckert, J.; Reif, A. 2015: P.1.a.014 Allelic variation in corticotropin-releasing hormone receptor 1 changes receptor activity by alternative splicing. European Neuropsychopharmacology 25: S166-S167

Petryshen, T.; Blokland, G. 2015: P.1.a.016 Investigating schizophrenia genome-wide association studies risk variants in cognitive and neuroimaging defects in the Genus Consortium collection. European Neuropsychopharmacology 25: S167-S168

Pucci, M.; DiBonaventura, M.V.M.; Vezzoli, V.; Scacchi, M.; Persani, L.; Mai, S.; DiFrancesco, A.; Maccarrone, M.; Cifani, C.; D'Addario, C. 2015: P.1.a.021 Genetic and epigenetic regulation of cannabinoid receptor type-1 in obesity. European Neuropsychopharmacology 25: S169-S170

Mandelli, L.; Han, C.; Lee, S.; Patkar, A.A.; Masand, P.S.; Serretti, A.; Pae, C. 2015: P1.a.023 Impact of a Snp in Sigmar1 on major depression, bipolar disorder and treatment response. European Neuropsychopharmacology 25: S170-S171

Houtepen, L.; Van Bergen, A.; Ophoff, R.A.; Kahn, R.S.; Vinkers, C.H.; Boks, M.P.M. 2015: P.1.a.024 Deoxyribonucleic acid methylation marks of psychotropic drug use in bipolar disorder patients; an explorative pilot study. European Neuropsychopharmacology 25: S171-S172

Borkowska, A.; Bieliński, M.; Gołota, S.; Tomaszewska, M.; Kałwa, A.; Junik, R.; Gołębiewski, M.; Sikora, M.; Tretyn, A. 2015: P.1.a.027 Association between the polymorphism of 5-Httlpr gene and affective temperament dimensions using the Temps-A scale in obesity. European Neuropsychopharmacology 25: S172-S173

Plazzotta, G.; Hepgul, N.; Luoni, A.; Schaefer, M.; Riva, M.A.; Pariante, C.M.; Cattaneo, A.R. 2015: P1.a.029 Early-life trauma as susceptibility to develop depression in hepatitis C virus patients following long-term treatment with interferon-alpha. European Neuropsychopharmacology 25: S173-S174

Zannas, A.; Carrillo-Roa, T.; Iurato, S.; Arloth, J.; Röh, S.; Ressler, K.; Nemeroff, C.; Smith, A.; Bradley, B.; Heim, C.; Lange, J.; Brückl, T.; Ising, M.; Wray, N.; Erhardt, A. 2015: P.1.a.031 Lifetime stress accelerates epigenetic aging. European Neuropsychopharmacology 25: S174-S175

Signorelli, M.S.; Rodolico, A.; Bianchini, O.; Previti, G.; Serretti, A.; Aguglia, E. 2015: P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review. European Neuropsychopharmacology 25: S175-S176

Israelyan, N. 2015: P.1.a.037 Compulsive behaviour in adolescent patients with anorexia nervosa. European Neuropsychopharmacology 25: S177-S178

Khachidze, I.; Maloletnev, V.; Gugushvili, M.; Makashvili, M. 2015: P.1.b.002 The Eeg specificity in children with attention deficit hyperactivity disorder (Adhd). European Neuropsychopharmacology 25: S178-S179

Mesdaghinia, A.; Banafshe, H.R.; Alinejad, M.; Mokhtari, R. 2015: P.1.b.004 Chronic supplementation with thiamine enhances the anticonvulsant effect of diazepam on pentylenetetrazole induced seizure in mice. European Neuropsychopharmacology 25: S179-S180

Escuela, D.O.B.; Woolfenden, M.; Pinton, L.; Oflijan, J.; Narváez, M.; Brito, I.; Corrales, F.; Jimenez-Beristein, A.; Agnati, L.F. 2015: P.1.b.005 On the balance and distribution of adenosine A2A homoreceptor and A1-A2A isoreceptor complexes in the hippocampus of the rat brain. European Neuropsychopharmacology 25: S180-S181

Stanciu, G.D.; Musteata, M.; Solean, G. 2015: P.1.b.007 Idiopathic acute polyradiculoneuritis concurrent with acquired myasthenia gravis or a separate entity in a West Highland White Terrier dog?. European Neuropsychopharmacology 25: S181-S182

Colle, R.; Chupin, M.; Cury, C.; Vandendries, C.; Gressier, F.; Hardy, P.; Falissard, B.; Colliot, O.; Ducreux, D.; Corruble, E. 2015: P.1.b.009 Suicide attempts are associated with hippocampal volumes in depressed patients, independently from previous antidepressant treatments. European Neuropsychopharmacology 25: S182-S183

Gören, M.Z.; Saridoğan, G.E.; Aykaç, A.; Cabadak, H. 2015: P.1.b.011 The effect of a combination of D-cycloserine treatment and extinction therapy on M1 protein expression in rats traumatised with cat odor. European Neuropsychopharmacology 25: S183-S184

Bourke, J.; Lyons, G.; Wodehouse, T.; Constantinou, E.; Knopp, P.; Antoniades, M.; Howard, J.; White, P.; Rabiner, E.; Wall, M. 2015: P.1.b.013 Opioid and dopamine transmission in chronic pain and health are diametrically opposed: a phMri study. European Neuropsychopharmacology 25: S184-S185

Guerzoni, G.; Pérez, L.G.; Martínez, E.V. 2015: P.1.b.014 Agenesis of corpus callosum: incidental finding in a schizophrenic patient a case report. European Neuropsychopharmacology 25: S185-S186

Michot, B.; M'Dahoma, S.; Viguier, F.; Hamon, M.; Bourgoin, S. 2015: P.1.b.016 Differential features of allodynia associated with cephalic versus extra-cephalic neuropathic pain in rats. European Neuropsychopharmacology 25: S186-S187

Szewczyk, B.; Stachowicz, K.; Nowak, G.; Daigle, M.; Luckhart, C.; Cardin, V.; Hen, R.; Tanaka, K.F.; Albert, P.R. 2015: P.1.b.017 Effects of zinc treatment on the 5-Ht1A receptor function: behavioural responses. European Neuropsychopharmacology 25: S187-S188

Petronijevic, N.; Jevtic, G.; Nikolic, T.; Mircic, A.; Stojkovic, T.; Velimirovic, M. 2015: P.1.b.019 Effects of antipsychotic treatment on the proteins of glutamatergic synapse in the brain of rats perinatally treated with phencyclidine. European Neuropsychopharmacology 25: S188-S189

Joshi, G.; Gabrieli, J.; Biederman, J.; Whitfield-Gabrieli, S. 2015: P.1.b.022 Integration and segregation of default mode network resting-state functional connectivity in high-functioning autism spectrum disorder. European Neuropsychopharmacology 25: S190-S191

Kraus, C.; Stürkat, I.; Sladky, R.; Hahn, A.; Pfabigan, D.; Tik, M.; Köck, P.; Windischberger, C.; Lamm, C.; Lanzenberger, R. 2015: P.1.b.024 Altered structural plasticity in acute and remitted depressive patients investigated with ultra-high field magnetic resonance imaging. European Neuropsychopharmacology 25: S191-S192

Zinnamon, F.A.; Wenas, S.S.; Wang, K.H.; Linden, J.F. 2015: P.1.b.026 Abnormalities in the auditory and frontal cortices in a mouse model of 22q11.2 Deletion Syndrome. European Neuropsychopharmacology 25: S192-S193

Neves, B.C.; Freitas, F. 2015: P.1.b.029 Neurobiological correlates of aberrant motor functioning in schizophrenia. European Neuropsychopharmacology 25: S193-S194

DeLeeuw, S.M.; Kerkhofs, A.; Ferreira, S.G.; Cunha, R.A.; Mansvelder, H.D. 2015: P.1.b.031 The adenosine 1 receptor modulates basal synaptic activity in the pre-frontal cortex. European Neuropsychopharmacology 25: S194-S195

Nunez, N.I.; Ayala, L.G.; Martín, M.Z.; Itoiz, A.A.; Martínez, I.Z.; Peña, M.P.L.; Porta, O.; de Arrieta, P.P.M.ínez; Arrillaga, A.M.G.ález-P. 2015: P.1.b.032 Effectiveness of the combination of Ect and pharmacological drugs in patients with different diagnosis and description of the incidences observed. European Neuropsychopharmacology 25: S195-S196

Cattane, N.; Tosato, S.; Begni, V.; Tomassi, S.; Locatelli, S.; Lopizzo, N.; Plazzotta, G.; Riva, M.A.; Pariante, C.M.; Cattaneo, A. 2015: P.1.c.006 MiRnas peripheral signature associated with childhood trauma exposure. European Neuropsychopharmacology 25: S196-S197

Stark, T.; Kucerova, J.; Pekarik, V.; Iannotti, F.A.; Aveta, T.; Tabiova, K.; Drago, F.; DiMarzo, V.; Sulcova, A.; Micale, V. 2015: P.1.c.007 Prenatal influences facilitate the precipitation of a schizophrenia-like phenotype: assessing the role of the endocannabinoid system. European Neuropsychopharmacology 25: S197-S198

Fridman, M.; Quintero, J.; Chen, K.; Harpin, V.; Banaschewski, T.; Sikirica, V. 2015: P.1.c.010 Access to diagnosis, treatment and supportive services: results from the caregiver perspective on pediatric Adhd study in Europe. European Neuropsychopharmacology 25: S199-S200

Lamberti, M.; Siracusano, R.; Italiano, D.; Guerriero, L.; Germaniò, E.; Alosi, N.; Cucinotta, F.; Spina, E.; DiRosa, G.; Gagliano, A. 2015: P.1.c.012 Open-label study comparing the efficacy and tolerability of aripiprazole and risperidone in the treatment of children with autism spectrum disorder and Adhd. European Neuropsychopharmacology 25: S200-S201

Lamberti, M.; Guerriero, L.; Italiano, D.; Germanò, E.; Siracusano, R.; D'Amico, G.; Ingrassia, M.; Calabrò, M.; Spina, E.; Gagliano, A. 2015: P.1.c.013 Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children with Adhd: A new electrocardiographic T-waves marker. European Neuropsychopharmacology 25: S201-S202

Capraz, N.; Akdeniz, C.; Schaefer, A.; Bilek, E.; Streit, F.; Kirsch, P.; Meyer-Lindenberg, A.; Tost, H. 2015: P.1.C.016 Perceived social status mobility relates to perigenual anterior cingulate morphology in individuals with ethnic minority status. European Neuropsychopharmacology 25: S203-S204

Borella, V. 2015: P.1.C.019 Influences of sex and estrous cycle on behavioural and neurochemical alterations induced by the neonatal administration of ketamine to rats. European Neuropsychopharmacology 25: S205-S206

O'Farrell, K.; Lim, E.; Guillemin, G.J.; Harkin, A. 2015: P.1.d.002 A role for glial-associated kynurenine pathway activation in modulating neuronal outgrowth and complexity. European Neuropsychopharmacology 25: S206-S207

Jevtic, G.; Stojkovic, T.; Nikolic, T.; Velimirovic, M.; Petronijevic, N. 2015: P.1.d.003 Alterations of oligodendroglial cells in the rat brain in phencyclidine animal model of schizophrenia: effects of antipsychotic treatment. European Neuropsychopharmacology 25: S207-S208

Machado-Santos, A.R.; Mateus-Pinheiro, A.; Alves, N.D.; Patricio, P.; Morais, M.; Oliveira, J.F.; Sousa, N.; Pinto, L. 2015: P.1.d.005 Glial plasticity as a key mechanism underlying the pathophysiology of depression. European Neuropsychopharmacology 25: S208-S209

Rysz, M.; Bromek, E.; Daniel, W.A. 2015: P1.e.002 Activation of the brain serotonergic system decreases the expression and activity of liver cytochrome P450 isoforms Cyp1A, 2C11 and 3A. European Neuropsychopharmacology 25: S209-S210

Piccinni, A.; Marezziti, D.; Baroni, S.; Mucci, F.; Veltri, A.; Dell'Osso, L. 2015: P.1.e.003 Evaluation of cognitive function and brain-derived neurotrophic factor (Bdnf) levels in a sample of euthymic bipolar patients. European Neuropsychopharmacology 25: S210-S211

Vrieze, E.; Bruffaerts, R.; Hompes, T.; Hermans, D.; Sienaert, P.; DeBoer, P.; Schmidt, M.; Claes, S. 2015: P.1.e.005 Repeated stress hormone measurements after a social stressor in major depressive disorder: association patterns and predictive ability. European Neuropsychopharmacology 25: S211-S212

Milosavljevic, M.; Tosevski, D.L.; Rakic, S.; Stanojevic, D.; Soldatovic, I.; Ignjatovic, S. 2015: P.1.e.008 Cortisol and postpartum mental health. European Neuropsychopharmacology 25: S213-S214

D'Alessio, L.; Remedi, C.; Soria, C.; Roldán, E. 2015: P.1.e.009 Neurocognitive and neurochemical responses in patients with anxiety and allostatic load: beyond anxiolysis, can cognition be improved by alprazolam?. European Neuropsychopharmacology 25: S214-S215

Bratek, A.; Koźmin-Burzyńska, A.; Krysta, K.; Krupka-Matuszczyk, I. 2015: P.1.e.012 Relationship between the level of hormones and cognitive abilities of male schizophrenia patients preliminary results. European Neuropsychopharmacology 25: S215-S216

Hahn, A.; Kranz, G.; Sladky, R.; Kaufmann, U.; Ganger, S.; Hummer, A.; Seiger, R.; Spies, M.; Vanicek, T.; Winkler, D.; Kasper, S.; Windischberger, C.; Swaab, D.; Lanzenberger, R. 2015: P.1.e.015 Neuronal plasticity of language-related brain regions induced by long-term testosterone treatment. European Neuropsychopharmacology 25: S217-S218

Süer, C.; Liman, N.; Kandemir, B.; Tan, B.; Kavraal, S.; Bitiktaş, S.; Dursun, N.; Kurnaz, I.A. 2015: P.1.e.017 A decrease in phosphorylation of Creb may explain delayed place learning and attenuated long-term potentiation in adult-onset hyperthyroidism. European Neuropsychopharmacology 25: S218-S219

Tan, B.; Bitiktaş, S.; Ozdoğan, K.; Bakkaloğlu, U.; Aşçioğlu, M.; Süer, C. 2015: P.1.e.018 Maternal l-thyroxine treatment during lactation affects learning and anxiety-like behaviours but not spatial memory in adult rat progeny. European Neuropsychopharmacology 25: S219-S220

Spies, M.; Kiöbl, M.; Kranz, G.S.; Sladky, R.; Kaufmann, U.; Ganger, S.; Hahn, A.; Windischberger, C.; Kasper, S.; Lanzenberger, R. 2015: P.1.e.022 The influence of cross-sex hormone therapy in transgender persons on neural correlates of empathy. European Neuropsychopharmacology 25: S221-S222

Sitbon, J.; Kappeler, C.; Nicolas, A.; Henrion, A.; Rhee, J.; Leboyer, M.; Jamain, S. 2015: P.1.e.023 Functional mutations in Cadps identified in patients with early-onset bipolar disorder. European Neuropsychopharmacology 25: S222-S223

Besirli, A.; Esel, E.; Ozsoy, S.D.; Turan, T. 2015: P.1.e.025 Alterations of serum brain-derived neurotrophic factor levels and its effects on cognitive functions during early and late alcohol withdrawal. European Neuropsychopharmacology 25: S223-S224

Kim, S.H.; Jeong, H.G.J.; Lee, M.S.; Joe, S.H. 2015: P.1.e.026 Relationship between dehydroepiandrosterone sulfate (Dhea-s) levels and severity in patients with major depressive disorder. European Neuropsychopharmacology 25: S224-S225

Pohanka, M. 2015: P.1.f.002 Caffeine affects cytokine secretion after immunity stimulation by Freund's complete adjuvant. European Neuropsychopharmacology 25: S225-S226

Unal, G.; Terzioglu, G.; Sahin, C.; Demirel, G.Y.; Aricioglu, F. 2015: P.1.f.004 The effect of acute ketamine administration on Nlrp3 inflammasome activation in a sub-chronic stress model of rats. European Neuropsychopharmacology 25: S226-S227

Jansen, J.; Fernstrand, A.M.; Van de Loo, A.J.A.E.; Garssen, J.; Verster, J.C. 2015: P.1.f.005 Cytokines and mood in healthy young adults. European Neuropsychopharmacology 25: S227-S228

Hyun, K.; Kang, J.L. 2015: P.1.f.007 Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. European Neuropsychopharmacology 25: S228-S229

Gultekin, G.; Demirci, M.A.; Amil, R.; Saip, S.; Emul, M. 2015: P.1.f.009 Morningness and eveningness type in patients with multiple sclerosis and relation with clinical severity. European Neuropsychopharmacology 25: S229-S230

Dunjić-Kostić, B.; Stefanović, M.P.ć; Ivković, M.; Lačković, M.; Damjanović, A.; Radonjić, N.; Petronijević, N.; Velimirović, M.; Nikolić, T.; Jašović-Gašić, M. 2015: P.1.f.010 Is tumor necrosis factor-alpha a sensitive marker of acute exacerbation of severe mental illnesses?. European Neuropsychopharmacology 25: S230-S231

Larsen, J.H.; Reitan, S.K.; Iversen, V. 2015: P.1.f.012 Association of psychiatric disorders and diseases affecting the immune system. European Neuropsychopharmacology 25: S231-S232

Gene, A.; Kalelioglu, T.; Karamustafalioglu, N.; Tasdemir, A.; Genc, E.S.; Akkus, M.; Emul, M.H. 2015: P.1.f.013 Serum soluble urokinase-type plasminogen activator receptor (suPar) levels in male patients with acute exacerbation of schizophrenia. European Neuropsychopharmacology 25: S232-S233

Dempsey, E.; Abautret-Daly, A.; Downing, J.; Harkin, A.; Medina, C. 2015: P.1.f.015 Evidence for central molecular changes and changes to neuronal activity in an animal model of inflammatory bowel disease. European Neuropsychopharmacology 25: S233-S234

DePicker, L.; Staelens, S.; Ceyssens, S.; Verhaeghe, J.; Deleye, S.; Stroobants, S.; Sabbe, B.; Morrens, M. 2015: P.1.f.019 Methodological aspects of translocator protein positron emission tomography for microglial activation in schizophrenia patients. European Neuropsychopharmacology 25: S234-S235

Costi, S.; Hodes, G.E.; Schwartz, J.; Horn, S.; Collins, K.A.; Iosifescu, D.V.; Russo, S.J.; Murrough, J.W. 2015: P.1.f.020 Association between peripheral interleukin 6 and brain response to positive stimuli in a depressive spectrum. European Neuropsychopharmacology 25: S235-S236

Alcocer-Gómez, E.; Casas-Barquero, N.; Marín-Aguilar, F.; Bullón, P.; Carrión, A.M.; Sanchez-Alcazar, J.A.; Cordero, M.D. 2015: P.1.f.022 Nlrp3-inflammasome complex is implicated in depressive behaviour induced by stress. European Neuropsychopharmacology 25: S236-S237

Jaako, K.; Uibokand, K.; Noortoots, A.; Aonurm-Helm, A.; Kalda, A.; Zharkovsky, A. 2015: P.1.f.023 Increased prolyl endopeptidase induces alterations in the expression of neural cell adhesion molecule in Sh-Sy5Y neuroblastoma cells. European Neuropsychopharmacology 25: S237-S238

Nesterkina, M.; Alekseeva, E.; Kravchenko, I. 2015: P.1.g.002 Anticonvulsant screening of novel calixarene derivatives containing gamma-aminobutyric acid moieties. European Neuropsychopharmacology 25: S238-S239

Kunath, N.; Smith, D.; Brewer, R.; Van Groen, T.; Kumar, A.; Dozier-Sharpe, M.; Kadish, I. 2015: P.1.g.005 Long term ghrelin agonist treatment in mice does not increase weight but reduces fat mass in specific anatomical regions. European Neuropsychopharmacology 25: S240-S241

Demirtas, T.; Arkan, S.; Karson, A.; Utkan, T. 2015: P.1.g.007 Effect of chronic etanercept (a Tnf- inhibitor) treatment on depressive-like behaviour in aged rats. European Neuropsychopharmacology 25: S241-S242

Pekcec, A.; Isherwood, S.N.; Nicholson, J.R.; Robbins, T.W.; Dalley, J.W. 2015: P.1.g.009 Dissociable effects of mGluR5 modulation on motor and choice impulsivity in rats: interaction with Nmda receptor antagonism. European Neuropsychopharmacology 25: S242-S243

Doncheva, N.; Vasileva, L.; Saracheva, K.; Getova, D. 2015: P.1.g.011 Antinociceptive effects of ketamine and alpha-lipoic acid in rats with neuropathic pain. European Neuropsychopharmacology 25: S243-S244

Otvos, R.A.; Mladic, M.; Alpizar, G.A.; Niessen, W.M.A.; Somsen, G.W.; Smit, A.B.; Kool, J. 2015: P.1.g.013 Identification of novel bioactives on the alpha-7-nAchR using an at-line cellular bioassay after nanofractionation. European Neuropsychopharmacology 25: S244-S245

Hryb, A.B.R.; Cunha, M.P.; Pazini, F.L.; Neis, V.B.; Lieberknecht, V.; Kaster, M.P.; Rodrigues, A.L.S. 2015: P.1.g.014 Intracellular signaling pathways implicated in the antidepressant-like effect of ursolic acid in the tail suspension test. European Neuropsychopharmacology 25: S245-S246

Shokry, I.M.; Callanan, J.J.; Sousa, J.; Tao, R. 2015: P.1.g.016 Why direct intracerebroventricular injection of 3,4-methylenedioxymethamphetamine (ecstasy) failed to produce serotonin syndrome in animal models?. European Neuropsychopharmacology 25: S246-S247

Saracheva, K.; Getova, D. 2015: P.1.g.018 Study of the effects of serotonin 1B/1D selective agonists eletriptan and rizatriptan on pain reactions. European Neuropsychopharmacology 25: S247-S248

Bretin, S.; David, D.; Martinez, A.D.; Gardier, A.; Guilloux, J.P.; Mendez, R.L.; Maccari, S.; Mairesse, J.; David, I.M.; Papp, M.; Carro, A.P.; Mocaer, E. 2015: P.1.g.019 Antidepressant- and anxiolytic-like properties of S 47445, a novel positive allosteric modulator of Ampa type glutamate receptors. European Neuropsychopharmacology 25: S248-S249

Grassi, G.; Micheli, L.; DiCesare Mannelli, L.; Compagno, E.; Ghelardini, C.; Pallanti, S. 2015: P1.g.023 Atomoxetine for hoarding disorder: a preclinical and clinical investigation. European Neuropsychopharmacology 25: S249-S250

Zink, M. 2015: P.1.g.024 Effects of antipsychotic treatment on obsessive-compulsive symptoms in schizophrenia. European Neuropsychopharmacology 25: S250-S251

Lee, J.; Kang, D.; Kim, E.; Kim, B. 2015: P.1.g.026 Efficient strategy for obtaining reliable pharmacokinetic parameters in population compartmental approaches. European Neuropsychopharmacology 25: S251-S252

Irimie-Ana, A.; Militaru, M.; Turtoi, I.; Mihai, S. 2015: P.1.g.028 Attention deficit and hyperactivity disorder the pharmacological approach in our clinic. European Neuropsychopharmacology 25: S252-S253

Belyakova, A.; Voskresenskaya, O.G.; Sinjushin, A.A.; Golubovich, V.P.; Kamensky, A.A. 2015: P1.g.033 C-terminal fragment of arginine-vasopressin contributes more to the rate of memory trace formation, while its analog improves maintenance of the trace. European Neuropsychopharmacology 25: S254-S255

Hellwig, I.; Hörnle, M.; Kaschka, W.P.; Hodgkinson, S. 2015: P.1.g.035 Caenorhabditis elegans as a model of obesity caused by antipsychotics. European Neuropsychopharmacology 25: S255-S256

Jung, M.H.; Jon, D.; Hong, N. 2015: P.1.g.037 Clinical factors related with treatment adherence in psychotic patients with psychiatric hospitalisation experience. European Neuropsychopharmacology 25: S256-S257

Bohotin, C.; Alexa, T.; Luca, A.; Dondas, A.; Iliescu, R. 2015: P.1.g.039 Comparison between systemic and central administration of methylene blue and nitroglycerin on orofacial nociceptive behavior in mice. European Neuropsychopharmacology 25: S257-S258

Erasmus, M.; Shahid, M.; Sallinen, J.; Harvey, B. 2015: P.1.g.040 2C-selective antagonism with Orm10921 decreases behavioural despair and improves cognition in the Flinders sensitive line rat model of depression. European Neuropsychopharmacology 25: S258-S259

Logvinov, I.; Antipova, T.A.; Tarasiuk, A.V.; Gudasheva, T.A.; Seredenin, S.B. 2015: P.1.g.044 Dimeric dipeptide mimetics of the Bdnf loop 4 and loop 1 activate TrkB with different patterns of intracellular signal transduction. European Neuropsychopharmacology 25: S260-S261

Mollinedo-Gajate, I.; Gonzalez-Maeso, J.; Meana, J. 2015: P.1.g.045 Functional interaction between serotonin 2A and metabotropic glutamate 2 receptors in the regulation of dopamine release in mouse prefrontal cortex. European Neuropsychopharmacology 25: S261-S262

Mocking, R.J.T.; Nap, T.S.; Verburg, H.F.; Westerink, A.M.; Assies, J.; Vaz, F.M.; Koeter, M.W.J.; Ruhé, H.G.; Schene, A.H. 2015: P.1.g.047 Biological profiling of antidepressant response in depression: associations with neuroinflammation, fatty acid metabolism, and amygdala-reactivity. European Neuropsychopharmacology 25: S262-S263

Gobira, P.; Moreira, F. 2015: P.1.g.048 Blockade of Cb1 cannabinoid receptors and activation of Cb2 interact to prevent cocaine-responses. European Neuropsychopharmacology 25: S263-S264

Nackenoff, A.; Simmler, L.; Baganz, N.; Paffenroth, K.; Stanwood, G.; Pehrson, A.; Sanchez, C.; Blakely, R. 2015: P.1.g.052 Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed in studies of the Sert Met172 mouse. European Neuropsychopharmacology 25: S264-S265

Ciubotariu, D.; Ghiciuc, C.M.; Tartau, L.M.; Andritoiu, C.V.; Lupusoru, C.E. 2015: P.1.g.054 Zinc reduces morphine dependence with no effect on pain perception in rats possible beneficial role of zinc supplementation in opioid-users. European Neuropsychopharmacology 25: S265-S266

Koch, S.B.J.; Van Zuiden, M.; Nawijn, L.; Frijling, J.L.; Veltman, D.J.; Olff, M. 2015: P.1.g.055 Intranasal oxytocin dampens amygdala reactivity and normalises amygdala connectivity in Ptsd patients. European Neuropsychopharmacology 25: S266-S267

Ninkovic, M.; Jovic, N.J. 2015: P1.g.057 Psychiatric adverse effects of adjunctive levetiracetam for epilepsy in children and adolescents. European Neuropsychopharmacology 25: S267-S268

Mocaer, E.; Chenaf, C.; Lolignier, S.; Chapuy, E.; Bertrand, M.; Gabriel, C.; Eschalier, A. 2015: P.1.g.059 Further evidences of the efficacy of agomelatine in animal models of neuropathic pain. European Neuropsychopharmacology 25: S268-S269

Bartova, L.; Vogl, S.E.; Stamenkovic, M.; Praschak-Rieder, N.; Naderi-Heiden, A.; Kasper, S.; Willeit, M. 2015: P.1.g.062 Combined administration of oral tranylcypromine and intravenous S-ketamine in treatment-resistant depression: A case report. European Neuropsychopharmacology 25: S270-S271

DiMiceli, M.; Gronier, B. 2015: P.1.g.065 Excitatory glutamate component involved in the electrophysiological response of ventral tegmental area dopamine neurons to methylphenidate. European Neuropsychopharmacology 25: S271-S272

Parshukova, D.; Smirnova, L.P.; Buneva, V.N.; Semke, A.V.; Ivanova, S.A. 2015: P.1.g.066 Proteolytic hydrolysis of myelin basic protein by IgGs during long-term treatment of schizophrenia. European Neuropsychopharmacology 25: S272-S273

Mascarenhas, D.; Gomes, K.; Nunes-de-Souza, R. 2015: P1.g.068 Phosphorylation of Trpv1 located within the dorsal periaqueductal gray enhances social defeat stress-induced analgesia in mice. European Neuropsychopharmacology 25: S273-S274

Sorregotti, T.; Cipriano, A.C.; Nunes-de-Souza, R. 2015: P.1.g.070 Amygdala inactivation produces antinociception without changing threatening-induced pain inhibition in mice. European Neuropsychopharmacology 25: S274-S275

Oosterhof, C.A.; ElMansari, M.; Blier, P. 2015: P1.g.074 Brexpiprazole alters monoaminergic systems following its subacute and long-term administration: an in vivo electrophysiological study. European Neuropsychopharmacology 25: S276-S277

Gatti, S. 2015: P.1.g.077 The discovery of Rg1578: a metabotropic glutamate receptor 2/3 negative allosteric modulator with antidepressant and cognitive enhancing properties. European Neuropsychopharmacology 25: S278-S279

Vanani, Z.F. 2015: P.1.g.082 Activation of cannabinoid system in nucleus accumbens affects cost-benefit decision making. European Neuropsychopharmacology 25: S279-S280

Gailledreau, J.; Desbonnet, P.; Soussan, P.K.; Gailledreau, B.; Desbonnet, N.; Becque, S. 2015: P.1.g.084 Could luminosity be part of the placebo effect in antidepressant trials?. European Neuropsychopharmacology 25: S280-S281

Ozgur, B.G.; Aksu, H.; Ozgur, E.; Cesur, G. 2015: P.1.h.003 Effect of congenital and acquired hypothyroidism on forced swimming test in juvenile rats. European Neuropsychopharmacology 25: S282-S283

Sahin, C.; Podda, G.; Grayson, B.; Marsh, S.; Aricioglu, F.; Neill, J.C. 2015: P.1.h.005 The deficit in anticipatory motivation as a negative symptom of schizophrenia: phencyclidine treated rats exhibit pessimism in an optimistic bias task. European Neuropsychopharmacology 25: S283-S284

Oguz, M.; Emre, U.; Guner, U.; Ipek, K.C.; Furuzan, A.; Faruk, E.; Leman, H.; Pelin, T. 2015: P.1.h.006 Effects of antipsychotic drugs asenapine, paliperidone, quetiapine and aripiprazole on pain and locomotion in mice. European Neuropsychopharmacology 25: S284-S285

Wolmarans, P.; Stein, D.J.; Harvey, B.H. 2015: P.1.h.008 Social behaviour in deer mice as a novel interactive paradigm of relevance for obsessive-compulsive disorder (Ocd). European Neuropsychopharmacology 25: S285-S286

Samardzic, J.; Strac, D.S.; Jadzic, D.; Djuric, M.; Obradovic, D.I. 2015: P1.h.010 Behavioural characterisation of dehydroepiandrosterone effects in rats: further evaluation and the role of Gaba(A) receptors. European Neuropsychopharmacology 25: S286-S287

Stamenic, T.T.; Santrac, A.; Divovic, B.; Poe, M.; James, C.M.; Savic, M.M. 2015: P.1.h.011 Effects of positive 5-selective modulation of Gabaa receptors on amphetamine-induced hyperactivation. European Neuropsychopharmacology 25: S287-S288

Brand, S.; Wegener, G.; Harvey, B. 2015: P.1.h.014 Time dependent sensitisation exaggerates depressive-like symptoms in Flinders sensitive line (Fsl) rats, a genetic animal model of depression. European Neuropsychopharmacology 25: S288-S289

Geoffroy, H.; Marie, N.; Canestrelli, C.; Noble, F. 2015: P.1.h.016 Impact of stress on neuronal plasticity in rats. European Neuropsychopharmacology 25: S289-S290

Podlacha, M.; Grzybowska, M.; Chwiej, M.; Laska, E.; Wrona, D. 2015: P.1.h.018 Enhancement of locomotor activity following intraseptal Nmda glutamate receptor agonist injection in high and low responders to novelty. European Neuropsychopharmacology 25: S290-S291

Levy, M.J.F.; Boulle, F.; Martin, V.S.; Poilbout, C.; Rognan, D.; Lanfumey, L. 2015: P.1.h.021 Effect of fluoxetine and Miml411, a novel tropomyosin-related kinase receptor agonist, in a lipopolysaccharide-induced model of depression. European Neuropsychopharmacology 25: S292-S293

Petrovic, J. 2015: P.1.h.024 Chronic magnesium administration ameliorates depressive- and anxiety-like behaviour in Acth-treated rats. European Neuropsychopharmacology 25: S294-S295

Luca, A.; Alexa, T.; Dondas, A.; Cracana, I.; Bohotin, C. 2015: P.1.h.026 The effects of repeated disulfiram and nitroglycerin on thermonociception and visceral pain in mice. European Neuropsychopharmacology 25: S295-S296

Balazsfi, D.; Zelena, D.; Mikics, E.; Varga, J.; Klausz, B.; Urban, E.; Sipos, E.; Biro, L.; Miskolczi, C.; Kovacs, K.; Ferenczi, S.; Haller, J. 2015: P.1.h.030 Enduring erasure of remote fear memories by the blockade of calcium-permeable Ampa receptors applied before extinction training. European Neuropsychopharmacology 25: S297-S298

Plucinska, K.; Jerzemowska, G.; Podlacha, M. 2015: P.1.h.031 Functional reorganization of the mesolimbic dopaminergic system after its terminal area glutamate injection. European Neuropsychopharmacology 25: S298-S299

Sayar, G.H.; Salcini, C.; Tan, O. 2015: P.1.i.001 Neurocognitive effects of repetitive transcranial magnetic stimulation in drug free treatment-resistant depression patients. European Neuropsychopharmacology 25: S299-S300

Kim, Y.T. 2015: P.1.i.004 Lead-induced impairments in neural processes in relation to executive function. European Neuropsychopharmacology 25: S300-S301

Soeiro-de-Souza, M.; Hennig, A.; Pastorello, B.; Costa Leite, C.; Moreno, R.; Moreno, D.; Otaduy, M.C.G. 2015: P.1.i.007 Glutamatergic activity measured by 1H-Mrs is decreased in euthymic bipolar I disorder subjects. European Neuropsychopharmacology 25: S302-S303

Bloemen, O.; Vingerhoets, W.; Bakker, G.; Boot, E.; DaSilva Alves, F.; Van Amelsvoort, T. 2015: P.1.i.010 Spectroscopy differences between at risk populations for psychosis. European Neuropsychopharmacology 25: S304-S305

Van der Meer, D.; Hartman, C.A.; Pruim, R.H.R.; Mennes, M.; Heslenfeld, D.J.; Oosterlaan, J.; Faraone, S.V.; Franke, B.; Buitelaar, J.K.; Hoekstra, P.J. 2015: P.1.i.012 Serotonin transporter genotype moderates the effect of psychosocial stress on executive control and default mode network connectivity. European Neuropsychopharmacology 25: S305-S306

DaCunha-Bang, S.; Fisher, P.M.D.; Skibsted, A.P.; Perfalk, E.; Hjordt, L.V.; Bock, C.; Sestoft, D.; Baandrup, A.O.; Knudsen, G.M. 2015: P.1.i.013 Neural correlates of reactive aggression in psychopathic violent offenders; a functional magnetic resonance study. European Neuropsychopharmacology 25: S306-S307

Schröder, A.; Giorgi, R.S.; Van Wingen, G.; Vulink, N.; Denys, D. 2015: P.1.i.015 Impulsive aggression in misophonia: results from a functional magnetic resonance imaging study. European Neuropsychopharmacology 25: S307-S308

Iwabuchi, S.J.; Auer, D.P.; Raschke, F.; Lankappa, S.; Palaniyappan, L. 2015: P.1.i.016 Fronto-insular network and prefrontal Gaba levels following targeted transcranial theta-burst magnetic stimulation. European Neuropsychopharmacology 25: S308-S309

Ettrup, A.; Svarer, C.; McMahon, B.; DaCunha-Bang, S.; Lehel, S.; Møller, K.; Dyssegaard, A.; Ganz, M.; Beliveau, V.; Jørgensen, L.M.; Gillings, N.; Knudsen, G.M. 2015: P.1.i.018 Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: test-retest reproducibility and comparison with [18F]altanserin. European Neuropsychopharmacology 25: S309-S310

Gondek, T.M.; Zacharzewska-Gondek, A.; Bladowska, J.; Pokryszko-Dragan, A.; Sasiadek, M. 2015: P.1.i.020 Changes in apparent diffusion coefficient values in patients with multiple sclerosis with regard to treatment with interferon beta. European Neuropsychopharmacology 25: S310-S311

Tozzi, L.; Doolin, K.; Carballedo, A.; Lavelle, G.; Doyle, M.; McCarthy, H.; O'Keane, V.; Frodl, T. 2015: P.1.i.021 Improvement of well-being measures after regular physical exercise correlates with resting state connectivity in attentional and default mode networks. European Neuropsychopharmacology 25: S311-S312

Kirschner, M.; Stämpfli, P.; Hodel, M.; Hösli, S.; Engeli, E.; Hulka, L.; Sulzer, J.; Seifritz, E.; Quednow, B.B.; Herdener, M. 2015: P.1.i.023 Self-regulation of the dopaminergic reward system via real time fMri neurofeedback: a novel treatment approach for cocaine addiction. European Neuropsychopharmacology 25: S312-S313

Takano, A.; Stepanov, V.; Nakao, R.; Amini, N.; Kimura, H.; Halldin, C. 2015: P.1.i.025 Brain Pet measurement of phosphodiesterase 10A occupancy by Tak-063, a new phosphodiesterase 10A inhibitor, using [11C]T-773 in nonhuman primates. European Neuropsychopharmacology 25: S313-S314

Browning, M.; Smith, J.; Conen, S.; Smallman, R.; Buchbjerg, J.; Larsen, K.G.; Olsen, C.K.; Christensen, S.R.; Dawson, G.R.; Deakin, W.F.; Morris, R.; Goodwin, G.M.; Harmer, C.J. 2015: P.1.i.026 Vortioxetine reduces Bold signal during performance of the N-back task in subjects remitted from depression and healthy control participants. European Neuropsychopharmacology 25: S314-S315

Spangaro, M.; Bollettini, I.; Poletti, S.; Mazza, E.; Cavallaro, R.; Benedetti, F. 2015: P1.i.029 Effect of catechol-O-methyltransferase polymorphism on subcortical volumes in schizophrenia. European Neuropsychopharmacology 25: S316-S317

Aggio, V.; Poletti, S.; Bollettini, I.; Mazza, E.; Cavallaro, R.; Smeraldi, E.; Benedetti, F. 2015: P.1.i.030 The modulatory role of catechol-O-methyltransferase Val158Met polymorphism on the association between white matter microstructure and cognitive performances in schizophrenia. European Neuropsychopharmacology 25: S317-S318

Gryglewski, G.; Hienert, M.; Sigurdardottir, H.; Komorowski, A.; Vanicek, T.; Spies, M.; Mitterhauser, M.; Wadsak, W.; Kasper, S.; Lanzenberger, R. 2015: P.1.i.032 Interpolation of sparse mRna samples to create comprehensive atlases of cerebral protein transcription. European Neuropsychopharmacology 25: S318-S319

Komorowski, A.; Gryglewski, G.; James, G.; Hienert, M.; Kasper, S.; Lanzenberger, R. 2015: P.1.i.034 Gene expression and protein distribution of serotonergic key proteins in the human brain revealed by Pet in vivo and postmortem quantification. European Neuropsychopharmacology 25: S319-S320

Rikandi, E.; Pamilo, S.; Mäntylä, T.; Suvisaari, J.; Hari, R.; Seppä, M.; Raij, T. 2015: P.1.i.035 Differentiation between first-episode psychosis patients and healthy subjects on the basis of precuneus activation. European Neuropsychopharmacology 25: S320-S321

Sigurdardottir, H.; Kranz, G.; Rami-Mark, C.; James, G.; Vanicek, T.; Mitterhauser, M.; Wadsak, W.; Rujescu, D.; Kasper, S.; Lanzenberger, R. 2015: P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with Adhd using Pet. European Neuropsychopharmacology 25: S321-S322

Piguet, C.; Desseilles, M.; Sterpenich, V.; Cojan, Y.; Dayer, A.; Bertschy, G.; Aubry, J.-M.; Vuilleumier, P. 2015: P.1.i.038 Activity in the parahippocampal gyrus during cognitive tasks correlates with the tendency to ruminate. European Neuropsychopharmacology 25: S322-S323

Nawijn, L.; Van Zuiden, M.; Koch, S.B.J.; Frijling, J.L.; Veltman, D.J.; Olff, M. 2015: P.1.i.040 Effects of intranasal oxytocin on reward anticipation in patients with post-traumatic stress disorder: an fMri study. European Neuropsychopharmacology 25: S323-S324

Oliveira-Maia, A.J.; Garcia-Guarniz, A.-L.; Asinanis, A.; Press, D.; Pascual-Leone, A. 2015: P.1.i.041 A retrospective open-label study to compare antidepressant efficacy of repetitive transcranial magnetic stimulation using two different devices. European Neuropsychopharmacology 25: S324-S325

Solleveld, M.M.; Schrantee, A.; Bouziane, C.; Ruhé, H.G.; Reneman, L. 2015: P.1.i.043 Age-dependent effects of selective serotonin reuptake inhibitor exposure on the development of the Gaba-ergic system. European Neuropsychopharmacology 25: S325-S326

Schrantee, A.; Mutsaerts, H.; Tamminga, G.; Bouziane, C.; Bottelier, M.; Rombouts, S.; Reneman, L. 2015: P.1.i.044 The effects of methylphenidate on striatal dopamine system are dependent on age: a pharmacological magnetic resonance imaging study. European Neuropsychopharmacology 25: S326-S327

James, G.; Kranz, G.; Hahn, A.; Gryglewski, G.; Hienert, M.; Spies, M.; Wadsak, W.; Mitterhauser, M.; Kasper, S.; Lanzenberger, R. 2015: P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors. European Neuropsychopharmacology 25: S327-S328

Bation, R.; Brunelin, J.; Saoud, M.; Poulet, E. 2015: P.1.i.051 Intermittent Theta Burst Stimulation of the left dorsolateral prefrontal cortex for the treatment of persistent negative symptoms in schizophrenia. European Neuropsychopharmacology 25: S329-S330

Lange, I.; Goossens, L.; Lissek, S.; Van Amelsvoort, T.; Schruers, K. 2015: P.1.i.053 Low behavioural pattern separation is linked to reduced dentate gyrus activation during fear generalisation. European Neuropsychopharmacology 25: S330-S331

Via Virgili, E.; Fullana, M.; Soriano-Mas, C.; López-Solà, C.; Goldberg, X.; Pujol, J.; Martínez-Zalacaín, I.; Tinoco, D.; Blasco, M.; Davey, C.; Menchón, J.; Cardoner, N.; Harrison, B. 2015: P.1.i.055 Generalized anxiety disorder is characterised by a non-discriminative response of the ventromedial prefrontal cortex during fear learning. European Neuropsychopharmacology 25: S331-S332

Berdzenishvili, E.; Chkonia, E.; Okruashvili, M.; Roinishvili, M. 2015: P.1.j.001 Cognitive deficit and social functioning in patients with first psychotic episode. European Neuropsychopharmacology 25: S332-S333

Kurzbuch, K.; Pauli, E.; Chang, B.S.; Romatoski, K.; Barnard, M.E.; Kasper, B.S. 2015: P.1.j.003 Neuropsychological profiles in periventricular nodular heterotopia. European Neuropsychopharmacology 25: S333-S334

Kokova, V.; Apostolova, E.; Peychev, L. 2015: P.1.j.004 Effects of etifoxine on passive avoidance tests and locomotor activity in rats. European Neuropsychopharmacology 25: S334-S335

Borbely-Ipkovich, E.; Janacsek, K.; Nemeth, D.; Gonda, X. 2015: P.1.j.006 New neurocognitive endophenotype for major depressive episode: the role of working memory and implicit learning in the acute phase of depression. European Neuropsychopharmacology 25: S335-S336

Enkelaar, R.; Van de Loo, A.J.A.E.; Mooren, L.; Bervoets, A.C.; Roth, T.; Verster, J.C. 2015: P.1.j.009 Awareness of driving impairment: lapses versus excursions out-of-lane during highway driving. European Neuropsychopharmacology 25: S337-S338

Beselia, G.; Dashniani, M.; Burjanadze, M.; Chkhikvishvili, N.; Kruashvili, L.; Rusadze, K. 2015: P.1.j.012 Memantine treatment does not improve spatial learning in medial septal lesioned rats. European Neuropsychopharmacology 25: S339-S340

Valcheva-Kuzmanova, S.; Georgieva, A.; Todorova-Nenova, K.; Belcheva, S.; Tashev, R. 2015: P.1.j.014 Effects of gallic acid and quercetin on learning and memory processes in young/healthy rats. European Neuropsychopharmacology 25: S340-S341

Demirtas, T.; Utkan, T.; Gocmez, S.S.; Karson, A. 2015: P.1.j.017 Effects of chronic etanercept, a Tnf- inhibitor, on cognitive dysfunction in cafeteria diet-fed rats. European Neuropsychopharmacology 25: S342-S343

Raij, T.T.; Mantylä, T.; Suvisaari, J. 2015: P.1.j.020 Functioning of the posterior cingulate cortex predicts development of insight into one's illness in patients with first-episode psychosis. European Neuropsychopharmacology 25: S343-S344

Nieman, D.H.; Domen, A.C.; Kumar, R.; Harrison, J.; DeHaan, L.; Denys, D.A. 2015: P.1.j.022 Cognitive remediation in psychiatric patients with an online cognitive game and assessment tool. European Neuropsychopharmacology 25: S344-S345

Wincewicz, D.; Braszko, J. 2015: P.1.j.023 Alleviation of stress-induced cognitive decline by telmisartan goes beyond peroxisome proliferator-activated receptor gamma agonism, targeting Hpa axis deactivation. European Neuropsychopharmacology 25: S345-S346

Bruehl, A.; Van Ghesel Grothe, A.; Dafflon, J.; Gillan, C.; Garner, M.; Morein-Zamir, S.; Robbins, T.; Sahakian, B. 2015: P.1.j.025 Effects of acute stress and anxiety induced by the inhalation of air enriched with Co2 on model-based and model-free behaviour. European Neuropsychopharmacology 25: S346-S347

Schwitzer, T.; Schwan, R.; Giersch, A.; Laprevote, V. 2015: P.1.j.026 The retinal pathways as a model to understand brain damages in cannabis users. European Neuropsychopharmacology 25: S347-S348

Van Ghesel Grothe, A.S.; D'Arienzo, P.D.; Garner, M.J.; Morein-Zamir, S.; Robbins, T.W.; Sahakian, B.J.; Brühl, A.B. 2015: P.1.j.028 Differences in affective go/no go performance during acute stress and anxiety induced by Co2-enriched air are moderated by reaction time. European Neuropsychopharmacology 25: S348-S349

Malania, M.; Chkonia, E.; Chkhaidze, A.; Kezeli, A.; Wolf, W.; Sharikadze, M. 2015: P.1.j.030 Are schizophrenia patients worse performers of dual-tasking? Insights from motor timing. European Neuropsychopharmacology 25: S349-S350

Aksoz, E.; Gocmez, S.S.; Demirtas, T.; Utkan, T. 2015: P.1.j.032 Protective effects of metformin in scopolamine-induced cognitive impairment in rats. European Neuropsychopharmacology 25: S350-S351

Zijlmans, J.; Smirnov, A.A.; Marhe, R.; Popma, A. 2015: P.1.j.034 Error processing and psychopathy in multiproblem young adults: preliminary Eeg results. European Neuropsychopharmacology 25: S351-S352

Tahon, K.; Talpos, J.; Steckler, T.; Drinkenburg, W. 2015: P.1.j.037 Imaging neurophysiological dynamics underlying cognitive performance in a rat touch-screen reversal learning paradigm. European Neuropsychopharmacology 25: S353-S354

Konishi, T.; Hayashi, K.; Sugiyama, H. 2015: P.1.k.001 Clinical conditions relevant to the depressive mental states of Japanese patients with subacute myelo-optic neuropathy (Smon). European Neuropsychopharmacology 25: S354-S355

Gomez, L.P.; García, M.J.M.; Martínez, M.G.; Fernandez, A.G. 2015: P.1.k.003 Borderline personality disorder experience in mental health centre. European Neuropsychopharmacology 25: S355-S356

Stuhec, M.; Marusic, A.P. 2015: P.1.k.006 Collaborative care between clinical pharmacists and general practitioners in patients with polypharmacy: a focus on psychiatric and neurological drugs. European Neuropsychopharmacology 25: S356-S357

Kim, S.H.; Park, S.H.; Choo, I.H.; Kim, S.G. 2015: P.1.k.008 Prevalence and factors related to depressive symptoms among Korean university students. European Neuropsychopharmacology 25: S357-S358

Manvelyan, A.; Mkrtchyan, A.; Martirosyan, A. 2015: P.1.k.009 Borderline personality disorder revealed in Armenian population using Dsm-5 criteria as screening tool. European Neuropsychopharmacology 25: S358-S359

Tezcan, B.; Barlas, F.; Vardar, M.K. 2015: P.1.k.011 Examination of self-esteem, body image, and past incidents of trauma in patients with obesity. European Neuropsychopharmacology 25: S359-S360

Shin, I.; Baek, H.; Shin, H.; Kim, J.; Kim, S.; Yoon, J. 2015: P.1.k.013 Predictors of subjective successful aging in community-dwelling elderly: Comparing elders living alone and those living with others. European Neuropsychopharmacology 25: S360-S361

Fernández-Quintana, A.; García-Mahía, M.C.; Vidal-Millares, M. 2015: P.1.k.015 Sleep quality in psychiatric outpatients. European Neuropsychopharmacology 25: S361-S362

Tutuncu, R.; Ates, A.; Algul, A.; Balibey, H.; Basoglu, C. 2015: P.1.k.016 Turkish reliability and validity of psychopathy checklist revised. European Neuropsychopharmacology 25: S362-S363

Woo, J.; Seo, M.J.; Kang, G.W.; Ahn, K.S. 2015: P.1.k.018 Associations among psychosocial factor, medical factor and quality of life in patients with end-stage renal disease. European Neuropsychopharmacology 25: S363-S364

Mahia, M.C.G.; Quintana, A.F.; Ferreiro-Fernández, B. 2015: P.1.k.020 Prevalence of depressive symptoms and cognitive deterioration in elderly people. European Neuropsychopharmacology 25: S364-S365

Blokhina, E.A.; Krupitsky, E.; Cheng, D.; Bridden, C.; Gnatenko, N.; Toussova, O.; Yaroslavtseva, T.; Samet, J. 2015: P.1.k.022 Changes of illicit opioid use among Hiv-infected opioid users in Russia (20042014). European Neuropsychopharmacology 25: S365-S366

Choi, J.H.; Kang, S.H.; Kim, T.Y.; Chung, H.Y.; So, H.S.; Yoon, I.-N.; Lee, S.D. 2015: P.1.k.023 The prevalence and impact on insomnia of periodic limb movements during sleep in the Korean elderly. European Neuropsychopharmacology 25: S366-S367

Ozmut, O.; Tutuncu, R.; Balibey, H.; Ates, M.; Algul, A.; Ebrinc, S.; Basoglu, C. 2015: P.1.k.026 The sociodemographic characteristics, habits, trends and forensic aspects of young male soldiers who applied to psychiatry clinic. European Neuropsychopharmacology 25: S367-S368

Ozten, E.; Tufan, A.E.; Eryilmaz, G.; Hizli Sayar, G. 2015: P.1.k.028 The prevalence of adult separation anxiety disorder in patients with attention-deficit/hyperactivity disorder: a preliminary study from Turkey. European Neuropsychopharmacology 25: S368-S369

Bloemen, A.; Boschloo, L.; Havinga, P.; Penninx, B.; Schoevers, R.; Hartman, C. 2015: P1.k.030 Neuropsychological functioning as a risk factor for depression and anxiety disorders: A 10-year study in young people with parental psychopathology. European Neuropsychopharmacology 25: S369-S370

Currò, V.; Cordova, F.; Mento, C.; Guccione, F.; Zoccali, R.A.; Navarra, G. 2015: P.1.k.031 Personality traits and emotional profiles in severely obese patients in a preoperative evaluation. European Neuropsychopharmacology 25: S370-S371

Detke, M.; Echevarria, B.; Osman, D.; Garzio, L.M.; Williams, J.B.W. 2015: P.1.k.033 A new platform to improve quality of Panns and Madrs administration. European Neuropsychopharmacology 25: S371-S372

Gonçalves, M.; Silva, T.; Santos, Z. 2015: P1.k.035 Gender difference among involuntarily admitted patients in a psychiatric service during 2014. European Neuropsychopharmacology 25: S372-S373

Uno, J. 2015: P.1.k.037 Prescription survey of orexin receptor antagonist suvorexant. European Neuropsychopharmacology 25: S373-S374

Shaker, S.C.; Ashok, J.; Kumar, B.B.; Priram, M. 2015: P.2.a.001 Effect of sesamol pretreatment against lipopolysaccharide-induced depressive and anxiety-like behaviour in Swiss albino mice. European Neuropsychopharmacology 25: S374-S375

Popa, E.G.; Cristofor, A.C.; Lupusoru, C.E.; Valeanu, A.S.N.; Sindrilar, E.V.; Tartau, L.M. 2015: P.2.a.002 Experimental investigation on the effects of some antidepressants on spatial memory performance of old rats. European Neuropsychopharmacology 25: S375-S376

Dalla, C.; Pastromas, N.; Kokras, N. 2015: P.2.a.004 Sustained aromatase inhibition: brain effects in both sexes. European Neuropsychopharmacology 25: S376-S377

Podkowa, K.; Pile, A.; Palucha-Poniewiera, A. 2015: P.2.a.007 The potential antidepressant effect of the joint administration of ketamine and mGlu2/3 receptor antagonist, Ly341495 in the forced swim test in rats. European Neuropsychopharmacology 25: S378-S379

Burke, N.N.; Deaver, D.R.; Finn, D.P.; Roche, M.; Kelly, J.P. 2015: P.2.a.009 Chronic administration of buprenorphine in combination with samidorphan produces antidepressant-like effects in rats without locomotor sensitization. European Neuropsychopharmacology 25: S379-S380

Ryan, K.M.; Smyth, P.S.; Blackshields, G.; Sheils, O.; McLoughlin, D.M. 2015: P.2.a.010 Analysis of the rat hippocampal microRna expression profile following chronic electroconvulsive stimulation. European Neuropsychopharmacology 25: S380-S381

Alboni, S.; Benatti, C.; Tascedda, F.; Brunello, N. 2015: P.2.a.012 Co-administration of fluoxetine with acetylsalicylic acid, but not flurbiprofen or celecoxib, for one week shows an antidepressant-like effect. European Neuropsychopharmacology 25: S381-S382

Ebrahimzadeh, M.; ElMansari, M.; Blier, P. 2015: P.2.a.014 Effect of subacute and long-term administration of vortioxetine on firing activity of catecholaminergic neurons. European Neuropsychopharmacology 25: S382-S383

Mandelli, L. 2015: P.2.b.002 Life events in childhood and before onset in major depression. prevalence, specificity and their impact on disease features and causal relationships. European Neuropsychopharmacology 25: S385-S386

Permoda-Osip, A.; Dorszewska, J.; Rybakowski, J. 2015: P.2.b.004 Homocysteine and asymmetric dimethylarginine in bipolar depression: the effect of pharmacological treatment. European Neuropsychopharmacology 25: S386-S387

Tuna, O.C.; Balaban, O.D.; Mutlu, C.; Eradamlar, N. 2015: P.2.b.007 Depression and the cognitive distortions among the patients with end stage renal disease. European Neuropsychopharmacology 25: S388-S389

Gonda, X.; Rihmer, Z.; Hal, M.; Kapitany, B.; Vargha, M.; Dome, P. 2015: P.2.b.009 Environmental effects on suicidal behaviour: association of drinking-water arsenic levels and suicide. European Neuropsychopharmacology 25: S389-S390

Serati, M.; Buoli, M.; Redaelli, M.; Colombo, E.M.; Altamura, A.C. 2015: P.2.b.015 Which pregnant bipolar women have an increased risk of delayed psychiatric treatment?. European Neuropsychopharmacology 25: S392-S393

Gourion, D.; Mouchabac, S. 2015: P.2.b.016 A longitudinal study of the relationships between anhedonia and functioning in a large cohort of depressed patients treated by general practitioners. European Neuropsychopharmacology 25: S393-S394

Schmaal, L.; Veltman, D.J.; Van Erp, T.G.; Sämann, P.G.; Frodl, T.; Jahanshad, N.; Loehrer, E.; Tiemeier, H.; Hofman, A.; Niessen, W.J.; Vernooij, M.W.; Ikram, M.A.; Wittfeld, K.; Grabe, H.J.; Block, A. 2015: P.2.b.017 Structural brain alterations in major depression: findings from the Enigma Major Depressive Disorder Working Group. European Neuropsychopharmacology 25: S394-S395

Atake, K.; Reiji, Y.; Hikaru, H.; Asuka, K.; Jun, N. 2015: P.2.b.019 Association between clinical response to duloxetine treatment and brain-derived neurotrophic factor or catecholamine metabolites. European Neuropsychopharmacology 25: S395-S396

Pirlog, M.; Cara, L.; Chirita, A.; Paraschiv, G.; Purnichi, T. 2015: P.2.b.021 Pharmacologic treatment patterns and social functioning in depressive outpatients. European Neuropsychopharmacology 25: S396-S397

Lemke, M.R.; Hajak, G.; Barthel, B. 2015: P.2.b.022 Antidepressant effect and tolerabilty of agomelatine in smokers/non-smokers/ex-smokers: results of a subgroup-analysis over 6 months (Vital-study). European Neuropsychopharmacology 25: S397-S398

Gosek, P.; Parnowski, T. 2015: P.2.b.024 Psychosocial burden of unipolar and bipolar depression in the course of disease during three subsequent depressive episodes. European Neuropsychopharmacology 25: S398-S399

Kjærstad, H.L.; Vinberg, M.; Køster, N.; Støttrup, M.M.; Knorr, U.; Kessing, L.V.; Miskowiak, K.W. 2015: P.2.b.027 Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: a pilot study of a novel experimental paradigm. European Neuropsychopharmacology 25: S400-S401

Karaoulanis, S.; Sevlianou, A. 2015: P.2.b.030 The validation of Premenstrual Symptoms Screening Tool (Psst) in the Greek population: Preliminary results. European Neuropsychopharmacology 25: S401-S402

Soria, V.; Labad, J.; Salvat, N.; DeArriba, A.; Segalàs, C.; Real, E.; Urretavizcaya, M.; Menchón, J.M. 2015: P.2.b.031 Stressful life events, memory performance and Hpa axis negative feedback sensitivity in major depression: a structural equation modelling approach. European Neuropsychopharmacology 25: S402-S403

Sun, Y.; Wang, D.; Salvadore, G.; Singh, J.; Casper, C.; Van Rhee, F.; Vermeulen, J.; Caers, I.; Kent, J.; Drevets, W.; Chen, G.; Wittenberg, G. 2015: P.2.b.033 Siltuximab improves depressive symptoms in a randomised, placebo-controlled, phase 2 study in patients with multicentric Castlemen's disease. European Neuropsychopharmacology 25: S403-S404

DeSantiago, A.I. 2015: P.2.b.035 Agomelatine safety: monitoring liver function in observational study. European Neuropsychopharmacology 25: S404-S405

Ju, P.; Ming-Hong, H.; Jeng-Yuan, C.; Yu-Hsun, W. 2015: P.2.b.036 The outcome of major depressive disorder comorbid diabetes. European Neuropsychopharmacology 25: S405-S406

Kittel-Schneider, S.; Lorenz, C.; Auer, J.; Reif, A. 2015: P.2.C.002 Gene expression profile of Dgkh risk variant carriers with bipolar disorder. European Neuropsychopharmacology 25: S406-S407

Abdelkarim Garcia, M.; Galling, B. 2015: P.2.c.004 Safety and tolerability of antipsychotic-mood stabilizer co-treatment in acute bipolar disorder; a systematic review and exploratory meta-analysis. European Neuropsychopharmacology 25: S407-S408

Ustün, N.; Tan, R.E.; Varlık, D.S.ıkaya; Varlık, C.; Eradamlar, N. 2015: P.2.c.006 Extensity and dispersion of personality disorder in bipolar patients. European Neuropsychopharmacology 25: S408-S409

de Souza, G.C.; DeSouza Gomes, J.A.; Maia, F.T.S.R.; Cavalcante, L.M.; DeJesus Souza Machado, M.; de Queiroz, A.I.G.; Borela, V.C.M.; Custódio, C.S.; Ferreira Mello, B.S.; Freitas de Lucena, D.; Gaspar, D.M. 2015: P.2.c.007 Neurotrophic mechanisms of candesartan in an animal model of mania induced by D-amphetamine. European Neuropsychopharmacology 25: S409-S410

Herane, A.; Papadopoulos, A.; King, S.; Chang, C.K.; Cheung, E.; Halari, R.; DeAngel, V.; Cleare, A.; Young, A.H. 2015: P.2.d.001 Cortisol levels in nails and neurocognitive performance in euthymic bipolar I patients and healthy controls. European Neuropsychopharmacology 25: S410-S411

Jang, S.H. 2015: P.2.d.004 Influence of body mass index on quality of life in patients with bipolar disorder. European Neuropsychopharmacology 25: S412-S413

Jon, D.; Hong, N.; Bahk, W.; Yoon, B.; Shin, Y.; Min, K.; Lee, S.; Jung, M. 2015: P.2.d.006 The validity of the modified Korean version of the mood disorder questionnaire. European Neuropsychopharmacology 25: S413-S414

DaPonte, G.; Sousa, A.; Paiva, A. 2015: P.2.d.009 Cyamemazine and pancytopenia in a bipolar patient with psychosomatic complaints. European Neuropsychopharmacology 25: S415-S416

Cansiz, A.; Kalelioglu, T.; Karamustafalioglu, N.; Akkus, M.; Gene, A.; Gene, E.; Emul, M. 2015: P.2.d.011 Increased mean platelet volume in patients with bipolar disorder in manic and euthymic states. European Neuropsychopharmacology 25: S416-S417

Durgam, S.; Laszlovszky, I.; Lu, K.; Ruth, A.; Debelle, M.; Zukin, S. 2015: P.2.d.014 Categorical improvement across mania symptoms: pooled analyses of cariprazine phase Ii/Iii trials. European Neuropsychopharmacology 25: S418-S419

Adriane, R.; Barbe-Tuana, F.; Psrisi, M.; Fries, G.; Panizzutti, B.; Guma, F.; Kapczinski, F.; Gama, C. 2015: P.2.d.015 Short telomeres in subjects with remitted bipolar disorder. European Neuropsychopharmacology 25: S419-S420

Ketter, T.; Tsai, J.; Silva, R.; Kroger, H.; Cucchiaro, J.; Loebel, A. 2015: P.2.d.017 Lurasidone in the long-term treatment of patients with bipolar i disorder: responder and remitter status during a 24-week open-label extension study. European Neuropsychopharmacology 25: S420-S421

Guillena, S.L.R.; Gotor, F.; de Diego, B.O.P.G.; Santamaria, O. 2015: P.2.d.019 Functioning, theory of mind, and cognitive dysfunction in bipolar disorder. European Neuropsychopharmacology 25: S421-S422

Saricicek, A.; Yalin, N.; Hidiroglu, C.; Cavusoglu, B.; Tas, C.; Ceylan, D.; Ada, E.; Tunca, Z.; Ozerdem, A. 2015: P.2.d.020 Enlarged inferior frontal gyrus volume might be a structural endophenotype for bipolar disorder: A voxel-based morphometry study. European Neuropsychopharmacology 25: S422-S423

Cho, Y.-S.; Kwon, Y.-J.; Lee, H.-Y.; Lee, J.-Y.; Shim, S.-H. 2015: P.2.d.022 Mental disorders in offspring of parents with bipolar disorder. European Neuropsychopharmacology 25: S423-S424

Bulgarelli, C.; Vai, B.; Aggio, V.; Poletti, S.; Bollettini, I.; Benedetti, F. 2015: P.2.d.023 Effects of the interaction between lithium and glycogen synthase kinase 3 in effective connectivity on neural response to emotional processing in bipolar disorder. European Neuropsychopharmacology 25: S424-S425

Marinova, P.; Hranov, L. 2015: P.2.d.026 A model to uncover bipolarity in recurrent depressive episodes. European Neuropsychopharmacology 25: S425-S426

Yasmine, L.; Ben Alaya, S.; Hajri, A.; Ouali, U.; Nacef, F. 2015: P.2.d.028 Emotion dysregulation and bipolar I disorder. European Neuropsychopharmacology 25: S426-S427

Brioschi, S.; Delmonte, D.; Cassulo, F.; Fossati, F.; Barbini, B.; Franchini, L.; Colombo, C. 2015: P.2.d.031 Integrated mania management: an observational study at the rehabilitative mood disorder unit of San Raffaele hospital in Milan. European Neuropsychopharmacology 25: S427-S428

Yalin, N.; Saricicek, A.; Zugman, A.; Hidiroglu, C.; Ada, E.; Cavusoglu, B.; Er, A.; Isik, G.; Ceylan, D.; Tunca, Z.; Kempton, M.J. 2015: P.2.d.033 Role of cortical thickness as an endophenotype for bipolar disorder: a vertex-wise analysis in bipolar disorder patients and first degree relatives. European Neuropsychopharmacology 25: S428-S429

Murru, A.; Callari, A.; Varo, C.; Torra, M.; Gonzalez, B.; Vieta, E.; Colom, F. 2015: P.2.d.035 Bioequivalence of blood and salivary levels of lithium and valproate: Implications for the clinical management of bipolar disorder. European Neuropsychopharmacology 25: S429-S430

García-Alocén, A.; Martinez-Cengotitabengoa, M.; González-Ortega, I.; Ruiz de Azua, S.; Fernandez, M.; Vega, P.; Bermúdez-Ampudia, C.; Zugasti, J.; González-Pinto, A. 2015: P.2.d.037 Telemedicine in bipolar disorder. European Neuropsychopharmacology 25: S430-S431

Gabriel Gracia, C.; Mocaer, E.; Seguin, L.; Diaz-Mataix, L.; Ledoux, J. 2015: P.2.e.003 Effect of acute administration of agomelatine on the memory processes triggered by threat responses to an auditory stimulus in rats. European Neuropsychopharmacology 25: S432-S433

Morais, M. 2015: P.2.e.007 Antipsychotic drugs in depression: the unexplored role of neuroplasticity. European Neuropsychopharmacology 25: S433-S434

Bodnar, A.; Ferensztajn, E.; Krzywotulski, M.; Bartkowska-Śniatkowska, A.; Lewandowska, A.; Chłopocka-Woźniak, M.; Rybakowski, J.K. 2015: P.2.f.002 The effect of ketamine anesthesia on the efficacy of electroconvulsive therapy and cognitive functions in treatment-resistant depression. European Neuropsychopharmacology 25: S434-S435

Grosse, L.; Carvalho, L.; Birkenhager, T.; Hoogendijk, W.; Drexhage, H.; Bergink, V. 2015: P.2.f.004 Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. European Neuropsychopharmacology 25: S435-S436

Kim, H.G.; Lee, K.H.; Park, Y.W.; Lee, J.H.; Koo, B.H.; Lee, S.J.; Sung, H.M.; Cheon, E.J. 2015: P.2.f.007 Comparison of aripiprazole versus bupropion augmentation for treatment of older patients with Mdd: a randomized prospective open-label multi-center study. European Neuropsychopharmacology 25: S437-S438

Batmaz, S. 2015: P.2.f.010 Treatment adherence and response to psychopharmacological treatment in borderline personality disorder with and without major depressive disorder. European Neuropsychopharmacology 25: S439-S440

Hegedus, K.; Kárpáti, J.; Szombathelyi, E.; Iljicsov, A.; Simió, M. 2015: P.2.f.012 Depression in multiple sclerosis focusing on treatment possibilities. European Neuropsychopharmacology 25: S440-S441

Mocking, R.J.T.; Assies, J.; Ruhe, H.G.; Koeter, M.W.J.; Schene, A.H. 2015: P.2.f.015 Omega-3 polyunsaturated fatty acids for major depressive disorder: an updated meta-analysis of randomised clinical trials. European Neuropsychopharmacology 25: S442-S443

Kikuchi, T.; Watanabe, K.; Tsuboi, T.; Asami, Y.; Siu, C.; Pappadopulos, E.; Kornstein, S.; Thase, M. 2015: P.2.f.016 Long-term outcomes in treatment of depression with venlafaxine Er 75225 mg/d in the acute and continuation phases (Prevent study). European Neuropsychopharmacology 25: S443-S444

Weiller, E.; McIntyre, R.S.; Zhang, P.; Weiss, C. 2015: P2.f.018 Effect of adjunctive brexpiprazole (Opc-34712) on depressive symptoms in patients with symptoms of anxious distress: results from post-hoc analyses. European Neuropsychopharmacology 25: S444-S445

Martin, S.; Voican, C.; Colle, R.; Verstuyft, C.; Laurent Becquemont, L.; Perlemuter, G.; Corruble, E. 2015: P.2.f.019 Liver function test abnormalities in depressed patients treated with antidepressants: an observational cohort study in a psychiatric department. European Neuropsychopharmacology 25: S445-S446

Baker, R.; Okame, T.; Perry, P.; Matsushima, Y.; Weiller, E. 2015: P.2.f.025 Switching from inadequate adjunctive treatments: Open-label study of brexpiprazole effects on depressive symptoms, cognitive and physical functioning. European Neuropsychopharmacology 25: S448-S449

Orsolini, L.; DeBerardis, D.; Vecchiotti, R.; Valchera, A. 2015: P.2.f.028 Antidepressant efficacy of S-adenosyl-L-methionine in major depressive disorder. European Neuropsychopharmacology 25: S450-S451

Dale, E.; Lu, D.; Yin, H.; Liu, H.; Yang, C.R.; Larsen, P.H.; Sanchez, C. 2015: P.2.g.002 Vortioxetine blocks serotonin excitation of Gabaergic interneurons and disinhibits pyramidal cell activity in the rat hippocampus. European Neuropsychopharmacology 25: S451-S452

Liaugaudaite, V.; Peceliuniene, J.; Raskauskiene, N.; Bunevicius, R.; Mickuviene, N. 2015: P.2.g.003 Suicidal ideation in primary care patients: comorbidity with depression, anxiety disorders, and somatic diagnoses. European Neuropsychopharmacology 25: S452-S453

Asellus, P.; Nordström, P.; Nordström, A.L.; Jokinen, J. 2015: P.2.h.001 Plasma apolipoprotein E and severity of suicidal behaviour. European Neuropsychopharmacology 25: S453-S454

Jeong, W.J.; Koh, J.S. 2015: P.2.h.004 The changes of psychometric profiles after treatment of lower urinary tract symptoms suggestive of benign prostate hyperplasia. European Neuropsychopharmacology 25: S455-S456

Reis, M.; Josefsson, A. 2015: P.2.h.006 Papa: Pharmacokinetics in Pregnancy and Antidepressant drugs. European Neuropsychopharmacology 25: S456-S457

Vieta, E.; Loft, H.; Florea, I. 2015: P.2.h.009 Maintenance of vortioxetine efficacy with long-term treatment of patients with major depressive disorder. European Neuropsychopharmacology 25: S458-S459

McIntyre, R.; Harrison, J.; Loft, H.; Jacobson, W.; Olsen, C. 2015: P.2.h.011 Meta-analysis of cognitive function in vortioxetine clinical trials in major depressive disorder. European Neuropsychopharmacology 25: S459-S460

Bottelier, M.A.; Schrantee, A.G.M.; Van Wingen, G.A.; Ruhé, H.G.; Reneman, L. 2015: P.2.h.014 Treatment with fluoxetine in adolescents may aggravate emotional dysregulation: a power analysis for future studies. European Neuropsychopharmacology 25: S461-S462

Visintin, E.; DePanfilis, C.; Antonucci, C.; Capecci, C.; Marchesi, C.; Sambataro, F. 2015: P.3.b.001 Exploring shared and variant alterations in brain function between schizophrenia and bipolar disorder using resting-state fMri. European Neuropsychopharmacology 25: S462-S463

Pastoriza, F.; Galindo, L.; Roé, N.; Bergé, D.; Mané, A.; Picado, M.; Bulbena, A.; Perez, V.; Vilarroya, O. 2015: P.3.b.002 Cortex morphology and subcortical brain grey matter deficits in schizophrenia and unaffected relatives. European Neuropsychopharmacology 25: S463-S464

Cao, H.; Schafer, A.; Grimm, O.; Haddad, L.; Walter, H.; Heinz, A.; Witt, S.; Rietschel, M.; Cichon, S.; Tost, H.; Meyer-Lindenberg, A. 2015: P3.b.004 Comt Drd2 epistasis modulates a putative emotional connectomic intermediate phenotype for schizophrenia. European Neuropsychopharmacology 25: S464-S465

Gotor, F.; Guillena, S.L.R.; Navarro, R.; de Diego, B.O.P.G. 2015: P.3.b.005 Theory of mind, experiential negative symptoms and schizophrenia. European Neuropsychopharmacology 25: S465-S466

Youn, T.; Chung, I.; Hwang, S.S.; Ahn, Y.M.; Kim, Y.S. 2015: P.3.b.007 Insight in schizophrenia: the role of neurocognitive functioning in relation to psychopathology. European Neuropsychopharmacology 25: S466-S467

Krivokapic, Z.; Knezevic, Z.; Djordjevic, V.; Layarevic, D.; Cosic, V.; Djordjevic, B. 2015: P.3.b.010 Low erythrocyte catalase activity in patients with schizophrenia. European Neuropsychopharmacology 25: S468-S469

Rebhi, H.; Cherif, W.; Larbi, L.; Ben Alaya, S.; Cheour, M. 2015: P.3.b.012 Duration of untreated psychosis and cognitive impairment. European Neuropsychopharmacology 25: S469-S470

García-Alocén, A.; Martinez-Cengotitabengoa, M.; González-Ortega, I.; Arango, C.; Baeza, I.; Graell, M.; García, S.; González-Pinto, A. 2015: P.3.b.013 Adolescents with family history of psychosis and the effect of family environment on the antioxidant defense system. European Neuropsychopharmacology 25: S470-S471

Loewen, G.; Kuan, H.; Dgetluck, N.; Hilt, D. 2015: P.3.b.015 Positive encenicline exposure-response relationships for cognition and clinical function in schizophrenia patients receiving atypical antipsychotics. European Neuropsychopharmacology 25: S471-S472

Boiko, A.; Ivanova, S.A.; Semke, A.V.; Bokhan, N.A. 2015: P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia. European Neuropsychopharmacology 25: S473-S474

Larabi, D.I.; Liemburg, E.J.; Pijnenborg, G.H.M.; DeVos, A.E.; Bais, L.; Knegtering, H.; Curčić-Blake, B.; Aleman, A. 2015: P.3.b.020 The association between dorsolateral prefrontal N-acetylaspartate and insight in psychotic disorders. European Neuropsychopharmacology 25: S474-S475

Bosia, M.; Pigoni, A.; Pirovano, A.; Lorenzi, C.; Buonocore, M.; Bechi, M.; Spangaro, M.; Cocchi, F.; Smeraldi, E.; Cavallaro, R. 2015: P.3.b.021 Interleukin-1, cognition and metabolic syndrome in schizophrenia. European Neuropsychopharmacology 25: S475-S476

Xu, P.; Klaasen, N.; Opmeer, E.; Pijnenborg, M.; Liemburg, E.; Aleman, A. 2015: P.3.b.023 Decreased intrinsic connectivity within mesocortical networks associated with apathy in patients with schizophrenia. European Neuropsychopharmacology 25: S476-S477

Bakker, I.M.; Van Dijk, L.; Caan, M.W.A.; Bloemen, O.J.N.; DaSilva-Alves, F.; DeKoning, M.; Boot, E.; Vingerhoets, W.A.M.; Nieman, D.H.; DeHaan, L.; Booij, J.; Van Amelsvoort, T.A.M.J. 2015: P.3.b.024 Changes in white matter microstructure integrity of the limbic system after psychosis in 22q11 deletion syndrome seems to be associated with psychosis. European Neuropsychopharmacology 25: S477-S478

Prades, R.; Munarriza-Cuezva, E.; Urigüen, L.; Royo, S.; Giralt, E.; Meana, J.; Tarragó, T. 2015: P.3.c.002 Selective prolyl oligopeptidase inhibition by Ipr19 as a new pharmacological treatment of the cognitive impairment associated with schizophrenia. European Neuropsychopharmacology 25: S479-S480

Velimirović, M.; Stojković, T.; Jevtić, G.; Lazović, M.; Zivković, M.; Petronijević, N.; Nikolić, T. 2015: P.3.c.005 Impact of antipsychotic treatment on levels of glucose, cholesterol and triacylglycerol in serum of rats perinatally treated with phencyclidine. European Neuropsychopharmacology 25: S480-S481

Santa, C.; Saraiva, S.C.; Anjo, S.I.; Mendes, V.M.; Baltazar, G.; Dunn, M.J.; Cotter, D.R.; Manadas, B. 2015: P.3.c.006 Study of the protein expression levels in the pre-frontal cortex of mice subjected to haloperidol chronic exposure. European Neuropsychopharmacology 25: S481-S482

Hajji, K.; Chebbi, W.; Marrag, I.; Younes, S.; Zarrouk, L.; Nasr, M. 2015: P.3.d.002 The role of electroconvulsive therapy in the treatment of schizophrenia. European Neuropsychopharmacology 25: S482-S483

Choi, Y.S.; Lee, Y.Y. 2015: P.3.d.005 The preference survey for long-acting injectable antipsychotics of community-dwelling patients with schizophrenia and their caregivers. European Neuropsychopharmacology 25: S483-S484

Fernandez-Miranda, J.J.; Diaz-Fernandez, S. 2015: P.3.d.010 Effectiveness, tolerability and treatment adherence of high doses of paliperidone palmitate in patients with severe schizophrenia. European Neuropsychopharmacology 25: S485-S486

Manli, H.; Liang, Y.; Jianbo, H.; Yi, H.; Jinkai, C.; Pingbo, J.; Yi, X. 2015: P.3.d.012 A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapine in first-episode schizophrenic patients. European Neuropsychopharmacology 25: S486-S487

Matei, V.; Mihailescu, A.; Purnichi, T.; Al-Bateineh, R. 2015: P.3.d.013 Weight gain and antipsychotics, data from Eufest study. European Neuropsychopharmacology 25: S487-S488

Toll Privat, A.; Morro Fernandez, L.; Mane Santacana, A.; Baquero, D.B.; Conesa, A.P.; Sola, V.P. 2015: P.3.d.015 Supported employment program in first episode psychosis: clinical outcome improvements at 1 year follow up. European Neuropsychopharmacology 25: S488-S489

Sulejmanpasic-Arslanagic, G.; Kapetanovic, D.; Srebrenka, B. 2015: P.3.d.018 Efficacy and safety of aripiprazole and haloperidol in patients with schizophrenia. European Neuropsychopharmacology 25: S490-S491

Moreno Monmany, J.; Castillo Magaña, S.; Mur Mila, E.; Cencerrado Muñoz, A.; Oller Canet, S. 2015: P.3.d.021 Psychopharmacologic treatment in bipolar, schizoaffective and schizophrenic patients: a descriptive study. European Neuropsychopharmacology 25: S492-S493

Sarikaya Varlik, D.; Uzun, U.E.; Güçlü, O.; Varlık, C.; Güler, A.; Erkıran, M. 2015: P.3.d.025 Relationship between treatment compliance, insight and hospitalisations among schizophrenia patients. European Neuropsychopharmacology 25: S493-S494

Froelich, F.; Guillin, O.; Alexanian, J.; Fourdrinier, V. 2015: P.3.d.029 Sodium nitroprusside in treatment-refractory schizophrenia: a case-report. European Neuropsychopharmacology 25: S495-S496

Torrecilla Olavarrieta, R.; Jaen Moreno, M.J.; Villalobos Martinez, E. 2015: P.3.d.032 Study of efficiency and tolerance after changing from olanzapine and risperidone to oral paliperidone in a sample of patients with schizophrenia. European Neuropsychopharmacology 25: S496-S497

Torrecilla, R.; Báez Amuedo, M.N.; Fernández Monge, M. 2015: P.3.d.033 Study of efficiency, physical health and tolerance of paliperidone palmitate in patients with severe mental disorder. European Neuropsychopharmacology 25: S497-S498

Kuzmanovic, A.; Zivkovic, N.; Djokic, G.; Curcic, D.; Zoric, K.; Djordjevic, M. 2015: P.3.d.035 Aripiprazole in treatment of first episode schizophrenia. European Neuropsychopharmacology 25: S498-S499

Koshikawa, Y.; Takekita, Y.; Kato, M.; Sakai, S.; Onohara, A.; Sunada, N.; Nishida, K.; Yoshimura, M.; Fabbri, C.; Serretti, A.; Kinoshita, T. 2015: P.3.d.038 The effects of risperidone long-acting injection versus paliperidone palmitate on cognitive and social function in schizophrenia an open pilot randomised controlled trial. European Neuropsychopharmacology 25: S500-S501

Guillena, S.L.R.; Mata Saenz, B.; Fashho Rodriguez, E.; Casas Barquero, N. 2015: P.3.d.040 Paliperidone palmitate versus conventional depots and oral antipsychotics in inpatients with schizophrenia. European Neuropsychopharmacology 25: S501-S502

Guillena, S.L.R.; Saenz, B.M.; de Diego, B.O.P.G. 2015: P.3.d.041 Efficacy and safety of extended-release paliperidone in patients at high risk of drug-drug interaction. European Neuropsychopharmacology 25: S502-S503

Guillena, S.L.R.; DeIngunza Barreiro, E.; Gotor, F. 2015: P.3.d.042 Treatment discontinuation in schizophrenia. Paliperidone palmitate versus oral antipsychotics. European Neuropsychopharmacology 25: S503-S504

González-Blanco, L.; Calzón, G.P.; Revuelta, J.R.; Arroyo, V.G. 2015: P.3.d.044 Self-reported antipsychotic adherence among outpatients with a severe mental disorder: a comparative study. European Neuropsychopharmacology 25: S504-S505

Zarranz, I.; Lopez, M.D.P.; Mendonza, S.B. 2015: P.3.d.047 Metabolic syndrome and functionality 2-year follow-up study of 33 outpatients with a mental disorder treatment with paliperidone palmitate. European Neuropsychopharmacology 25: S506-S507

Igata, R.; Hori, H.; Tominaga, H.; Beppu, H.; Katsuki, A.; Atake, K.; Yoshimura, R. 2015: P.3.d.049 Effects of antipsychotic switch on body weight, blood data, and vital signs in patients with acute-phase schizophrenia: a retrospective study. European Neuropsychopharmacology 25: S507-S508

Pablo, R.N.N.; Torres, V.H.; Martinez Leon, F. 2015: P.3.d.051 A descriptive study of the administration of paliperidone palmitate in a rural area. European Neuropsychopharmacology 25: S508-S509

Sunada, N.; Takekita, Y.; Onohara, A.; Koshikawa, Y.; Sakai, S.; Kato, M.; Kinoshita, T. 2015: P.3.d.052 Paliperidone palmitate effects on the electrocardiogram in Japanese patients with schizophrenia. European Neuropsychopharmacology 25: S509-S510

Hori, H.; Asuka, K.; Kiyokazu, A.; Reiji, Y.; Jun, N. 2015: P.3.d.054 Blonanserin versus aripiprazole for treatment of Japanese schizophrenia patients: a randomized control trial. European Neuropsychopharmacology 25: S510-S511

Peters-Strickland, T.; Raoufinia, A.; Nylander, A.; Baker, R.A.; Eramo, A.; Jin, N.; McQuade, R.D.; Hertel, P.; Larsen, F. 2015: P.3.d.056 Deltoid injection of aripiprazole once-monthly in the treatment of schizophrenia. European Neuropsychopharmacology 25: S511-S512

Durgam, S.; Earley, W.; Li, R.; Li, D.; Lu, K.; Laszlovszky, I.; Fleischhacker, W.W.; Lieberman, J.A. 2015: P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial. European Neuropsychopharmacology 25: S512-S513

Bustillo, M.; Querejeta, I.; Segarra, R.; González-Pinto, A.; Alonso, M.; Mentxaka, O.; Ugarte, A.; Santos, B.; Gutiérrez-Fraile, M.; Zabala, A. 2015: P.3.d.059 Plasma levels of second generation antipsychotics as indicators of clinical response and severity of side-effects in first-episode psychosis patients. European Neuropsychopharmacology 25: S513-S514

Novick, D.; Montgomery, W.; Aguado, J.; El-Shafei, A.; Katagari, H.; Kraemer, S.; Haro, J. 2015: P.3.d.060 Comparative clinical outcomes of orodispersable versus standard oral olanzapine tablets in non-adherent patients with schizophrenia or bipolar disorder. European Neuropsychopharmacology 25: S514-S515

Mata Iturralde, L.; Alvarez García, R.; Ovejero García, S.; Iza Cía, M.; Sánchez Alonso, S. 2015: P.3.d.062 Paliperidone palmitate: evaluation of effectiveness using a mirror image study. European Neuropsychopharmacology 25: S515-S516

Sousa, A.; Gomes, J.; Solana, C.; DaPonte, G.; Paiva, A. 2015: P.3.d.066 Qtc prolongation and antipsychotics: a connection to remember. European Neuropsychopharmacology 25: S518-S519

Samara, M.; Nikolakopoulou, A.; Salanti, G.; Leucht, S. 2015: P.3.d.069 How many patients with schizophrenia do not respond to antipsychotic drugs?. European Neuropsychopharmacology 25: S520-S521

Weiss, C.; Sugaya, K.; Perry, P.; Nagamizu, K.; Weiller, E.; Baker, R.; Malla, A. 2015: P.3.d.071 The effect of brexpiprazole (Opc-34712) in adult outpatients with early-episode schizophrenia: An exploratory study. European Neuropsychopharmacology 25: S521-S522

Correli, C.; Skuban, A.; Ouyang, J.; Weiss, C.; Weiller, E.; Kane, J.M. 2015: P.3.d.072 Efficacy and safety of brexpiprazole (Opc-34712) in acute schizophrenia: a pooled analysis of two pivotal studies. European Neuropsychopharmacology 25: S522-S523

Soto Ontoso, M.; López Saracho, I.; Sanchez Espin, S. 2015: P.3.d.074 Antipsychotic polytherapy and risk of readmission in a mental health hospitalisation unit. A cohort retrospective study. European Neuropsychopharmacology 25: S523-S524

Alphs, L.; Starr, H.L.; Mao, L.; Bossie, C.A.; Kim, E. 2015: P.3.d.075 Once-monthly paliperidone palmitate compared with oral conventional or oral atypical antipsychotic treatment in patients with schizophrenia. European Neuropsychopharmacology 25: S524-S525

Naber, D.; Hansen, K.; Forray, C.; Baker, R.A.; Sapin, C.; Beillat, M.; Peters-Strickland, T.; Nylander, A.; Hertel, P.; Steen Andersen, H.; Eramo, A.; Loze, J.; Potkin, S. 2015: P.3.d.077 Clinical Global Impression after aripiprazole once-monthly and paliperidone palmitate: Results from Qualify, a head-to-head study in schizophrenia. European Neuropsychopharmacology 25: S525-S526

Naber, D.; Hansen, K.; Forray, C.; Baker, R.A.; Sapin, C.; Beillat, M.; Peters-Strickland, T.; Nylander, A.; Hertel, P.; Steen Andersen, H.; Eramo, A.; Loze, J.; Potkin, S. 2015: P.3.d.080 Aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by age: Results from Qualify, a head-to-head study. European Neuropsychopharmacology 25: S527-S528

Pigoni, A.; Bosia, M.; Spangaro, M.; Bechi, M.; Buonocore, M.; Smeraldi, E.; Cavallaro, R. 2015: P.3.d.082 Enhancing cognitive remediation therapy with transcranial direct current stimulation: preliminary findings in schizophrenia. European Neuropsychopharmacology 25: S528-S529

Potkin, S.G.; Loze, J.; Forray, C.; Baker, R.A.; Sapin, C.; Peters-Strickland, T.; Beillat, M.; Nylander, A.; Hertel, P.; Andersen, H.S.; Eramo, A.; Hansen, K.; Naber, D. 2015: P.3.d.084 Aripiprazole once-monthly is superior to paliperidone palmitate: results from Qualify, a randomized, head-to-head clinical study in schizophrenia. European Neuropsychopharmacology 25: S529-S530

Ribeiro, H.P.; Silva, J. 2015: P.3.d.087 Tobacco smoking in patients taking antipsychotic long-acting injections and sexual dysfunction. European Neuropsychopharmacology 25: S531-S532

Chiliza, B.; Asmal, L.; Oosthuizen, P.; Van Niekerk, Y.; Erasmus, R.; Kidd, M.; Malhotra, A.; Emsley, R. 2015: P.3.d.089 Changes in body mass and metabolic profiles over 12 months in patients with first-episode schizophrenia treated with flupenthixol decanoate. European Neuropsychopharmacology 25: S532-S533

Gil, P.; Moreno, T.; Garcia, L.; Abajo, E.; Meaza, M.A.; Guillén Gil, V.; Sanmartin, V.; Rodriguez, J.M.; Caballero, P.; Bazozabal, I. 2015: P.3.d.092 Impact on hospitalisation of long acting injectable paliperidone in a first episode sample (Lehenak program). European Neuropsychopharmacology 25: S534-S535

Anand, E.; Berggren, L.; Landry, J.; Popescu, M.; Toth, A.; Detke, H.C. 2015: P.3.d.094 Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being. European Neuropsychopharmacology 25: S535-S536

Varlik, D.S.; Guclu, O.; Uzun, U.E.; Varlik, C.; Kahya, S.; Ozsoy, E.V.; Erkiran, M. 2015: P.3.f.001 Factors associated with re-hospitalizations in schizophrenia: a community mental health service research. European Neuropsychopharmacology 25: S536-S537

Botha, U.; Koen, L.; Niehaus, D.; Mikateko, M.; Jordaan, E. 2015: P.3.f.003 In search of an affordable post-discharge intervention for patients with severe mental illness in a developing country. European Neuropsychopharmacology 25: S537-S538

Aladashvili, T.; Tavadze, E.; Gorgodze, Q. 2015: P.3.f.005 Depressive symptoms in patients with schizophrenia. European Neuropsychopharmacology 25: S538-S539

Renemane, L.; Laptijeva, A. 2015: P.3.f.008 Specificity of mental disorders and social danger as prognostic factor of involuntary treatment of patients in mental hospital. European Neuropsychopharmacology 25: S539-S540

Guillena, S.L.R.; DeDiego, B.O.P.G.; Barquero, N.C.; Benitez, M.G.; Lopez, M.F.; Salguero, M.G. 2015: P.3.f.011 Effectiveness of audiovisual campaigns against the stigmatisation of schizophrenia. European Neuropsychopharmacology 25: S541-S542

Kim, S.; Lee, J.; Joe, S.; Ahn, J.; Park, J.; Choi, Y.; Yim, J. 2015: P.3.f.013 Prevalence of medical comorbidity in patients with schizophrenia. European Neuropsychopharmacology 25: S542-S543

Kott, A.; Daniel, D.G. 2015: P.3.f.014 Effects of Panss audio/video recordings on the presence of identical scorings across visits. European Neuropsychopharmacology 25: S543-S544

Coentre, R.; Silva-dos-Santos, A.; Lopes, J.; Gracias, M.; Talina, M. 2015: P.3.f.016 Initial medical work-up in first episode psychosis. European Neuropsychopharmacology 25: S544-S545

Tudose, C.; Traian, P.; Petre, M.V.; Marinescu, V.; Ciorica, G.I.; Maliche, C.E. 2015: P.3.f.018 Evolution of anhedonia and depressive symptoms in Romanian outpatients diagnosed with major depressive episode and treated with agomelatine. European Neuropsychopharmacology 25: S545-S546

Yalınçetin, B.; Alptekin, K.; Ulaş, H.; Binbay, T.; Akdede, B.B. 2015: P.3.f.019 The effect of thought disorders on remission of symptoms in schizophrenia. European Neuropsychopharmacology 25: S546-S547

Misiak, B.; Piotrowski, P.; Slezak, R.; Kiejna, A.; Dorota, F. 2015: P3.f.021 Baseline cardiometabolic risk in a cohort of first-episode schizophrenia patients. European Neuropsychopharmacology 25: S547-S548

Rondinoni, C.; Zanatta, D.P.; Souza-Zinader, J.; Louzada-Jr, P.; Menezes, P.R.; Santos, A.C.D.; Del-Ben, C.M. 2015: P.3.f.024 Tract-based statistics in first episode psychosis: preliminary results depending on substance abuse comorbidity. European Neuropsychopharmacology 25: S549-S550

Mazumder, A.H.; Islam, T.; Rushdy, M.A.; Hall, T.L.; Iwatani, J. 2015: P.3.f.026 Season of birth in schizophrenia in a lower latitude country of northern hemisphere Bangladesh perspective. European Neuropsychopharmacology 25: S550-S551

Onur, O.; Tabo, A.; Erkan, A. 2015: P.4.a.001 Impulsivity features of patients with obsessive-compulsive disorder and relationship between impulsivity and obsession subtypes. European Neuropsychopharmacology 25: S552-S553

Jukić, M.M.; Peñas-Lledó, E.; Courtet, P.; Llerena, A.; Ingelman-Sundberg, M. 2015: P4.a.003 Involvement of Cyp2C19 in stress-induced despair. European Neuropsychopharmacology 25: S553-S554

Regue, M.; Poilbout, C.; Lanfumey, L.; Mongeau, R. 2015: P.4.a.004 Fear extinction deficits and Bdnf dysregulation in mice with full 5-Ht2C receptor editing: a model for post-traumatic stress disorders?. European Neuropsychopharmacology 25: S554-S555

Avetyan, D.; Gohar, M. 2015: P.4.a.006 The role of nerve growth factor and its receptor in posttraumatic stress disorder. European Neuropsychopharmacology 25: S555-S556

Masdrakis, V.; Legaki, E.M.; Soldatos, C.; Ploumpidis, D.; Papageorgiou, C.; Oulis, P. 2015: P.4.b.001 Baseline heartbeat perception accuracy and short-term outcome of brief cognitive-behaviour therapy for panic disorder with agoraphobia. European Neuropsychopharmacology 25: S556-S557

Lee, K.S.; Kim, B.; Kim, M.K.; Kim, S.-W.; Choi, T.K.; Kim, N.K.; Lee, S.-H. 2015: P.4.b.002 Association of human micro Rnas miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. European Neuropsychopharmacology 25: S557-S558

Campinoti, G.; Bossini, L.; Caterini, C.; Fagiolini, A. 2015: P.4.b.004 Photosensitivity in panic disorder and effects of medication treatment. European Neuropsychopharmacology 25: S558-S559

Zakirov, F.; Gultekin, G.; Yuksek, E.; Yavuzer, H.; Emul, M. 2015: P.4.b.007 The lucidity features and dream anxiety level in elderly patients with generalized anxiety disorder. European Neuropsychopharmacology 25: S560-S561

Muzzarelli, L.; Mazza, M.; Bollettini, I.; Dallaspezia, S.; Poletti, S.; Smeraldi, E.; Benedetti, F. 2015: P.4.b.009 The white matter in obsessive compulsive disorder: effect of pharmacological treatment and symptom dimensions models. European Neuropsychopharmacology 25: S561-S562

Diniz, J.; Cappi, C.; Costa, D.; Reimer, A.; DeOliveira, A.; Brandão, M.; Hoexter, M.; Miguel, E.; Shavitt, R. 2015: P.4.b.010 Fear conditioning and Bdnf levels and genotype in obsessive-compulsive disorder patients pre and post treatment with sertraline: preliminary results. European Neuropsychopharmacology 25: S562-S563

Alves, N.; Machado-Santos, A.; Mateus-Pinheiro, A.; Patrício, P.; Correia, J.; Morais, M.; Bessa, J.; Sousa, N.; Pinto, L. 2015: P.4.c.004 Adult neuroplasticity as a pathological trigger of recurrence in depression. European Neuropsychopharmacology 25: S564-S565

Vilela-Costa, H.H.; Spiacci, A.J.; Sant'Ana, A.B.; Zangrossi, H.J. 2015: P.4.c.007 Involvement of dorsal raphe subnuclei in the regulation of anxiety-related defensive behaviour after acute and chronic treatment with imipramine. European Neuropsychopharmacology 25: S566-S567

Nardi, A.E.; Freire, R.; Machado, S.; Silva, A.; Hoirisch-Clapauch, S.; Amrein, R. 2015: P.4.d.001 A schedule for tapering out clonazepam in panic disorder patients after long-term treatment. European Neuropsychopharmacology 25: S567-S568

DeVries, Y.A.; DeJonge, P.; Van den Heuvel, E.; Turner, E.H.; Roest, A.M. 2015: P.4.d.004 The influence of baseline severity on antidepressant efficacy for anxiety disorders: a meta-analysis and meta-regression. European Neuropsychopharmacology 25: S568-S569

Amodeo, G.; Maina, G.; Rosso, G.; Viola, M.; Fagiolini, A. 2015: P.4.d.005 Combining clomipramine and paroxetine for treatment-resistant obsessive compulsive disorder. European Neuropsychopharmacology 25: S569-S570

Sulejmanpasic-Arslanagic, G.; Srebrenka, B.B. 2015: P.4.d.007 Olanzapine augmentation in alleviating treatment-resistant nightmares and insomnia in patients with combat-related Ptsd. European Neuropsychopharmacology 25: S570-S571

Martinez-Cengotitabengoa, M.; González-Ortega, I.; García-Alocén, A.; López Pérez, P.; Besga Basterra, A.; Bermúdez, S.; Chicote, N.; Cuesta, E.; Salem, H.; Dueñas, M.; Gonzáiez-Pinto, A. 2015: P.4.d.008 Gender differences in benzodiazepines prescription in old age patients. European Neuropsychopharmacology 25: S571-S572

Mongeau, R.; Ouradou, M.; Deou, E.; Leconte, C.; Besson, V.B.; Plotkine, M.; Marchand-Leroux, C. 2015: P.4.e.002 Traumatic brain injury induces post-traumatic stress disorder-like behaviors in mice: possible role of white matter alterations. European Neuropsychopharmacology 25: S572-S573

Bas-Hoogendam, J.M.; Van Steenbergen, H.; Westenberg, P.M.; Van der Wee, N.J.A. 2015: P.4.e.003 Social conditioning of neutral faces: A pilot-study on brain functioning in social anxiety patients and their unaffected first-degree relatives. European Neuropsychopharmacology 25: S573-S574

Gottwald, J.; Apergis-Schoute, A.; Morein-Zamir, S.; Kaser, M.; Sule, A.; Conway Morris, A.; Limmer, W.; Robbins, T.; Sahakian, B. 2015: P.4.f.002 The cognitive profile of early-onset obsessive-compulsive disorder; does age matter?. European Neuropsychopharmacology 25: S574-S575

Coimbra, Joao Carlos; Pinto, Iraja Damiani; Wurdig, Norma Luiza; Do Carmo, Dermeval Aparecido 2015: P.4.f.005 Bdnf transcripts modulation in the blood of subjects exposed to childhood trauma history. European Neuropsychopharmacology 25: S576-S577

Kassa, J.; Korabecny, J.; Nepovimova, E.; Misik, J. 2015: P.5.a.002 Therapeutic effect of novel 7-methoxytacrine-donepezil like hybrids on cognitive deficit in rats a potentiality for Alzheimer's disease treatment. European Neuropsychopharmacology 25: S577-S578

Dragomanova, S.; Tancheva, L.; Georgieva, M.; Georgieva, A.; Dishovsky, C.; Kalfin, R.; Atanasova, D.; Lazarov, N.; Pehlivanov, I. 2015: P.5.a.005 Preventive effect of the natural monoterpene myrtenal on cognitive disorders in dement mice. European Neuropsychopharmacology 25: S578-S579

Sonn, K.; Zharkovsky, A. 2015: P.5.a.009 Effects of chronic streptozocin-induced diabetes on neural stem cell proliferation in the 5Xfad mouse model of Alzheimer's disease. European Neuropsychopharmacology 25: S580-S581

Narayana, U.; Clifton, A.; Luxenberg, J.; Curran, S. 2015: P.5.b.001 Cochrane review of valproate preparations for agitation in dementia. European Neuropsychopharmacology 25: S581-S582

Shin, D.; Bae, D. 2015: P.5.b.003 The effect of memantine treatment for sleep disturbances in patients with alcohol-related dementia. European Neuropsychopharmacology 25: S582-S583

Reeves, S. 2015: P.5.b.007 Mechanisms underpinning antipsychotic drug sensitivity in Alzheimer's disease. European Neuropsychopharmacology 25: S584-S585

Zangrando, A.; Babici, F.; Pascolo-Fabrici, E.; Palcic, S.; Riolo, A. 2015: P.5.b.009 Are antidepressant drugs safer than antipsychotics in the behavioural and psychological symptoms of dementia?. European Neuropsychopharmacology 25: S585-S586

Moty, J.; Przykaza, �.; Kosson, P.; Boguszewski, P.; Strosznajder, J. 2015: P.5.c.002 Sphingosine kinase 1 mediated signalling in Parkinson's disease animal model. Neuroprotective effect of fingolimod and a D2/D3 dopamine receptor agonist. European Neuropsychopharmacology 25: S586-S587

Guillena, S.L.R.; Saenz, B.M.; Rodriguez, E.F.; Barquero, N.C. 2015: P.5.d.003 Relationship between psychiatric and neurological diagnosis in patients presenting to an outpatient neurology service with cognitive complaints. European Neuropsychopharmacology 25: S587-S588

Arnaoudova, M. 2015: P.5.d.004 Psychiatric comorbidity in elderly patients with vascular cognitive disorder. European Neuropsychopharmacology 25: S588-S589

Sirin, P.S.; Yazar, M.S.; Eradamlar, N. 2015: P.5.d.006 Neurosyphilis presenting with psychosis and dementia a case report. European Neuropsychopharmacology 25: S589-S590

Stankevich, Y.; Thurm, F.; Evens, R.; Riedel, O.; Storch, A.; Fauser, M.; Li, S.; Lueken, U. 2015: P.5.d.007 Improved spatial memory under dopaminergic medication in Parkinson's disease patients with subclinical depressive symptoms. European Neuropsychopharmacology 25: S590-S591

Kim, H.W.; Kim, H.G. 2015: P.5.f.001 The effectiveness of combination therapy with quetapine and valproic acid in delirium with aggressive tendency: a prospective, controlled trial study. European Neuropsychopharmacology 25: S591-S592

Lim, K.Y.; Chang, K.J.; Son, S.J.; Hong, C.H. 2015: P.5.f.002 Effect of antidepressant and anxiolytics on development of diabetes mellitus inpatients with Alzheimer's disease. European Neuropsychopharmacology 25: S592-S593

Manusheva, N.; Arsova, S.; Bajraktarov, S.; Videnova, V. 2015: P.5.f.005 Escitalopram in treatment of narcolepsy case report. European Neuropsychopharmacology 25: S593-S594

Jangra, A.; Shaker, S.C.; Iftikar, H.M.; Probhod, B.; Mangala, L. 2015: P.6.a.001 Alcohol exacerbates restraint stress-induced hippocampal damage and cognitive deficit: implication of poly(Adp)-ribose polymerase over-activation. European Neuropsychopharmacology 25: S595-S596

Yoshimoto, K.; Watanabe, Y.; Tanaka, M.; Yamaguchi, T.; Ueda, S.; Hiraga, Y.; Nagao, M.; Ochi, K. 2015: P.6.a.004 Habitual alcohol drinking behavior associated with active ghrelin and serotonin neurons in the amygdala and lateral hypothalamus. European Neuropsychopharmacology 25: S597-S598

Campbell, A.; Chambers, C.D.; Allen, C.P.G.; Sumner, P. 2015: P.6.a.007 Stopping hand and eye movements during acute alcohol intoxication. European Neuropsychopharmacology 25: S598-S599

Lupi, M.; Acciavatti, T.; Cinosi, E.; Marini, S.; Santacroce, R.; Sarchione, F.; Fiori, F.; Carlucci, M.; Martinotti, G.; DiGiannantonio, M.; Orsolini, L. 2015: P.6.b.002 Epidemiology and diffusion binge drinking phenomenon in an Italian population of young adults. European Neuropsychopharmacology 25: S600-S601

Lingford-Hughes, A.; McGonigle, J.; Mick, I.; Quelch, D.; Flechais, R.; Erritzoe, D.; Bolstridge, M.; Ramos, A.; Meulien, D.; Sluth, L.; Nilausen, D.; Von der Goltz, C.; Steiniger-Brach, B.; Nutt, D. 2015: P.6.b.005 An fMri study of nalmefene on alcohol effects in reward anticipation in alcohol dependence. European Neuropsychopharmacology 25: S602-S603

Hogewoning, A.; Raasveld, S.J.; Van de Loo, A.J.A.E.; Slot, K.A.; Verster, J.C. 2015: P.6.b.007 Measurement of hangover severity: can a 1-item question replace multi-item scales?. European Neuropsychopharmacology 25: S603-S604

Kütük, E.K.; Kumsar, N.A.; Dilbaz, N.; Kaya, H. 2015: P.6.b.010 Comparison of Hpa axis response to the stimulation of psychological stress in abstinence period of alcoholism with first degree relatives and control. European Neuropsychopharmacology 25: S604-S605

Vecchiotti, R.; Orsolini, L.; Marconi, M.; Panichi, M.; Valchera, A. 2015: P.6.b.011 Alexithymia in a sample of alcohol-dependent patients: clinical correlations and cognitive patterns. European Neuropsychopharmacology 25: S605-S606

Morris, L.; Dowell, N.; Cercignani, M.; Sawiak, S.; Harrison, N.; Voon, V. 2015: P.6.b.013 Neurochemical and microstructural aberrancies in binge alcohol consumption. European Neuropsychopharmacology 25: S606-S607

Boticario, V.; Vicente, S. 2015: P.6.b.014 Detection of alcohol problems: the sooner the best. European Neuropsychopharmacology 25: S607-S608

Mota, D.; Silva, S.; Madeira, N. 2015: P.6.b.016 Disulfiram psychosis in the treatment of alcoholism. European Neuropsychopharmacology 25: S608-S609

Pinton, L.; Borroto-Escuela, D.O.; Narvaez, M.; Jimenez-Beristein, A.; Oflijan, J.; Ferraro, L.; Agnati, L.F.; Fuxe, K. 2015: P.6.c.001 Dopamine D2 receptor dynamic and modulation in the D2R-Sigma 1 heteroreceptor complexes: role in cocaine action. European Neuropsychopharmacology 25: S609-S610

Engeli, E.J.E.; Hock, A.; Zölch, N.; Dafflon, J.; Scheidegger, M.; Hulka, L.M.; Seifritz, E.; Quednow, B.B.; Henning, A.; Herdener, M. 2015: P.6.c.004 Unveiling metabolic alterations within the human reward circuitry in addiction by using a novel small-voxel, 1H-Mrs (spectroscopy) protocol in the nucleus accumbens. European Neuropsychopharmacology 25: S610-S611

Konstantinopolsky, M.; Gudasheva, T.A.; Kolik, L.G. 2015: P.6.c.005 New generation of anxiolytics for treatment of opiate-like addiction: advantages and possible clinical application. European Neuropsychopharmacology 25: S611-S612

Oztürk, Z. 2015: P.6.d.003 Baby bonzai: a case of maternal exposure to synthetic cannabinoid during pregnancy. European Neuropsychopharmacology 25: S612-S613

Lawn, W.; Freeman, T.; Pope, R.; Joyce, A.; Harvey, L.; Hindocha, C.; Mokrysz, C.; Moss, A.; Das, R.; Curran, H. 2015: P.6.d.006 I was gonna process rewards but then I got high: the acute and chronic effects of cannabis and ketamine on reward processing. European Neuropsychopharmacology 25: S614-S615

Cinosi, E.; Corbo, M.; Matarazzo, I.; Acciavatti, T.; Marini, S.; Vellante, F.; DiTizio, L.; Lupi, M.; Santacroce, R.; Martinotti, G.; DiGiannantonio, M.; Orsolini, L. 2015: P.6.d.009 Polyabuse and diversion of drugs: methylphenidate/cannabis-induced manic like-symptoms. European Neuropsychopharmacology 25: S615-S616

Fernstrand, A.M.; Van den Borne, L.; Lensvelt, L.M.H.; Ribbert, L.L.A.; DeWith, A.C.; Goede, L.X.Y.; Garssen, J.; Verster, J.C. 2015: P.6.d.010 The 2D:4D digit ratio as biomarker for substance abuse. European Neuropsychopharmacology 25: S616-S617

Likhitsathian, S.; Aramrattana, A.; Assanangkornchai, S.; Angkurawaranon, C.; Thaikla, K.; Srisurapanont, M. 2015: P.6.d.012 Use of other substances among kratom users: findings from a 2011 national household survey in Thailand. European Neuropsychopharmacology 25: S617-S618

Hulka, L.; Vonmoos, M.; Preller, K.; Seifritz, E.; Gamma, A.; Quednow, B. 2015: P.6.d.013 Self-reported impulsivity and gambling decision-making but not delay discounting covary with changing cocaine use across one year. European Neuropsychopharmacology 25: S618-S619

Palma, A.; Galindo, L.; Grifell, M.; Quintana, P.; Toll, A.; Ventura, M.; Fornís, I.; Torrens, M.; Farré, M. 2015: P.6.d.016 An old chemical that became a new psychoactive substance: study on O-Acetylpsilocin samples handled for analysis and raise of awareness. European Neuropsychopharmacology 25: S620-S621

Van Hell, H.H.; Broyd, S.; Greenwood, L.; Croft, R.; Solowij, N. 2015: P6.d.018 Delta9-tetrahydrocannabinol (Thc) and cannabidiol (Cbd) alone and in combination affect brain activity during rest. European Neuropsychopharmacology 25: S621-S622

Bruguera, P.; Miquel, L.; López-Pelayo, H.; Balcells-Oliveró, M. 2015: P.6.d.019 Cannabinoid hyperemesis syndrome; a prevalence study. European Neuropsychopharmacology 25: S622-S623

Wunderli, M.; Vonmoos, M.; Preller, K.H.; Hulka, L.M.; Baumgartner, M.R.; Seifritz, E.; Eich-Höchli, D.; Quednow, B.B. 2015: P.6.d.022 Cognitive and emotional impairments in adults with attention-deficit/hyperactivity disorder and cocaine use: mutual effects of an unholy alliance. European Neuropsychopharmacology 25: S624-S625

Kupchik, Y.M.; Brown, R.M.; Gipson, C.D.; Stefanik, M.T.; Kalivas, P.W. 2015: P.6.e.001 When motivation becomes maladaptive similarities between drug addiction and obesity. European Neuropsychopharmacology 25: S626-S627

DiBonaventura, M.V.M.; Pucci, M.; Giusepponi, M.; Romano, A.; Maccarrone, M.; Ciccocioppo, R.; Cifani, C.; D'Addario, C. 2015: P.6.e.003 Epigenetic regulation of nociceptin/orphanin Fq and corticotropin-releasing factor system genes in frustration stress-induced binge eating. European Neuropsychopharmacology 25: S627-S628

Rodriguez-Rivera, C.; Perez-Garcia, C.; Munoz-Rodriguez, J.; Vicente-Rodriguez, M.; Polo, F.; Ford, R.; Segura, E.; Salas, E.; Herradon, G.; Gonzalez-Martin, C.; Beato, L.; Martin, J.; Merino, L.A. 2015: P.6.f.003 Identification of food craving biomarkers and potential drug targets in obesity: clusterin and serum amyloid p-component. European Neuropsychopharmacology 25: S628-S629

Evren, C.; Dalbudak, E.; Evren, B.; Aldemir, N.; Aldemir, S. 2015: P.6.f.004 Relationship of lifetime substance use and posttraumatic stress disorder among Turkish university students. European Neuropsychopharmacology 25: S629-S630

Nurhidayat, A.W. 2015: P.6.f.007 Efficacy of behavioural drug and risk counseling for patients in methadone maintenance treatment in Jakarta, Indonesia: a randomised clinical trial. European Neuropsychopharmacology 25: S631-S632

de Pablo, G.S.; Bernabeu, A.A.; Vallejo, S.G.; Alegret, M.S.; Nieto, M.D.; Espeso, E.A.R.; Castro, E.B.; Mejias, A.D.R.; Villamor, I.B.; Navarrete, F.F. 2015: P.6.f.009 Shopping dependence among women with eating disorders. European Neuropsychopharmacology 25: S632-S633

Brkovic, J.K. 2015: P.6.f.012 Correlation between depression and thyroid function disturbance in women opiate addicts. European Neuropsychopharmacology 25: S633-S634

Jovic, N.J.; Cekic, B.D. 2015: P.7.b.002 Epilepsy and Eeg paroxysmal abnormalities associated with autism spectrum disorders. European Neuropsychopharmacology 25: S635-S636

Aghajani, M.; Veer, I.; Van Hoof, M.; Rombouts, S.; Van der Wee, N.; Vermeiren, R. 2015: P.7.b.006 Abnormal functional architecture of amygdala-centered networks in adolescent posttraumatic stress disorder. European Neuropsychopharmacology 25: S637-S638

Arenzana, M.V.; Janssen, J.; Fraguas, D.; Castro-Fornieles, J.; Pinto, A.G.; Graell, M.; Otero, S.; Desco, M.; Pantelis, C.; Arango, C.; Rapado-Castro, M. 2015: P.7.b.008 Progressive loss of gray matter volume in the frontal lobe is associated with decreased working memory performance over time in adolescent psychosis. European Neuropsychopharmacology 25: S639-S640

Sukhanova, I.; Khukhareva, D.; Sebentsova, E.; Vyssokikh, M.; Levitskaya, N. 2015: P.7.c.001 Correction of negative effects of acute normobaric hypoxia in rats with a synthetic analog of Acth. European Neuropsychopharmacology 25: S640-S641

Maneeton, B.; Maneeton, N.; Likhitsatian, S.; Suttajit, S.; Narkpongphun, A.; Srisurapanont, M.; Woottiluk, P. 2015: P.7.d.001 A systematic review of lisdexamfetamine versus placebo in the treatment of child and adolescent Adhd. European Neuropsychopharmacology 25: S641-S642

Martsenkovskyi, D. 2015: P.7.d.004 Efficacy and safety of fluoxetine in the treatment of posttraumatic stress disorder in children and adolescents. European Neuropsychopharmacology 25: S643-S644

Voinescu, B.I. 2015: P.7.d.008 The impact of sleep on inattention, impulsiveness and cognitive failures. European Neuropsychopharmacology 25: S644-S645

Roldán, A.; Galling, B.; Correli, C. 2015: P.7.d.009 Are antipsychotics a risk factor for type 2 diabetes in youth? A meta-analysis of incidence rates compared to healthy and psychiatric controls. European Neuropsychopharmacology 25: S645-S646

Del Valle Rubido, M.; Umbricht, D.; Shic, F.; McCracken, J.T.; Scahill, L.; Khwaja, O.; Squassante, L.; Boak, L.; Bolognani, F.; Fontoura, P.; Wall, C.; Jou, R.; Loomis, R.; Lyons, M.; Gavaletz, A. 2015: P.7.d.011 Results from a phase I proof-of-mechanism study with a vasopressin 1A receptor antagonist in autism spectrum disorder. European Neuropsychopharmacology 25: S646-S647

Coghill, D.R.; Nagy, P.; Frick, G.; Adeyi, B.; Newcorn, J. 2015: P.7.d.012 Relative efficacy of lisdexamfetamine dimesylate and osmotic controlled-release methylphenidate in attention-deficit/hyperactivity disorder patients. European Neuropsychopharmacology 25: S647-S648

Cutler, A.; Harper, L.; Young, J.; Adeyi, B.; Dirks, B.; Wilens, T. 2015: P.7.d.014 Guanfacine extended release: daytime sleepiness outcomes from a phase 3 clinical study in adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology 25: S648-S649

Lim, Y.; Kim, B. 2015: P.7.f.001 Relationship between depressed mood, body mass index, and body weight perception in Korean adolescents. European Neuropsychopharmacology 25: S650-S651

Nam, B.; Shon, I.; Kim, M.H.; Seo, J.S.; Jung, Y.E. 2015: P.7.f.003 Public perspectives on pharmacological treatment of attention-deficit hyperactivity disorder. European Neuropsychopharmacology 25: S651-S652

Martín-Pérez, C.; Contreras-Rodríguez, O.; Verdejo-Román, J.; Vilar-López, R.; Verdejo-García, A. 2015: P.7.f.005 Homeostatic brain correlates of acute social stress in excess weight adolescents. European Neuropsychopharmacology 25: S652-S653

Harsh, R.; Kundi, P.S.; Ezeh, D. 2015: P.8.b.001 A systematic review of the effectiveness of psychological interventions for adult sex-offenders in prisons, community clinics and forensic hospitals. European Neuropsychopharmacology 25: S653-S654

Peters, L.; Fernstrand, A.M.; Garssen, J.; Verster, J.C. 2015: P.8.b.002 The effect of dietary intake of vitamin B6 on sleep quality and insomnia. European Neuropsychopharmacology 25: S654-S655

Bakomitrou, F.; Bousboulas, S.; Dimitriou, A.; Sittas, D.; Koutsovasilis, A.; Bousboula, A.; Spinaris, V. 2015: P.8.b.004 Correlation of group education with metabolic and psychosocial parameters in type 2 diabetes patients. European Neuropsychopharmacology 25: S655-S656

DiVolo, S.; Bolognesi, S.; Goracci, A.; Caterini, C.; Castellani, G.; Vuolo, G.; Ciuoli, C.; Fagiolini, A. 2015: P.8.b.006 Binge eating disorder and bariatric surgery: a pilot study. European Neuropsychopharmacology 25: S656-S657

Fuentes, M.; Gabler, G.; Koppmann, A.; Montane, I.; Feeder, S. 2015: P.8.b.007 Relation between the presence of obesogenic behaviors and the outcome of bariatric surgery. European Neuropsychopharmacology 25: S657-S658

Maaranen, P.; Sankelo, P.; Mainio, A.; Kekäle, M.; Karnell, A. 2015: P.8.b.009 Inhaled loxapine for the acute treatment of agitation: clinical experience from eastern and northern Finland. European Neuropsychopharmacology 25: S658-S659

Fagiolini, A. 2015: C.01.03 How to use anxiety, irritability, and agitation (Aia) for diagnosing mania with depressive symptoms patient cases. European Neuropsychopharmacology 25: S661-S662

Gorwood, P. 2015: C.02.02 Augmentation therapies in Mdd what are the unmet needs?. European Neuropsychopharmacology 25: S662-S663

Thase, M. 2015: C.02.04 Emerging clinical data in the adjunctive treatment of Mdd. European Neuropsychopharmacology 25: S663-S664

Jaeger, J. 2015: C.03.03 Pathways to improve cognitive dysfunction in depression. European Neuropsychopharmacology 25: S664-S665

Falkai, P. 2015: C.05.02 Assessment of functioning and quality of life in schizophrenia and the relevance for clinical practice. European Neuropsychopharmacology 25: S665-S666

Emsley, R. 2015: C.06.01 The treatment continuum in schizophrenia from the acute phase to maintenance. European Neuropsychopharmacology 25: S666-S667

Molodynski, A. 2015: C.08.03 Functioning and living well. European Neuropsychopharmacology 25: S670-S671

Rehm, J. 2015: C.11.02 Need for earlier intervention in alcohol dependence evidence from a large cross-sectional study. European Neuropsychopharmacology 25: S672-S673

Vieta, E. 2015: C.13.01 How I would manage a patient with Mdd and occupational impairment. European Neuropsychopharmacology 25: S673-S674

Hert, M.D. 2015: C.14.01 First witness cardiovascular risk. European Neuropsychopharmacology 25: S674-S675

Singewald, N.; Maurer, V.; Oberhauser, M.; Wille, A.; Lusser, A.; Sartori, S.; Sah, A.; Gstier, R.; Huttenhofer, A.; Sananbenesi, F.; Fisher, A.; Bredy, T.; Whittle, N.; Murphy, C. 2016: (Epi)genetic regulation of fear sensitivity in mouse models of anxiety. European Neuropsychopharmacology 26: S142-S143

Losenkov, I.; Pozhidaev, I.V.; Osmanova, D.Z.; Simutkin, G.G. 2016: Drd2 gene polymorphisms association with severity of depressive symptoms and antidepressive therapy response in patients with depressive disorders. European Neuropsychopharmacology 26: S173-S174

Fabbri, C.; Breen, G.; Tansey, K.; Perlis, R.; Uher, R.; Lewis, C. 2016: New insights into the pharmacogenomics of antidepressant response from the Gendep and Stard* studies: results of high-density imputation. European Neuropsychopharmacology 26: S177-S178

Castren, M.; Achuta, V.S.; Turconi, G. 2016: Neural progenitor type-dependent differences in responses to metabotropic glutamate receptor 5 antagonist in the absence of fragile X mental retardation protein. European Neuropsychopharmacology 26: S190-S191

Shamsizadeh, A.; Soltani, N.; Roohbakhsh, A.; Allahtavakoli, M. 2016: Heterogeneous effects of cholecystokinin on neuronal response properties in deep layers of rat barrel cortex. European Neuropsychopharmacology 26: S219-S220

Odagaki, Y.; Kinoshita, M.; Ota, T.; Meana, J.J.; Callado, L.F.; Garcia-Sevilla, J.A. 2016: Receptor-mediated activation of Galpha(q) and Galpha(i-3) assessed by [35S]GtpgammaS binding/immunoprecipitation assay in postmortem human brain membranes. European Neuropsychopharmacology 26: S231-S232

Gasull-Camós, J.; Artigas, F.; Castañé, A. 2016: Boosting glutamatergic neurotransmission in infralimbic but not prelimbic cortex evokes antidepressant-like responses in rats through Ampa receptor activation. European Neuropsychopharmacology 26: S243-S244

Dolder, P.C.; Schmid, Y.; Mueller, F.; Borgwardt, S.; Rentsch, K.M.; Liechti, M.E. 2016: Acute dose-response effects of Lsd in healthy humans. European Neuropsychopharmacology 26: S248-S249

Almada, R.C.; Roncon, C.M.; Elias-Filho, D.H.; Wotjak, C.T.; Coimbra, N.C. 2016: Striatonigral-nigrotectal circuits regulate the expression of innate fear responses via cannabinoid receptor type 1 on Gabaergic neurons. European Neuropsychopharmacology 26: S255-S256

Jørgensen, A.; Magnusson, P.; Hanson, L.; Kirkegaard, T.; Benveniste, H.; Lee, H.; Svarer, C.; Mikkelsen, J.; Fink-Jensen, A.; Knudsen, G.; Paulson, O.B.; Bolwig, T.; Jørgensen, M. 2016: Regional brain volumes, diffusivity, and metabolite changes after electroconvulsive therapy for severe depression. European Neuropsychopharmacology 26: S304-S305

Ettrup, A.; McMahon, B.; Skibsted, A.; DaCunha-Bang, S.; Lehel, S.; Dyssegaard, A.; Jørgensen, L.; Møller, K.; Gillings, N.; Svarer, C.; Knudsen, G. 2016: Serotonin 2A receptor agonist binding with [11C]Cimbi-36 in the human brain is unaltered by citalopram/pindolol and acute tryptophan depletion. European Neuropsychopharmacology 26: S307-S308

Vanicek, T.; Berroteran-Infante, N.; James, G.; Kautzky, A.; Hahn, A.; Kranz, G.; Sigurdardottir, H.; Höflich, A.; Traub-Weidinger, T.; Hacker, M.; Wadsak, W.; Mitterhauser, M.; Kasper, S.; Lanzenberger, R. 2016: Interregional associations of Net binding in attention deficit/hyperactivity disorder; assessed with (S,S)-[18F]FmeNer-D2. European Neuropsychopharmacology 26: S317-S318

Fond, G.; Gavaret, M.; Llorca, P.; Boyer, L.; Micoulaud-Franchi, J.; Domenech, P. 2016: (Mis)use of prescribed stimulants in the medical student community: Motives and behaviors. A population-based cross-sectional study. European Neuropsychopharmacology 26: S348-S349

Chang, S.M.; Kim, J.H.; Won, S.H. 2016: Mental-physical comorbidity in Korean adults: results from a nationwide general population survey in Korea. European Neuropsychopharmacology 26: S351-S352

Garcia-Alocen, A.; Martinez-Cengotitabengoa, M.; Macdowell, K.; Garcia-Bueno, B.; Alberich, S.; Parellada, M.; Saiz, P.; Rodriguez, R.; Berrocoso, E.; Bernardo, M.; Gonzalez-Pinto, A.; Leza, J. 2016: Neurotrophin signaling in first episode psychosis: relation to response to antipsychotics after 1 year of follow-up. European Neuropsychopharmacology 26: S361-S362

Booij, L.; Levesque, M.L.; Fahim, C.; Ismaylova, E.; Vitaro, F.; Brendgen, M.; Dionne, G.; Boivin, M.; Szyf, M.; Tremblay, R.E. 2016: Serotonin transporter methylation, neural responses to sadness and resting state functional connectivity: a study in adolescent monozygotic twins. European Neuropsychopharmacology 26: S362-S363

Atake, K.; Yamana, M.; Igata, R.; Hori, H.; Katsuki, A.; Konishi, Y.; Yoshimura, R. 2016: Plasma levels of 3-methoxy-4-hydroxyphenylglycol (Mhpg) can be a prediction marker of response to escitalopram treatment in Japanese major depressive disorder patients: Preliminary data. European Neuropsychopharmacology 26: S391-S392

Bengesser, S.A.; Lackner, N.L.; Birner, A.; Fellendorf, F.F.; Platzer, M.P.; Queissner, R.Q.; Reininghaus, E.Z.R.; Kapfhammer, H.P.K.; Kainzbauer, N.K.; Tropper, B.T.; Liebmann-Wallner, S.L.W.; Meier-Allard, N.M.A.; Stracke, A.S.; Fuchs, R.F. 2016: Endoplasmatic reticulum stress and the unfolded protein response in bipolar disorder Xbp1 splicing, BiP and Chop gene expression. European Neuropsychopharmacology 26: S420-S421

Poggini, S.; Alboni, S.; Garofalo, S.; Milior, G.; Brunello, N.; Wolfer, D.P.; Limatola, C.; Maggi, L.; Branchi, I. 2016: Fluoxetine treatment affects the inflammatory response according to the quality of the living environment. European Neuropsychopharmacology 26: S452-S453

Yoshimura, R.; Hori, H.; Katsuki, A.; Atake, K. 2016: Plasma 3-methoxy-4-hydroxyphenylglycol level and the response to antidepressants. European Neuropsychopharmacology 26: S455-S456

Ryan, K.M.; Glaviano, A.; O'Donovan, S.M.; Kolshus, E.; Tucker, G.; Dunn, M.J.; McLoughlin, D.M. 2016: The plasma proteome following electroconvulsive therapy: a role for pigment epithelium-derived factor (Pedf) in depression and treatment response?. European Neuropsychopharmacology 26: S464-S465

Komulainen, E.; Heikkilä, R.; Meskanen, K.; Nummenmaa, L.; Raij, T.T.; Isometsä, E.; Ekelund, J. 2016: One-week administration of escitalopram decreases neural responses to self-referential processing in major depression. European Neuropsychopharmacology 26: S465-S466

Berger, M.; Kraeuter, A.; Romanik, D.; Malouf, P.; Amminger, G.; Sarnyai, Z. 2016: Cortisol awakening response in patients with schizophrenia, first-episode psychosis and at-risk mental states: a meta-analysis. European Neuropsychopharmacology 26: S487-S488

Marcatili, M.; Marsoner, F.; D'Agostino, A.; Scarone, S.; Conti, L. 2016: Cellular reprogramming in schizophrenia: from disease modelling to the molecular bases of treatment response. European Neuropsychopharmacology 26: S492-S493

Rodríguez, A.G.; Catalán, R.; Penadés, R.; Cortés, V.R.; Torra, M.; Bernardo, M. 2016: High Fsh:Lh ratio may be associated with poor response of negative symptoms in postmenopausal schizophrenia women. European Neuropsychopharmacology 26: S538-S539

Catalán, R.; González-Rodríguez, A.; Arranz, M.; Penadés, R.; Gutiérrez, B.; Pérez-Blanco, F.; Bernardo, M. 2016: Impact of nicotine consumption on antipsychotic response based on genetic variants of cytochrome P450 2D6 and multi-drug resistance 1 C3435T in schizophrenia. European Neuropsychopharmacology 26: S552-S553

Sugai, T. 2016: High prevalence of underweight and under-nutrition in Japanese inpatients with schizophrenia: a nationwide survey. European Neuropsychopharmacology 26: S586-S587

Benatti, B.; Camuri, G.; Dell'Osso, B.; Cremaschi, L.; Oldani, L.; Palazzo, C.; Dobrea, C.; Grancini, B.; Arici, C.; Vismara, M.; DeCagna, F.; Altamura, C. 2016: Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder and obsessive-compulsive disorder?. European Neuropsychopharmacology 26: S608-S609

Turton, S.; Myers, J.; Mick, I.; Rabiner, E.; Gunn, R.; Nutt, D.; Lingford-Hughes, A. 2016: Alcohol dependent patients have blunted endogenous opioid release measured using [11C]carfentanil Pet and dexamphetamine challenge. European Neuropsychopharmacology 26: S676-S677

Nemoda, Z.; Angyal, N.; Kruk, E.; Bognar, E.; Tarnok, Z. 2016: Genetic determinants of methylphenidate response in children with attention deficit hyperactivity disorder. European Neuropsychopharmacology 26: S737-S738

Saudou, F. 2016: S.01.01 Autobahns in the brain: axonal transport and its disruption in neurological disorders. European Neuropsychopharmacology 26: S1-S2

Camps, E.B.; Colell, A. 2016: P.1.001 Sterol regulatory element binding protein-2 (Srebp-2)-mediated cholesterol accumulation regulates mitophagy in amyloid precursor protein (App)/presenilin 1 (Ps1)/Srebp-2 mice. European Neuropsychopharmacology 26: S2-S3

Berthoux, C.; Hamieh, A.M.; Bockaert, J.; Marin, P.; Bécamel, C. 2016: P.1.002 Cognitive deficits due to chronic consumption of 9-tetrahydrocannabinol during adolescence: role of 5-Ht6-mTor pathway. European Neuropsychopharmacology 26: S3-S4

Breen, M.S.; Uhlmann, A.; Nday, C.; Glatt, S.; Metsalpu, A.; Stein, D.; Illing, N. 2016: P.1.003 Gene networks and blood biomarkers of methamphetamine-associated psychosis: a preliminary integrative Rna-Seq report. European Neuropsychopharmacology 26: S4-S5

Hegarty, S.; O'Leary, E.; Wyatt, S.; Sullivan, A.; O'Keeffe, G. 2016: P.1.004 Novel neurotrophic strategy: interrogation of intracellular molecules regulating growth of midbrain dopaminergic neurons. European Neuropsychopharmacology 26: S5-S6

Silva, J.; Rodrigues, S.; Marques, M.B.; Ludovico, P.; Sousa, N.; Sotiropoulos, I. 2016: P.1.005 The stressed autophagy: chronic stress exacerbates Tau pathology by blocking autophagy clearance system. European Neuropsychopharmacology 26: S6-S7

Gururajan, A.; Peterson, V.; Burokas, A.; Moloney, G.; Dinan, T.; Cryan, J. 2016: P.1.006 Sweating the small stuff: chronic psychosocial stress regulates microRna expression in the hippocampus of the mouse. European Neuropsychopharmacology 26: S7-S8

Cavalleri, L.; Chiamulera, C.; Millan, M.J.; Pich, E.M.; Spano, P.; Collo, G. 2016: P.1.007 Ketamine-induced plasticity in mouse-primary and human-iPsc-derived dopaminergic neurons involves D3R and mTor pathway. European Neuropsychopharmacology 26: S8-S9

Candemir, E.; Kollert, L.; Weißflog, L.; Geis, M.; Müller, A.; Post, A.; O'Leary, A.; Harro, J.; Reif, A.; Freudenberg, F. 2016: P.1.008 Interaction of nitric oxide synthase 1 with its adaptor protein: effects on schizophrenia-related dendritic alterations. European Neuropsychopharmacology 26: S9-S10

Buonaguro, E.F.; Latte, G.; Avvisati, L.; Marmo, F.; Iasevoli, F.; Tomasetti, C.; DeBartolomeis, A. 2016: P.1.009 Effects of caffeine, nicotine and their combination with haloperidol on Psd molecules: relevance to psychiatric diseases. European Neuropsychopharmacology 26: S10-S11

Misztak, P.; Pańczyszyn-Trzewik, P.; Nowak, G.; Sowa-Kućma, M. 2016: P.1.011 Changes in miR-212/132 expression in the hippocampus of rats subjected to olfactory bulbectomy. European Neuropsychopharmacology 26: S11-S12

Menon, R.; Slattery, D.A.; Neumann, I.D. 2016: P.1.012 Epigenetic regulation of oxytocinergic system during social fear conditioning. European Neuropsychopharmacology 26: S12-S13

Noworyta-Sokołowska, K.; Kamińska, K.; Gołembiowska, K. 2016: P.1.013 Synthetic hallucinogen 5-methoxy-N,N-diisopropyltryptamine and its action in the rat brain. European Neuropsychopharmacology 26: S13-S14

Pujol, C.; Séveno, M.; Bockaert, J.; Marin, P.; Chaumont-Dubel, S. 2016: P.1.017 Gprin1, a new 5-Ht6 receptor partner involved in its constitutive activity and receptor-induced neuronal differentiation. European Neuropsychopharmacology 26: S16-S17

Kelly, L.; Swinny, J. 2016: P.1.018 Molecular and functional characterisation of the glycine-receptor system in the mouse locus coeruleus nucleus. European Neuropsychopharmacology 26: S17-S18

Pathak, H. 2016: P.1.019 Functional investigation of the Aldh2 promoter: a regulatory genetic-epigenetic interplay. European Neuropsychopharmacology 26: S18-S19

Yao, N.; Svenningson, P.; Chergui, K. 2016: P.1.020 Ketamine inhibits long-term potentiation and promotes long-term depression in the nucleus accumbens. European Neuropsychopharmacology 26: S19-S20

Parshukova, D.; Borodyuk, Y.; Smirnova, L.; Buneva, V.; Ivanova, S.; Semke, A. 2016: P.1.021 The G-immunoglobulins of schizophrenic patients demonstrate proteolytic activity. European Neuropsychopharmacology 26: S20-S21

DuPreez, A.; Musaelyan, K.; Egeland, M.; Hye, A.; Zunszain, P.; Pariante, C.; Thuret, S.; Fernandes, C. 2016: P.1.022 The type of stress matters: different stressors can lead to different biological profiles. European Neuropsychopharmacology 26: S21-S22

Dinan, T. 2016: S.02.01 How the gut influences the brain: the intestinal microbiome as a new dimension for understanding mental health. European Neuropsychopharmacology 26: S23-S24

Josselyn, S. 2016: S.02.02 The making and breaking of memory: from molecules to networks. European Neuropsychopharmacology 26: S24-S25

Lorrai, I. 2016: P.2.001 Reducing effect of saikosaponin A on alcohol self-administration in rats: possible involvement of the Gabab receptor. European Neuropsychopharmacology 26: S25-S26

Das, A.; Dines, M.; Lamprecht, R. 2016: P.2.002 Rac1 Gtpase and Pak activities in lateral amygdala constrain fear memory formation. European Neuropsychopharmacology 26: S26-S27

Huber, S.; Lenz, B.; Kornhuber, J.; Müller, C. 2016: P.2.006 Prenatal testosterone activity determines adult alcohol drinking and morphology in mice. European Neuropsychopharmacology 26: S28-S29

Wahab, M.; Solinas, M. 2016: P.2.007 A novel self-adjusting delay discounting procedure for the study of choice impulsivity in rats. European Neuropsychopharmacology 26: S29-S30

Zanda, M.T.; Antinori, S.; Mutti, A.; Mancini, L.; Padovani, L.; Scherma, M.; Collu, R.; Aroni, S.; Muntoni, A.L.; Fratta, W.; Fadda, P.; Chiamulera, C.; Fattore, L. 2016: P.2.008 Effect of acute and chronic administration of a new psychoactive drug, methoxetamine, on behaviour, mood and reward. European Neuropsychopharmacology 26: S30-S31

Foraster, M.A.; Celada, P.; Jensen, A.A.; Plath, N.; Herrik, K.F.; Artigas, F. 2016: P.2.010 Ketamine inhibits the activity of thalamic neurons in anesthetized rats. European Neuropsychopharmacology 26: S31-S32

Dourojeanni, J.F.; Adan, R.; Vanderschuren, L. 2016: P.2.011 The role of ascending ventral tegmental area projections in impulsivity and attention. European Neuropsychopharmacology 26: S32-S33

Jacob, S.; Tahon, K.; Steckler, T.; Drinkenburg, P. 2016: P.2.012 Glutamatergic manipulation in spatial search processes: advanced cognitive neurophysiological analysis in rats. European Neuropsychopharmacology 26: S33-S34

Dorofeikova, M.; Bespalov, A. 2016: P.2.013 Effects of Mk-801 and medial prefrontal cortex lesions on cognitive flexibility in a novel task based on the change of interval schedules. European Neuropsychopharmacology 26: S34-S35

Gottschalk, M.; Ruland, T.; Leussis, M.; Gjeluci, K.; Petryshen, T.; Bahn, S. 2016: P.2.014 Lithium ameliorates manic-like behaviour in Ank3+/- mice via the kinesin cargo system: a protein interaction network view. European Neuropsychopharmacology 26: S35-S36

Van Hagen, B.; Van Goethem, N.P.; Schreiber, R.; Newman-Tancredi, A.; Varney, M.; Prickaerts, J. 2016: P.2.015 Chronic effects of biased 5-Ht1A receptor agonists on object pattern separation performance and hippocampal plasticity. European Neuropsychopharmacology 26: S36-S37

Pilipenko, V.; Pupure, J.; Rumaks, J.; Beitnere, U.; Dzirkale, Z.; Jansone, B.; Skumbins, R.; Klusa, V. 2016: P.2.016 Muscimol effectively reverses impaired spatial memory in Alzheimer's disease-type streptozocin icv rat model. European Neuropsychopharmacology 26: S37-S38

Fanni, S.; Frau, R.; Tronci, E.; Fidalgo, C.; Lisci, C.; Pardu, A.; Pes, R.; Saba, P.; Devoto, P.; Bortolato, M.; Carta, M. 2016: P.2.018 Role of 5-alpha reductase in the pathophysiology of L-Dopa induced dyskinesia. European Neuropsychopharmacology 26: S38-S39

Karamyan, S.; Balasanyan, M.; Topchyan, H. 2016: P.2.019 Improvement of experimental focal ischemic outcomes by triflusal. European Neuropsychopharmacology 26: S39-S40

Van den Munkhof, H.; Celada, P.; Artigas, F. 2016: P.2.020 The novel antipsychotic brexpiprazole partly reverses a disruption of thalamocortical function induced by phencyclidine. European Neuropsychopharmacology 26: S40-S41

Collu, R.; Scherma, M.; Satta, V.; Bratzu, J.; Castelli, M.P.; Boi, M.F.; Usai, P.; Fattore, L.; Fadda, P.; Fratta, W. 2016: P.2.021 The endocannabinoid system: possible new pharmacological target in the treatment of anorexia nervosa. European Neuropsychopharmacology 26: S41-S42

Batinic, B.; Stankovic, T.; Savic, M. 2016: P.2.022 Attaining in vivo selectivity of positive modulation of a3 Gaba-A receptors in rats: a hard task. European Neuropsychopharmacology 26: S42-S43

Antinori, S.; Fattore, L.; Saba, P.; Fratta, W.; Gessa, G.L.; Devoto, P. 2016: P.2.023 Role of levo-dihydroxyphenylalanine on cocaine-taking and cocaine-seeking behaviour in rats. European Neuropsychopharmacology 26: S43-S44

Voineskos, A.; Lett, T.; Felsky, D.; Daskalakis, Z.; Malhotra, A. 2016: S.03.01 Why white matter matters: oligodendrocytes, myelin and brain connectivity - disruption linked to schizophrenia. European Neuropsychopharmacology 26: S45-S46

Charlet, K.; Wulkau, L.; Beck, A.; Jorde, A.; Zois, E.; Vollstädt-Klein, S.; Kirsch, M.; Walter, H.; Kiefer, F.; Heinz, A. 2016: P.3.001 Influence of habitual negative affect on processing of negative facial stimuli in alcoholic patients. European Neuropsychopharmacology 26: S46-S47

Naaijen, J.; Bralten, J.; Faraone, S.; Glennon, J.; Franke, B.; Buitelaar, J. 2016: P.3.002 Glutamatergic and Gabaergic gene-sets in Adhd: association to overlapping traits in Adhd and autism. European Neuropsychopharmacology 26: S47-S48

Carrillo-Roa, T.; Dunlop, B.W.; McGrath, C.L.; Czamara, D.; Zaanas, A.S.; Kelley, M.E.; Nemeroff, C.B.; Craighead, W.E.; Mayberg, H.S.; Binder, E.B. 2016: P.3.004 Neuroimaging derived polygenic scores predict outcomes to psychotherapy and medication treatments for depression. European Neuropsychopharmacology 26: S48-S49

Al-Bataineh, R.; Crasan, A.; Purnichi, T.; Matei, V. 2016: P.3.005 Is diagnosis indeed prognosis? 12 months outcome for schizophrenia, schizophreniform and schizoaffective disorder. European Neuropsychopharmacology 26: S49-S50

Bould, H.; Carnegie, R.; Allward, H.; Bacon, E.; Sapseid, M.; Button, K.; Lewis, G.; Skinner, A.; Broome, M.; Park, R.; Harmer, C.; Penton-Voak, I.; Munafò, M. 2016: P.3.006 Effects of visual adaptation on perception of and satisfaction with own body size: two randomised studies. European Neuropsychopharmacology 26: S50-S51

Müller, L.E.; Herpertz, S.C.; Volman, I.; Roelofs, K.; Bertsch, K. 2016: P.3.007 Modulation of the approach-avoidance tendencies of persons with high social anxiety by the neuropeptide oxytocin. European Neuropsychopharmacology 26: S51-S52

Figueroa, C.; Ruhé, H.; Van Wingen, G.; Martens, S.; Mocking, R.; Schene, A. 2016: P.3.008 Attenuated resting-state default mode network connectivity in remitted depression after sad autobiographical recall. European Neuropsychopharmacology 26: S52-S53

Kirli, U.; Binbay, T.; Elbi, H.; Kayahan, B.; Gokcelli, D.; Alptekin, K.; Van Os, J. 2016: P.3.009 Quitting cannabis decreases but does not eliminate psychosis risk: evidence from a 7 years large population-based cohort. European Neuropsychopharmacology 26: S53-S54

Perfalk, E.; Bang, S.D.-C.; Holst, K.K.; Frokjaer, V.G.; Knudsen, G.M. 2016: P.3.010 Endogenous plasma testosterone in healthy men is negatively associated with hippocampal serotonin receptor 4 binding. European Neuropsychopharmacology 26: S54-S55

Liu, I.; Hellmann-Regen, J.; Otte, C.; Hinkelmann, K. 2016: P.3.011 Attenuated cortisol response to blockade of the mineralocorticoid receptor in depressed patients. European Neuropsychopharmacology 26: S55-S56

Popovic, A.; Bauer, M.; Bartova, L.; Sauerzopf, U.; Praschak-Rieder, N.; Rami-Mark, C.; Nics, L.; Philippe, C.; Mitterhauser, M.; Wadsak, W.; Kasper, S.; Willeit, M. 2016: P.3.012 Sensitisation effects induced by d-amphetamine in healthy humans measured with the D2,3 radioligand [11C]-(+)-Phno. European Neuropsychopharmacology 26: S56-S57

Gage, S.; Jones, H.; Taylor, A.; Zammit, S.; Munafo, M. 2016: P.3.013 Using publicly available data to investigate causal associations between substance use and mental health. European Neuropsychopharmacology 26: S57-S58

Iurato, S.; Carrillo-Roa, T.; Czamara, D.; Ising, M.; Lucae, S.; Binder, E.B.; Erhardt-Lehmann, A. 2016: P.3.015 Dna methylation signatures of susceptibility to panic disorder. European Neuropsychopharmacology 26: S58-S59

Opel, N.; Jukic, M.; Ingelman-Sundberg, M.; Dannlowski, U. 2016: P.3.016 Cyp2C19 enzymatic capacity predicts hippocampal volume in healthy subjects. European Neuropsychopharmacology 26: S59-S60

Androne, F.T.; Candea, C.; Alboaie, A.F.; Patrascu, M. 2016: P.3.017 Evaluation of cognitive functioning during antidepressant treatment in young patients with severe major depressive disorder. European Neuropsychopharmacology 26: S60-S61

Zhao, J.; Cosgrove, D.; Kelly, S.; Corvin, A.; Gill, M.; Cannon, D.; McDonald, C.; Morris, D.; Donohoe, G. 2016: P.3.018 Schizophrenia susceptibility gene Cacna1C associates with microstructure of fornix. European Neuropsychopharmacology 26: S61-S62

Schür, R.; Boks, M.; Geuze, E.; Prinsen, B.; Verhoeven-Duif, N.; Joels, M.; Kahn, R.; Vermetten, E.; Vinkers, C. 2016: P.3.019 Development of psychopathology in deployed armed forces is related to increasing plasma Gaba levels. European Neuropsychopharmacology 26: S62-S63

Reijnen, A.; Geuze, E.; Eekhout, I.; Vermetten, E. 2016: P.3.020 Is plasma neuropeptide Ya susceptibility marker for posttraumatic stress symptoms over time?. European Neuropsychopharmacology 26: S63-S64

Malpighi, C.; Plazzotta, G.; Luoni, A.; Mondelli, V.; Pariante, C.M.; Riva, M.A.; Cattaneo, A. 2016: P.3.021 Long-term signature after stress early in life by using mRna-miRna integration approach in rats and humans. European Neuropsychopharmacology 26: S64-S65

Frijling, J.L.; Van Zuiden, M.; Nawijn, L.; Koch, S.B.J.; Veltman, D.J.; Olff, M. 2016: P.3.022 Repeated intranasal oxytocin administration as early preventive intervention for Ptsd: a randomized controlled trial. European Neuropsychopharmacology 26: S65-S66

Masaki, C.; Sharpley, A.; Godlewska, B.; Berrington, A.; Hashimoto, T.; Singh, N.; Vasudevan, S.; Emir, U.; Churchill, G.; Cowen, P. 2016: P.3.023 Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study. European Neuropsychopharmacology 26: S66-S67

Chesters, R.A.; Stone, J.M.; Hughes, E.; Howes, O.; Cooper, J.D.; Vernon, A.C. 2016: P.3.024 Translational neuroimaging reveals differential effects of chronic ketamine on brain macrostructure in humans and mice. European Neuropsychopharmacology 26: S67-S68

Aggio, V.; Poletti, S.; Ambrée, O.; Colombo, C.; Arolt, V.; Benedetti, F. 2016: P.3.025 Brain-derived neurotrophic factor associates with gray matter volumes and early adverse experiences in bipolar disorder. European Neuropsychopharmacology 26: S68-S69